<?xml version="1.0" encoding="iso-8859-1"?> 
<rss version="2.0" xmlns:creativeCommons="http://backend.userland.com/creativeCommonsRssModule" 
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" 
xmlns:atom="http://www.w3.org/2005/Atom"
>
<channel>
<title>International Journal of Biological Sciences</title> 
<link>http://www.ijbs.com</link> 
<description>International Journal of Biological Sciences RSS feed -- Volume 17</description> 
<language>en-us</language> 
<pubDate>Mon, 19 Apr 2021 04:00:00 GMT</pubDate>
<lastBuildDate>Mon, 19 Apr 2021 04:00:00 GMT</lastBuildDate> 

<item>
<link>http://www.ijbs.com/v17p1731.htm</link> 
<title>The emerging function and clinical significance of circRNAs in Thyroid Cancer and Autoimmune Thyroid Diseases</title> 
<description><![CDATA[ <p>Thyroid cancer (TC) is one of the most common malignant tumors, with high morbidity and mortality rates worldwide. The incidence of TC, especially that of papillary thyroid carcinoma (PTC); has increased rapidly in recent decades. Autoimmune thyroid disease (AITD) is closely related to TC and has an estimated prevalence of 5%. Thus, it is becoming increasingly important to identify potential diagnostic biomarkers and therapeutic targets for TC and AITD. Circular RNAs (circRNAs) are a class of non-coding RNAs with covalently bonded circular structures that lack 5'-3' polarity and polyadenylated tails. Several circRNAs play crucial roles in the development of various diseases, including TC and AITD, and could be important new biomarkers and/or targets for the diagnosis and therapy of such disorders. Although there are four subtypes of TC, research on circRNA has largely focused on its connection to PTC. Therefore, this review mainly summarizes the relationships between circRNAs and PTC and AITD, including the molecular mechanisms underlying these relationships. In particular, the functions of &#8220;miRNA sponges&#8221; and their interactions with proteins and RNA are discussed. The possible targeting of circRNAs for the prevention, diagnosis, and treatment of TC and AITD is also described. CircRNAs could be potential biomarkers of TC and AITD, although validation will be required before they can be implemented in clinical practice.</p> ]]></description>  
<dc:creator>Yu Zhang, Dong-Dong Jia, Yi-Fei Zhang, Meng-Die Cheng, Wen-Xiu Zhu, Pei-Feng Li, Yin-Feng Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1731</prism:startingPage> 
<prism:endingPage>1741</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1716.htm</link> 
<title>NDRG1 regulates Filopodia-induced Colorectal Cancer invasiveness via modulating CDC42 activity</title> 
<description><![CDATA[ <p>N-myc downstream regulated gene-1 (NDRG1) has been identified as a putative metastasis suppressor gene and proved to be a key player in cancer spreading and proliferation in our previous work. However, the effects of NDRG1 on tumor invasion and the mechanisms behind it are rarely understood. Here we provided <i>in silico</i> evidence that NDRG1 plays a crucial role in actin reorganization in colorectal cancer (CRC). Through <i>in vitro</i> experiments, we next observed filopodia formation was altered in NDRG1-modified cell lines, while cell division cycle-42 (CDC42) displayed excessive activation in NDRG1-silenced cells. Mechanistically, NDRG1 loss disrupts the binding between RhoGDI&#945; and CDC42 and triggers the activation of CDC42 and the downstream cascades PAK1/Cofilin, thereby promotes the formation of filopodia and invasiveness of CRC. The knockdown of NDRG1 led to enhanced dissemination of CRC cells <i>in vivo</i> and correlates with active CDC42 expression. Using clinical sample analysis, we found an elevated level of active CDC42 in patients with advanced T stage, and it was negatively related to NDRG1 expression. In sum, these results uncover a mechanism utilized by NDRG1 to regulate CDC42 activity in coordinating cytoskeleton reorganization, which was crucial in cancer invasion.</p> ]]></description>  
<dc:creator>Batuer Aikemu, Yanfei Shao, Guang Yang, Junjun Ma, Sen Zhang, Xiao Yang, Hiju Hong, Galiya Yesseyeva, Ling Huang, Hongtao Jia, Chenxing Wang, Lu Zang, Jing Sun, Minhua Zheng</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1716</prism:startingPage> 
<prism:endingPage>1730</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1708.htm</link> 
<title>Splicing factor SRSF2-centric gene regulation</title> 
<description><![CDATA[ <p>Serine/arginine-rich splicing factor 2 (SRSF2) is a splicing factor that is widely expressed in a variety of mammalian cell types. Increasing evidence has confirmed that SRSF2 plays vital roles in a number of biological and pathological processes. Therefore, it is important to understand how its expression is regulated, and how it regulates the expression of its target genes. Recently, we found that SRSF2 expression could be upregulated by herpes simplex virus-1 (HSV-1) infection<i>,</i> and that altered SRSF2 expression, in turn, epigenetically regulates the transcription of HSV-1 genes. Further studies on T cell exhaustion demonstrated that upregulated SRSF2 in exhausted T cells elevated the levels of multiple immune checkpoint molecules by associating with the acyl-transferases, P300 and CBP, and by altering histone modification near the transcription start sites of these genes, thereby influencing signal transducer and activator of transcription 3 binding to these gene promoters. These findings suggest that SRSF2 acts as an important sensor and effector during disease progression. Here, we discuss the molecules that regulate <i>SRSF2</i> gene expression and their associated mechanisms, and the mechanisms via which SRSF2 regulates the expression of target genes, thus providing novel insights into the central role of SRSF2 in gene regulation.</p> ]]></description>  
<dc:creator>Kun Li, Ziqiang Wang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1708</prism:startingPage> 
<prism:endingPage>1715</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1693.htm</link> 
<title>Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver</title> 
<description><![CDATA[ <p>This study is to investigate the relationship between berberine (BBR) and mitochondrial complex I in lipid metabolism. BBR reversed high-fat diet-induced obesity, hepatic steatosis, hyperlipidemia and insulin resistance in mice. Fatty acid consumption, &#946;-oxidation and lipogenesis were attenuated in liver after BBR treatment which may be through reduction in SCD1, FABP1, CD36 and CPT1A. BBR promoted fecal lipid excretion, which may result from the reduction in intestinal CD36 and SCD1. Moreover, BBR inhibited mitochondrial complex I-dependent oxygen consumption and ATP synthesis of liver and gut, but no impact on activities of complex II, III and IV. BBR ameliorated mitochondrial swelling, facilitated mitochondrial fusion, and reduced mtDNA and citrate synthase activity. BBR decreased the abundance and diversity of gut microbiome. However, no change in metabolism of recipient mice was observed after fecal microbiota transplantation from BBR treated mice. In primary hepatocytes, BBR and AMPK activator A769662 normalized oleic acid-induced lipid deposition. Although both the agents activated AMPK, BBR decreased oxygen consumption whereas A769662 increased it. Collectively, these findings indicated that BBR repressed complex I in gut and liver and consequently inhibited lipid metabolism which led to alleviation of obesity and fatty liver. This process was independent of intestinal bacteria.</p> ]]></description>  
<dc:creator>Muyu Yu, Miriayi Alimujiang, Lili Hu, Fang Liu, Yuqian Bao, Jun Yin</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1693</prism:startingPage> 
<prism:endingPage>1707</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1682.htm</link> 
<title>Regulation of RNA N6-methyladenosine modification and its emerging roles in skeletal muscle development</title> 
<description><![CDATA[ <p>N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) is one of the most widespread and highly conserved chemical modifications in cellular RNAs of eukaryotic genomes. Owing to the development of high-throughput m<sup>6</sup>A sequencing, the functions and mechanisms of m<sup>6</sup>A modification in development and diseases have been revealed. Recent studies have shown that RNA m<sup>6</sup>A methylation plays a critical role in skeletal muscle development, which regulates myoblast proliferation and differentiation, and muscle regeneration. Exploration of the functions of m<sup>6</sup>A modification and its regulators provides a deeper understanding of the regulatory mechanisms underlying skeletal muscle development. In the present review, we aim to summarize recent breakthroughs concerning the global landscape of m<sup>6</sup>A modification in mammals and examine the biological functions and mechanisms of enzymes regulating m<sup>6</sup>A RNA methylation. We describe the interplay between m<sup>6</sup>A and other epigenetic modifications and highlight the regulatory roles of m<sup>6</sup>A in development, especially that of skeletal muscle. m<sup>6</sup>A and its regulators are expected to be targets for the treatment of human muscle-related diseases and novel epigenetic markers for animal breeding in meat production.</p> ]]></description>  
<dc:creator>Jiju Li, Yangli Pei, Rong Zhou, Zhonglin Tang, Yalan Yang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1682</prism:startingPage> 
<prism:endingPage>1692</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1671.htm</link> 
<title>MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer</title> 
<description><![CDATA[ <p>The immune checkpoint ligand programmed death-ligand 1 (PD-L1) and the transmembrane mucin (MUC) 3A are upregulated in non-small cell lung cancer (NSCLC), contributing to the aggressive pathogenesis and poor prognosis. Here, we report that knocking down the oncogenic MUC3A suppresses the PD-L1 expression in NSCLC cells. MUC3A is a potent regulator of epidermal growth factor receptor (EGFR) stability, and MUC3A deficiency downregulates the activation of the PI3K/Akt and MAPK pathways, which subsequently reduces the expression of PD-L1. Furthermore, knockdown of MUC3A and tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC cells play a synergistic effect on inhibited proliferation and promoted apoptosis <i>in vitro</i>. In the BALB/c nude mice xenograft model, MUC3A deficiency enhances EGFR-mutated NSCLC sensitivity to TKIs. Our study shows that transmembrane mucin MUC3A induces PD-L1, thereby promoting immune escape in NSCLC, while downregulation of MUC3A enhances TKIs effects in EGFR-mutant NSCLC. These findings offer insights into the design of novel combination treatment for NSCLC.</p> ]]></description>  
<dc:creator>Yuan Luo, Shijing Ma, Yingming Sun, Shan Peng, Zihang Zeng, Linzhi Han, Shuying Li, Wenjie Sun, Jieyu Xu, Xiaoli Tian, Feng Wang, Qiuji Wu, Yu Xiao, Junhong Zhang, Yan Gong, Conghua Xie</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1671</prism:startingPage> 
<prism:endingPage>1681</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1660.htm</link> 
<title>CHD4 as an important mediator in regulating the malignant behaviors of colorectal cancer</title> 
<description><![CDATA[ <p>Colorectal cancer (CRC) has ranked first in terms of incidence in Taiwan. Surgical resection combined with chemo-, radio-, or targeted-therapies are the main treatments for CRC patients in current clinical practice. However, many CRC patients still respond poorly to these treatments, leading to tumor recurrence and an unacceptably high incidence of metastasis and death. Therefore, appropriate diagnosis, treatment, and drug selection are pressing issues in clinical practice.</p><p>The Mi-2/nucleosome remodeling and deacetylase complex is an important epigenetic regulator of chromatin structure and gene expression. An important component of this complex is chromodomain-helicase-DNA-binding protein 4 (CHD4), which is involved in DNA repair after injury. Recent studies have indicated that CHD4 has oncogenic functions that inhibit multiple tumor suppressor genes through epigenetic regulation. However, the role of CHD4 in CRC has not yet been well investigated.</p><p>In this study, we compared CHD4 expression in CRC patients from The Cancer Genome Atlas database. We found higher levels of CHD4 expression in CRC patients. In a series of <i>in vitro</i> experiments, we found that CHD4 affected cell motility and drug sensitivity in CRC cells. In animal models, the depletion of CHD4 affected CRC tumor growth, and the combination of a histone deacetylase 1 (HDAC1) inhibitor and platinum drugs inhibited CHD4 expression and increased the cytotoxicity of platinum drugs. Moreover, CHD4 expression was also a prognostic biomarker in CRC patients.</p><p>Based on the above results, we believe that CHD4 expression is a viable biomarker for predicting metastasis CRC patients, and it has the potential to become a target for drug development.</p> ]]></description>  
<dc:creator>Chia-Lo Chang, Chi-Ruei Huang, Shu-Jyuan Chang, Chun-Chieh Wu, Hong-Hwa Chen, Chi-Wen Luo, Hon-Kan Yip</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1660</prism:startingPage> 
<prism:endingPage>1670</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1644.htm</link> 
<title>Wnt/&#946;-catenin Signaling Inhibitors suppress the Tumor-initiating properties of a CD44+CD133+ subpopulation of Caco-2 cells</title> 
<description><![CDATA[ <p>Tumor-initiating cells or cancer stem cells are a subset of cancer cells that have tumorigenic potential in human cancer. Although several markers have been proposed to distinguish tumor-initiating cells from colorectal cancer cells, little is known about how this subpopulation contributes to tumorigenesis. Here, we characterized a tumor-initiating cell subpopulation from Caco-2 colorectal cancer cells. Based on the findings that Caco-2 cell subpopulations express different cell surface markers, we were able to discriminate three main fractions, CD44<sup>-</sup>CD133<sup>-</sup>, CD44<sup>-</sup>CD133<sup>+</sup>, and CD44<sup>+</sup>CD133<sup>+</sup> subsets, and characterized their biochemical and tumorigenic properties. Our results show that CD44<sup>+</sup>CD133<sup>+</sup> cells possessed an unusual capacity to proliferate and could form tumors when transplanted into NSG mice. Additionally, primary tumors grown from CD44<sup>+</sup>CD133<sup>+</sup> Caco-2 cells contained mixed populations of CD44<sup>+</sup>CD133<sup>+</sup> and non-CD44<sup>+</sup>CD133<sup>+</sup> Caco-2 cells, indicating that the full phenotypic heterogeneity of the parental Caco-2 cells was re-created. Notably, only the CD44<sup>+</sup>CD133<sup>+</sup> subset of Caco-2-derived primary tumors had tumorigenic potential in NSG mice, and the tumor growth of CD44<sup>+</sup>CD133<sup>+</sup> cells was faster in secondary xenografts than in primary transplants. Gene expression analysis revealed that the Wnt/&#946;-catenin pathway was over-activated in CD44<sup>+</sup>CD133<sup>+</sup> cells, and the growth and tumorigenic potential of this subpopulation were significantly suppressed by small-molecule Wnt/&#946;-catenin signaling inhibitors. Our findings suggest that the CD44<sup>+</sup>CD133<sup>+</sup> subpopulation from Caco-2 cells was highly enriched in tumorigenic cells and will be useful for investigating the mechanisms leading to human colorectal cancer development.</p> ]]></description>  
<dc:creator>Junghoon Kim, Kyeng-Won Choi, Jungwoon Lee, Jaeyoung Lee, Seonock Lee, Ruijing Sun, Jungho Kim</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1644</prism:startingPage> 
<prism:endingPage>1659</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1629.htm</link> 
<title>YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis</title> 
<description><![CDATA[ <p>Long non-coding RNA (lncRNA) small nucleolar RNA host gene 12 (SNHG12) plays important roles in the pathogenesis and progression of cancers. However, the role of SNHG12 in the metastasis of gastric cancer (GC) has not yet been thoroughly investigated. In the present study, we demonstrated that SNHG12 was upregulated in GC tissues and cell lines. In addition, the expression level of SNHG12 in GC samples was significantly related to tumor invasion depth, TNM stage and lymph node metastasis and was associated with disease-free survival (DFS) and overall survival (OS) in GC patients. <i>In vivo</i> and <i>in vitro</i> assays indicated that SNHG12 promotes GC metastasis and epithelial-mesenchymal transition (EMT). Bioinformatics and mechanistic analyses revealed that SNHG12 can directly target miR-218-5p to regulate YWHAZ mRNA, forming an SNHG12/miR-218-5p/YWHAZ axis and decreasing the ubiquitination of &#946;-catenin. In addition, SNHG12 stabilizes CTNNB1 mRNA by binding with HuR, thus activating the &#946;-catenin signaling pathway. Further analysis also revealed that the transcription factor YY1 negatively modulates SNHG12 transcription. In conclusion, SNHG12 is a potential prognostic marker and therapeutic target for GC. Negatively modulated by YY1, SNHG12 promotes GC metastasis and EMT by regulating the miR-218-5p/YWHAZ axis and stabilizing CTNNB1 via activation of the &#946;-catenin signaling pathway.</p> ]]></description>  
<dc:creator>Tianqi Zhang, Maneesh Kumarsing Beeharry, Zhenqiang Wang, Zhenggang Zhu, Jianfang Li, Chen Li</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1629</prism:startingPage> 
<prism:endingPage>1643</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1613.htm</link> 
<title>Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway</title> 
<description><![CDATA[ <p>The treatment of advanced prostate cancer, castration-resistant prostate cancer, remains challenging. The mechanisms of action of ATP binding cassette subfamily C member 5 (ABCC5) in prostate cancer and its relationship with drug resistance are still unclear. Expression and prognostic analyses of ABCC5 were performed through bioinformatic methods and immunohistochemistry analyses in multiple public databases as well as in our own prostate cancer cohort. The biological function of ABCC5 in prostate cancer cells was evaluated by <i>in vitro</i> and <i>in vivo</i> cell proliferation and migration and invasion assays. The regulation of CDK1 by ABCC5 was determined via RT-qPCR, western blots, and immunofluorescence. ABCC5 was significantly overexpressed in prostate cancer and positively associated with unfavorable clinicopathological features and prognosis. Upregulation of ABCC5 could enhance the cell proliferation, migration, and invasion of prostate cancer <i>in vitro</i> and <i>in vivo</i>. Mechanistically, ABCC5 exerts a protumor effect by binding to and inhibiting the protein degradation of CDK1, which promotes the phosphorylation of AR at Ser81 by CDK1 and activates the transcriptional activity of AR on target genes. Moreover, the addition of a CDK1 inhibitor or knockdown of CDK1 significantly improved the efficacy of enzalutamide on prostate cancer cells. The ABCC5-CDK1-AR regulatory pathway could be a potential therapeutic target for advanced prostate cancer, especially castration-resistant prostate cancer (CRPC), to enhance the therapeutic effect of enzalutamide.</p> ]]></description>  
<dc:creator>Guangjie Ji, Shiming He, Cong Huang, Yanqing Gong, Xuesong Li, Liqun Zhou</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>7</prism:number> 
<prism:startingPage>1613</prism:startingPage> 
<prism:endingPage>1628</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1600.htm</link> 
<title>From impossible to possible: the lessons from the control of recent COVID-19 outbreaks in China</title> 
<description><![CDATA[ <p>The COVID-19 pandemic has catastrophically impacted the world. Before the success in vaccination, this virus shows no sign of stop spreading. Nearly all the countries have implemented stringent approaches to slow down the transmission of the virus, but the virus still caused over 2 million deaths and the number is increasing. Therefore, preventing the virus spreading is still necessary to protect most people, especially the ones with pre-conditions. Mainland China has successfully eradicated the COVID-19 virus infection in Wuhan in 2020. After that, several small-scale outbreaks occurred in many cities in China, but none of these COVID-19 virus infections caused the widespread. In this review, we would like to give a detailed presentation of the approaches that were implemented by the China government to suppress the virus spreading by considering the unique characteristics of this virus and the paths of the virus transmission. Both the pros and cons of these strategies will also be analyzed. The experiences and lessons learned during the virus-fighting in China, expectedly, will be a useful source of reference for other regions in overcoming the threat caused by the COVID-19 virus.</p> ]]></description>  
<dc:creator>Lixin Tai, Kengieng Wong, Li Wang, Li-jun Di</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1600</prism:startingPage> 
<prism:endingPage>1612</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1588.htm</link> 
<title>Global landscape of patents related to human coronaviruses</title> 
<description><![CDATA[ <p>At present, the COVID-19 pandemic is running rampant, having caused 2.18 million deaths. Characterizing the global patent landscape of coronaviruses is essential not only for informing research and policy, given the current pandemic crisis, but also for anticipating important future developments. While patents are a promising indicator of technological knowledge production widely used in innovation research, they are often an underused resource in biological sciences. In this study, we present a patent landscape for the seven coronaviruses known to infect humans. The information included in this paper provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines along with a deeper discussion of intellectual property rights under epidemic conditions. The results show that there has been a rapid increase in human coronavirus patents, especially COVID-19 patents. China and the United States play an outstanding role in global cooperation and patent application. The leading role of academic institutions and government is increasingly apparent. Notable technological issues related to human coronaviruses include pharmacochemical treatment, diagnosis of viral infection, viral-vector vaccines, and traditional Chinese medicine. Furthermore, a critical challenge lies in balancing commercial competition, enterprise profit, knowledge sharing, and public interest.</p> ]]></description>  
<dc:creator>Kunmeng Liu, Zixuan Gu, Md Sahidul Islam, Thomas Scherngell, Xiangjun Kong, Jing Zhao, Xin Chen, Yuanjia Hu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1588</prism:startingPage> 
<prism:endingPage>1599</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1581.htm</link> 
<title>Artificial intelligence in the diagnosis of COVID-19: challenges and perspectives</title> 
<description><![CDATA[ <p>Artificial intelligence (AI) is being used to aid in various aspects of the COVID-19 crisis, including epidemiology, molecular research and drug development, medical diagnosis and treatment, and socioeconomics. The association of AI and COVID-19 can accelerate to rapidly diagnose positive patients. To learn the dynamics of a pandemic with relevance to AI, we search the literature using the different academic databases (PubMed, PubMed Central, Scopus, Google Scholar) and preprint servers (bioRxiv, medRxiv, arXiv). In the present review, we address the clinical applications of machine learning and deep learning, including clinical characteristics, electronic medical records, medical images (CT, X-ray, ultrasound images, etc.) in the COVID-19 diagnosis. The current challenges and future perspectives provided in this review can be used to direct an ideal deployment of AI technology in a pandemic.</p> ]]></description>  
<dc:creator>Shigao Huang, Jie Yang, Simon Fong, Qi Zhao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1581</prism:startingPage> 
<prism:endingPage>1587</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1574.htm</link> 
<title>Construction and applications of SARS-CoV-2 pseudoviruses: a mini review</title> 
<description><![CDATA[ <p>The ongoing coronavirus disease 2019 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a serious threat to global public health and social stability. There is an urgent need for understanding the nature and infection mechanism of the virus. Owing to its high infectivity and pathogenicity and lack of effective treatments, live SARS-CoV-2 has to be handled in biosafety level 3 laboratories, which has impeded research into SARS-CoV-2 and the development of vaccines and therapeutics. Pseudotyped viruses that lack certain gene sequences of the virulent virus are safer and can be investigated in biosafety level 2 laboratories, providing a useful virological tool for the study of SARS-CoV-2. In this review, we will discuss the construction of SARS-CoV-2 pseudoviruses based on different packaging systems, current applications, limitations, and further explorations.</p> ]]></description>  
<dc:creator>Minghai Chen, Xian-En Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1574</prism:startingPage> 
<prism:endingPage>1580</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1565.htm</link> 
<title>Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients</title> 
<description><![CDATA[ <p>Dysregulated immune response and abnormal repairment could cause secondary pulmonary fibrosis of varying severity in COVID-19, especially for the elders. The Krebs Von den Lungen-6 (KL-6) as a sensitive marker reflects the degree of fibrosis and this study will focus on analyzing the evaluative efficacy and predictive role of KL-6 in COVID-19 secondary pulmonary fibrosis. The study lasted more than three months and included total 289 COVID-19 patients who were divided into moderate (n=226) and severe groups (n=63) according to the severity of illness. Clinical information such as inflammation indicators, radiological results and lung function tests were collected. The time points of nucleic acid test were also recorded. Furthermore, based on Chest radiology detection, it was identified that 80 (27.7%) patients developed reversible pulmonary fibrosis and 34 (11.8%) patients developed irreversible pulmonary fibrosis. Receiver operating characteristic (ROC) curve analysis shows that KL-6 could diagnose the severity of COVID-19 (AUC=0.862) and predict the occurrence of pulmonary fibrosis (AUC = 0.741) and irreversible pulmonary fibrosis (AUC=0.872). Importantly, the cross-correlation analysis demonstrates that KL-6 rises earlier than the development of lung radiology fibrosis, thus also illuminating the predictive function of KL-6. We set specific values (505U/mL and 674U/mL) for KL-6 in order to assess the risk of pulmonary fibrosis after SARS-CoV-2 infection. The survival curves for days in hospital show that the higher the KL-6 levels, the longer the hospital stay (P&#60;0.0001). In conclusion, KL-6 could be used as an important predictor to evaluate the secondary pulmonary fibrosis degree for COVID-19.</p> ]]></description>  
<dc:creator>Mingshan Xue, Teng Zhang, Hao Chen, Yifeng Zeng, Runpei Lin, Yingjie Zhen, Ning Li, Zhifeng Huang, Haisheng Hu, Luqian Zhou, Hui Wang, Xiaohua Douglas Zhang, Baoqing Sun</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1565</prism:startingPage> 
<prism:endingPage>1573</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1555.htm</link> 
<title>In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor</title> 
<description><![CDATA[ <p>The Coronavirus Disease 2019 (COVID-19) pandemic caused by the novel lineage B betacoroanvirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality, morbidity, and socioeconomic disruptions worldwide. Effective antivirals are urgently needed for COVID-19. The main protease (M<sup>pro</sup>) of SARS-CoV-2 is an attractive antiviral target because of its essential role in the cleavage of the viral polypeptide. In this study, we performed an <i>in silico</i> structure-based screening of a large chemical library to identify potential SARS-CoV-2 M<sup>pro</sup> inhibitors. Among 8,820 compounds in the library, our screening identified trichostatin A, a histone deacetylase inhibitor and an antifungal compound, as an inhibitor of SARS-CoV-2 M<sup>pro</sup> activity and replication. The half maximal effective concentration of trichostatin A against SARS-CoV-2 replication was 1.5 to 2.7&#181;M, which was markedly below its 50% effective cytotoxic concentration (75.7&#181;M) and peak serum concentration (132&#181;M). Further drug compound optimization to develop more stable analogues with longer half-lives should be performed. This structure-based drug discovery platform should facilitate the identification of additional enzyme inhibitors of SARS-CoV-2.</p> ]]></description>  
<dc:creator>Lei Wen, Kaiming Tang, Kenn Ka-Heng Chik, Chris Chun-Yiu Chan, Jessica Oi-Ling Tsang, Ronghui Liang, Jianli Cao, Yaoqiang Huang, Cuiting Luo, Jian-Piao Cai, Zi-Wei Ye, Feifei Yin, Hin Chu, Dong-Yan Jin, Kwok-Yung Yuen, Shuofeng Yuan, Jasper Fuk-Woo Chan</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1555</prism:startingPage> 
<prism:endingPage>1564</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1547.htm</link> 
<title>SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3</title> 
<description><![CDATA[ <p>Suppression of type I interferon (IFN) response is one pathological outcome of the infection of highly pathogenic human coronaviruses. To effect this, severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 encode multiple IFN antagonists. In this study, we reported on the IFN antagonism of SARS-CoV-2 main protease NSP5. NSP5 proteins of both SARS-CoV and SARS-CoV-2 counteracted Sendai virus-induced IFN production. NSP5 variants G15S and K90R commonly seen in circulating strains of SARS-CoV-2 retained the IFN-antagonizing property. The suppressive effect of NSP5 on IFN-&#946; gene transcription induced by RIG-I, MAVS, TBK1 and IKK&#1013; suggested that NSP5 likely acts at a step downstream of IRF3 phosphorylation in the cytoplasm. NSP5 did not influence steady-state expression or phosphorylation of IRF3, suggesting that IRF3, regardless of its phosphorylation state, might not be the substrate of NSP5 protease. However, nuclear translocation of phosphorylated IRF3 was severely compromised in NSP5-expressing cells. Taken together, our work revealed a new mechanism by which NSP5 proteins encoded by SARS-CoV and SARS-CoV-2 antagonize IFN production by retaining phosphorylated IRF3 in the cytoplasm. Our findings have implications in rational design and development of antiviral agents against SARS-CoV-2.</p> ]]></description>  
<dc:creator>Sin-Yee Fung, Kam-Leung Siu, Huayue Lin, Man Lung Yeung, Dong-Yan Jin</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1547</prism:startingPage> 
<prism:endingPage>1554</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1538.htm</link> 
<title>Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery</title> 
<description><![CDATA[ <p>The outbreak of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic. One major challenge in the battle against this deadly disease is to find effective therapy. Due to the availability and proven clinical record of hydroxychloroquine (HCQ) and chloroquine (CQ) in various human diseases, there have been enormous efforts in repurposing these two drugs as therapeutics for COVID-19. To date, substantial amount of work at cellular, animal models and clinical trials have been performed to verify their therapeutic potential against COVID-19. However, neither lab-based studies nor clinical trials have provided consistent and convincing evidence to support the therapeutic value of HCQ/CQ in the treatment of COVID-19. In this mini review we provide a systematic summary on this important topic and aim to reveal some truth covered by the mystery regarding the therapeutic value of HCQ/CQ in COVID-19.</p> ]]></description>  
<dc:creator>Yao Chen, Mei-Xiu Li, Guo-Dong Lu, Han-Ming Shen, Jing Zhou</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1538</prism:startingPage> 
<prism:endingPage>1546</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1530.htm</link> 
<title>Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers</title> 
<description><![CDATA[ <p>Glucocorticoids are important steroid hormones. As an outstanding scientific discovery, the scientist who discovered glucocorticoids was awarded the Nobel Prize in Physiology and Medicine in 1950. Cortisone (hydrocortisone) is a natural glucocorticoid, which is secreted with circadian rhythm by the cortical cells of adrenal glands. Physiologically, about 10-20 mg of hydrocortisone are secreted each day for maintaining homeostasis. Since the biological half-life of natural glucocorticoid is short, scientists developed various synthetic glucocorticoids including prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, betamethasone, and so on. These synthetic glucocorticoids are generated by modifying some structures based on the cortisone backbone, leading to extension of their biological half-life with stronger activities. In the face of severe infection, allergy, shock, trauma, pain, and other stresses, the demand for glucocorticoids increases dramatically. It is critical to supplement extra glucocorticoids to protect the biological functions of vital organs. However, the amount and duration of glucocorticoid administration need to be carefully adjusted, because a series of side effects may occur after long-term or high-dose usage of glucocorticoids. This review article will discuss the application of glucocorticoids in the treatment of patients with severe or critical COVID-19 and solid tumors of advanced stage. The controversy of using glucocorticoid in medical community will also be discussed. This review article will help doctors and basic researchers better understand the practical application of glucocorticoids.</p> ]]></description>  
<dc:creator>Ruixin Yang, Yingyan Yu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1530</prism:startingPage> 
<prism:endingPage>1537</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1521.htm</link> 
<title>Developing effective siRNAs to reduce the expression of key viral genes of COVID-19</title> 
<description><![CDATA[ <p>The COVID-19 pandemic has been raging worldwide for more than a year. Many efforts have been made to create vaccines and develop new antiviral drugs to cope with the disease. Here, we propose the application of short interfering RNAs (siRNAs) to degrade the viral genome, thus reducing viral infection. By introducing the concept of the probability of binding efficiency (PBE) and combining the secondary structures of RNA molecules, we designed 11 siRNAs that target the consensus regions of three key viral genes: the spike (S), nucleocapsid (N) and membrane (M) genes of SARS-CoV-2. The silencing efficiencies of the siRNAs were determined in human lung and endothelial cells overexpressing these viral genes. The results suggested that most of the siRNAs could significantly reduce the expression of the viral genes with inhibition rates above 50% in 24 hours. This work not only provides a strategy for designing potentially effective siRNAs against target genes but also validates several potent siRNAs that can be used in the clinical development of preventative medication for COVID-19 in the future.</p> ]]></description>  
<dc:creator>Renfei Wu, Kathy Qian Luo</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1521</prism:startingPage> 
<prism:endingPage>1529</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1507.htm</link> 
<title>The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment</title> 
<description><![CDATA[ <p>The severe cases of Coronavirus Disease 2019 (COVID-19) frequently exhibit excessive inflammatory responses, acute respiratory distress syndrome (ARDS), coagulopathy, and organ damage. The most striking immunopathology of advanced COVID-19 is cytokine release syndrome or &#8220;cytokine storm&#8221; that is attributable to the deficiencies in immune regulatory mechanisms. CD4<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells (Tregs) are central regulators of immune responses and play an indispensable role in the maintenance of immune homeostasis. Tregs are likely involved in the attenuation of antiviral defense at the early stage of infection and ameliorating inflammation-induced organ injury at the late stage of COVID-19. In this article, we review and summarize the current understanding of the change of Tregs in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss the potential role of Tregs in the immunopathology of COVID-19. The emerging concept of Treg-targeted therapies, including both adoptive Treg transfer and low dose of IL-2 treatment, is introduced. Furthermore, the potential Treg-boosting effect of therapeutic agents used in the treatment of COVID-19, including dexamethasone, vitamin D, tocilizumab and sarilumab, chloroquine, hydroxychloroquine, azithromycin, adalimumab and tetrandrine, is discussed. The problems in the current study of Treg cells in COVID-19 and future perspectives are also addressed.</p> ]]></description>  
<dc:creator>Yifei Wang, Jingbin Zheng, Md Sahidul Islam, Yang Yang, Yuanjia Hu, Xin Chen</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1507</prism:startingPage> 
<prism:endingPage>1520</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1497.htm</link> 
<title>Inflammatory stress in SARS-COV-2 associated Acute Kidney Injury</title> 
<description><![CDATA[ <p>Increasing clinical evidence shows that acute kidney injury (AKI) is a common and severe complication in critically ill COVID-19 patients. The older age, the severity of COVID-19 infection, the ethnicity, and the history of smoking, diabetes, hypertension, and cardiovascular disease are the risk factor for AKI in COVID-19 patients. Of them, inflammation may be a key player in the pathogenesis of AKI in patients with COVID-19. It is highly possible that SARS-COV-2 infection may trigger the activation of multiple inflammatory pathways including angiotensin II, cytokine storm such as interleukin-6 (IL-6), C-reactive protein (CRP), TGF-&#946; signaling, complement activation, and lung-kidney crosstalk to cause AKI. Thus, treatments by targeting these inflammatory molecules and pathways with a monoclonal antibody against IL-6 (Tocilizumab), C3 inhibitor AMY-101, anti-C5 antibody, anti-TGF-&#946; OT-101, and the use of CRRT in critically ill patients may represent as novel and specific therapies for AKI in COVID-19 patients.</p> ]]></description>  
<dc:creator>Junzhe Chen, Wenbiao Wang, Ying Tang, Xiao-ru Huang, Xueqing Yu, Hui-Yao Lan</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1497</prism:startingPage> 
<prism:endingPage>1506</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1486.htm</link> 
<title>Development and application of therapeutic antibodies against COVID-19</title> 
<description><![CDATA[ <p>The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis. Fundamental studies at genome, transcriptome, proteome, and interactome levels have revealed many viral and host targets for therapeutic interventions. Hundreds of antibodies for treating COVID-19 have been developed at preclinical and clinical stages in the format of polyclonal antibodies, monoclonal antibodies, and cocktail antibodies. Four products, <i>i.e.</i>, convalescent plasma, bamlanivimab, REGN-Cov2, and the cocktail of bamlanivimab and etesevimab have been authorized by the U.S. Food and Drug Administration (FDA) for emergency use. Hundreds of relevant clinical trials are ongoing worldwide. Therapeutic antibody therapies have been a very active and crucial part of COVID-19 treatment. In this review, we focus on the progress of therapeutic COVID-19 antibody development and application, discuss corresponding problems and challenges, suggesting new strategies and solutions.</p> ]]></description>  
<dc:creator>Lin Ning, Hamza B. Abagna, Qianhu Jiang, Siqi Liu, Jian Huang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1486</prism:startingPage> 
<prism:endingPage>1496</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1476.htm</link> 
<title>The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?</title> 
<description><![CDATA[ <p>The pandemic of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is far from being controlled despite the great effort that have been taken throughout the world. Herd immunity through vaccination is our major expectation to rein the virus. However, the emergence of widespread genetic variants could potentially undermine the vaccines. The evidence that some variants could evade immune responses elicited by vaccines and previous infection is growing. In this review, we summarized the current understanding on five notable genetic variants, i.e., D614G, Cluster 5, VOC 202012/01, 501Y.V2 and P.1, and discussed the potential impact of these variants on the virus transmission, pathogenesis and vaccine efficacy. We also highlight that mutations in the N-terminal domain of spike protein should be considered when evaluating the antibody neutralization abilities. Among these genetic variants, a concern of genetic variant 501Y.V2 to escape the protection by vaccines was raised. We therefore call for new vaccines targeting this variant to be developed.</p> ]]></description>  
<dc:creator>Shuxin Guo, Kefang Liu, Jun Zheng</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1476</prism:startingPage> 
<prism:endingPage>1485</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1469.htm</link> 
<title>Attitudes toward COVID-19 vaccines in Chinese college students</title> 
<description><![CDATA[ <p><b>Background:</b> Vaccination is an important preventative measure against the coronavirus disease 19 (COVID-19) pandemic. To implement vaccination and immunization programs effectively, it is essential to investigate public attitudes toward COVID-19 vaccines. This study examined the attitudes of Chinese college students toward COVID-19 vaccines and its associated factors.</p><p><b>Methods:</b> A cross-sectional study was conducted in college students nationwide from December 27, 2020 to January 18, 2021. Attitudes toward the COVID-19 vaccines and acceptance of future vaccination programs were assessed.</p><p><b>Results:</b> Totally, 2,781 college students participated in this survey; of them, 76.3% (95% CI: 74.8% - 77.9%) were willing to accept a COVID-19 vaccine in future. Multiple logistic analysis revealed that students living in urban (OR=1.409, 95% CI: 1.152 - 1.724, p=0.001) and those studying health-related courses (OR=1.581, 95% CI: 1.291 - 1.935, p&#60;0.001) were more likely to have a positive attitude toward COVID-19 vaccines. In addition, those who were worried about being infected with COVID-19 (very much vs no, OR=1.690, 95% CI: 1.212-2.356, p=0.002), heard previously about COVID-19 vaccines (OR=1.659, 95% CI: 1.268-2.170, p&#60;0.001), believed that vaccines are safe (Yes vs No, OR=3.570, 95% CI: 1.825-6.980), thought that vaccines can protect people from being infected with COVID-19 (Yes vs No, OR=1.957, 95% CI: 1.286-2.979, p=0.002), and had encouraged their family and friends to have a vaccine (Yes vs No, OR=17.745, 95% CI: 12.271-25.660, p&#60;0.001) had higher acceptance of COVID-19 vaccination.</p><p><b>Conclusions:</b> A high rate of acceptance of COVID-19 vaccines was found among Chinese college students. However, vaccine uptake may be reduced by concerns about vaccine safety and efficacy. Alleviating these concerns and enhancing public confidence in vaccines are crucial for future immunization programs against the COVID-19 pandemic.</p> ]]></description>  
<dc:creator>Wei Bai, Hong Cai, Shou Liu, Huanzhong Liu, Han Qi, Xu Chen, Rui Liu, Teris Cheung, Zhaohui Su, Chee H. Ng, Yu-Tao Xiang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1469</prism:startingPage> 
<prism:endingPage>1475</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1461.htm</link> 
<title>Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces</title> 
<description><![CDATA[ <p>A year after the initial outbreak of Covid-19 pandemic, several Phase III clinical trials investigating vaccine safety and efficacy have been published. These vaccine candidates were developed by different research groups and pharmaceutical companies with various vaccine technologies including mRNA, recombinant protein, adenoviral vector and inactivated virus-based platforms. Despite numerous successful clinical trials, participants enrolled in these trials are limited by trial inclusion and exclusion criteria, geographic location and viral outbreak situation. Many questions still remain, especially for specific subgroups, including the elderly, females with pregnancy and breastfeeding status, and adolescents. At the same time, vaccine efficacy towards asymptomatic infection and specific viral variants are still largely unknown. This review will cover vaccine candidates with Phase III clinical trial data released and discuss the scientific data available so far for these vaccine candidates for different subgroups of people and different viral variants.</p> ]]></description>  
<dc:creator>Hang Fai Kwok</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1461</prism:startingPage> 
<prism:endingPage>1468</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1446.htm</link> 
<title>mRNA vaccines for COVID-19: what, why and how</title> 
<description><![CDATA[ <p>The Coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2), has impacted human lives in the most profound ways with millions of infections and deaths. Scientists and pharmaceutical companies have been in race to produce vaccines against SARS-CoV-2. Vaccine generation usually demands years of developing and testing for efficacy and safety. However, it only took less than one year to generate two mRNA vaccines from their development to deployment. The rapid production time, cost-effectiveness, versatility in vaccine design, and clinically proven ability to induce cellular and humoral immune response have crowned mRNA vaccines with spotlights as most promising vaccine candidates in the fight against the pandemic. In this review, we discuss the general principles of mRNA vaccine design and working mechanisms of the vaccines, and provide an up-to-date summary of pre-clinical and clinical trials on seven anti-COVID-19 mRNA candidate vaccines, with the focus on the two mRNA vaccines already licensed for vaccination. In addition, we highlight the key strategies in designing mRNA vaccines to maximize the expression of immunogens and avoid intrinsic innate immune response. We also provide some perspective for future vaccine development against COVID-19 and other pathogens.</p> ]]></description>  
<dc:creator>Jung Woo Park, Philip N.P. Lagniton, Yu Liu, Ren-He Xu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1446</prism:startingPage> 
<prism:endingPage>1460</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1443.htm</link> 
<title>Should people with severe mental illness be prioritized for the COVID-19 vaccination?</title> 
<description><![CDATA[ <p>The coronavirus disease-19 (COVID-19) has spread throughout the world, affecting many vulnerable populations including patients with severe mental illness (SMI). Recent studies have found that patients with SMI compared to the general population could have a greater risk of morbidity and mortality from COVID-19 due to cognitive impairment, poor awareness of risk, and difficulties in complying with infection control measures. Although some researchers have suggested that patients with SMI should be prioritized for COVID-19 vaccination to reduce the risk of infection, this issue remains controversial.</p> ]]></description>  
<dc:creator>Yuan Yang, Wen Li, Qinge Zhang, Ling Zhang, Teris Cheung, Chee H Ng, Yu-Tao Xiang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1443</prism:startingPage> 
<prism:endingPage>1445</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Commentary</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1440.htm</link> 
<title>The continued global battle against SARS-CoV-2 and COVID-19</title> 
<description><![CDATA[  ]]></description>  
<dc:creator>Chu-Xia Deng</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>1440</prism:startingPage> 
<prism:endingPage>1442</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Editorial</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1428.htm</link> 
<title>Promising diagnostic and therapeutic circRNAs for skeletal and chondral disorders</title> 
<description><![CDATA[ <p>Circular RNAs (circRNAs) belong to a highly conserved subtype of non-coding RNAs, produced by the back-splicing of specific regions of pre-mRNA. CircRNAs have wide-ranging effects on eukaryotic physiology and pathology by acting as transcription regulators, miRNA sponges, protein sponges, and templates for translation. Skeletal and chondral disorders are the leading causes of pain and disability, especially for elders, affecting hundreds of millions of people worldwide. Plenty of evidence have shown that circRNAs are dysregulated and play vital roles in the occurrence and progression of skeletal and chondral disorders. Herein, we systematically summarize the emerging roles and underlying molecular mechanisms of hub circRNAs in the pathogenesis of several representative skeletal and chondral disorders. Our findings may provide further insight into the mechanistic details of the role of circRNA in bone or cartilage metabolism, and highlight the promising application of circRNAs in serving as potential diagnostic or therapeutic targets for the prevention and treatment of skeletal and chondral disorders.</p> ]]></description>  
<dc:creator>Gaoyang Chen, Wanze Tang, Shang Wang, Canling Long, Xiaoqin He, Dazhi Yang, Songlin Peng</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1428</prism:startingPage> 
<prism:endingPage>1439</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1413.htm</link> 
<title>Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity</title> 
<description><![CDATA[ <p>In this study, we aimed to use ESTIMATE and CIBERSORT computational methods to analyse transcriptional information on COAD and STAD in TCGA. We downloaded transcriptome RNA-seq data of 446 patients with colon cancer from TCGA and estimated the amount of immune and stromal components in the COAD samples using CIBERSORT algorithms. We analysed differentially expressed genes in 446 TCGA samples and 585 Series GSE39582 samples, in high- and low-scoring groups, using Cox regression. The expression of <i>LRRC4C</i>, correlated positively with clinicopathological characteristics and negatively with the survival of patients with COAD. Single-gene survival analysis using Gene Expression Profiling Interactive Analysis 2.0 and Kaplan-Meier plotter revealed an association between high levels of <i>LRRC4C</i> expression and poor prognosis in patients with colon and gastric cancers. Gene set enrichment analysis of COAD and STAD samples indicated that genes in groups expressing high and low <i>LRRC4C</i> levels were mainly enriched in immune-related activities and metabolic pathways, respectively. Difference and correlation analyses of the relationship between <i>LRRC4C</i> expression and tumour-infiltrating immune cells, determined using CIBERSORT algorithms, revealed that monocytes, resting mast cells, and M2 macrophages were positively correlated with <i>LRRC4C</i> expression.</p> ]]></description>  
<dc:creator>XiaoFeng Yang, Purun Lei, Lijun Huang, Xiao Tang, Bo Wei, HongBo Wei</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1413</prism:startingPage> 
<prism:endingPage>1427</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1395.htm</link> 
<title>Moderate mechanical stimulation rescues degenerative annulus fibrosus by suppressing caveolin-1 mediated pro-inflammatory signaling pathway</title> 
<description><![CDATA[ <p>Mechanical loading can induce or antagonize the extracellular matrix (ECM) synthesis, proliferation, migration, and inflammatory responses of annulus fibrosus cells (AFCs), depending on the loading mode and level. Caveolin-1 (Cav1), the core protein of caveolae, plays an important role in cellular mechanotransduction and inflammatory responses. In the present study, we presented that AFCs demonstrated different behaviors when subjected to cyclic tensile strain (CTS) for 24 h at a magnitude of 0%, 2%, 5% and 12%, respectively. It was found that 5% CTS had positive effects on cell proliferation, migration and anabolism, while 12% CTS had the opposite effects. Besides, cells exposed to interleukin-1&#946; stimulus exhibited an increase expression in inflammatory genes, and the expression of these genes decreased after exposure to moderate mechanical loading with 5% CTS. In addition, 5% CTS decreased the level of Cav1 and integrin &#946;1 and exhibited anti-inflammatory effects. Moreover, the expression of integrin &#946;1 and p-p65 increased in AFCs transfected with Cav1 plasmids. <i>In vivo</i> results revealed that moderate mechanical stimulation could recover the water content and morphology of the discs. In conclusion, moderate mechanical stimulation restrained Cav1-mediated signaling pathway and exhibited anti-inflammatory effects on AFCs. Together with <i>in vivo</i> results, this study expounds the underlying molecular mechanisms on the effect of moderate mechanical stimulation on intervertebral discs (IVDs) and may provide a new therapeutic strategy for the treatment of IVD degeneration.</p> ]]></description>  
<dc:creator>Weidong Zhang, Huan Wang, Zhangqin Yuan, Genglei Chu, Heng Sun, Zilin Yu, Huan Liang, Tao Liu, Feng Zhou, Bin Li</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1395</prism:startingPage> 
<prism:endingPage>1412</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1382.htm</link> 
<title>Inhibition of Sirtuin 3 prevents titanium particle-induced bone resorption and osteoclastsogenesis via suppressing ERK and JNK signaling</title> 
<description><![CDATA[ <p>Implant-derived wear particles can be phagocytosed by local macrophages, triggering an inflammatory cascade that can drive the activation and recruitment of osteoclasts, thereby inducing peri-prosthetic osteolysis. Efforts to suppress pro-inflammatory cytokine release and osteoclastsogenesis thus represent primary approaches to treating and preventing such osteolysis. Sirtuin 3 (SIRT3) is a NAD<sup>+</sup>-dependent deacetylases that control diverse metabolic processes. However, whether SIRT3 could mitigate wear debris-induced osteolysis has not been reported. Herein we explored the impact of the SIRT3 on titanium particle-induced osteolysis. Tartrate resistant acid phosphatase (TRAP) staining revealed that the inhibition of SIRT3 suppressed nuclear factor-&#954;B ligand (RANKL)-mediated osteoclasts activation in a dose-dependent fashion. Notably, inhibition of SIRT3 also suppressed matrix metallopeptidase 9 (MMP9) and nuclear factor of activated T&#8208;cell cytoplasmic 1 (NFATc1) expression at the mRNA and protein levels, while also inhibiting the mRNA expression of dendritic cell-specific transmembrane protein (DC-STAMP), ATPase H<sup>+</sup> Transporting V0 Subunit D2 (Atp6v0d2), TRAP and Cathepsin K (CTSK) . In addition, inhibition of SIRT3 suppressed titanium particle-induced tumor necrosis factor-alpha (TNF-&#945;), interleukin-1&#946; (IL-1&#946;) and interleukin-6 (IL-6) expression and prevented titanium particle-induced osteolysis and bone loss <i>in vivo</i>. This inhibition of osteoclasts differentiation was found to be linked to the downregulation and reduced phosphorylation of JNK and ERK. Taken together, inhibition of SIRT3 may be a potential target for titanium particle-induced bone loss.</p> ]]></description>  
<dc:creator>Ning Li, Xiaoping Li, Kai Zheng, Jiaxiang Bai, Weicheng Zhang, Houyi Sun, Gaoran Ge, Wei Wang, Zhen Wang, Ye Gu, Yi Xue, Yaozeng Xu, Dechun Geng, Jun Zhou</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1382</prism:startingPage> 
<prism:endingPage>1394</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1361.htm</link> 
<title>Application of phototherapeutic-based nanoparticles in colorectal cancer</title> 
<description><![CDATA[ <p>Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer death, which accounts for approximately 10% of all new cancer cases worldwide. Surgery is the main method for treatment of early-stage CRC. However, it is not effective for most metastatic tumors, and new treatment and diagnosis strategies need to be developed. Photosensitizers (PSs) play an important role in the treatment of CRC. Phototherapy also has a broad prospect in the treatment of CRC because of its low invasiveness and low toxicity. However, most PSs are associated with limitations including poor solubility, poor selectivity and high toxicity. The application of nanomaterials in PSs has added many advantages, including increased solubility, bioavailability, targeting, stability and low toxicity. In this review, based on phototherapy, we discuss the characteristics and development progress of PSs, the targeting of PSs at organ, cell and molecular levels, and the current methods of optimizing PSs, especially the application of nanoparticles as carriers in CRC. We introduce the photosensitizer (PS) targeting process in photodynamic therapy (PDT), the damage mechanism of PDT, and the application of classic PS in CRC. The action process and damage mechanism of photothermal therapy (PTT) and the types of ablation agents. In addition, we present the imaging examination and the application of PDT / PTT in tumor, including (fluorescence imaging, photoacoustic imaging, nuclear magnetic resonance imaging, nuclear imaging) to provide the basis for the early diagnosis of CRC. Notably, single phototherapy has several limitations <i>in vivo</i>, especially for deep tumors. Here, we discuss the advantages of the combination therapy of PDT and PTT compared with the single therapy. At the same time, this review summarizes the clinical application of PS in CRC. Although a variety of nanomaterials are in the research and development stage, few of them are actually on the market, they will show great advantages in the treatment of CRC in the near future.</p> ]]></description>  
<dc:creator>Jiaxin Yan, Chunli Wang, Xiaomei Jiang, Yiqu Wei, Qun Wang, Kunli Cui, Xiao Xu, Feng Wang, Lei Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1361</prism:startingPage> 
<prism:endingPage>1381</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1353.htm</link> 
<title>IKKe in osteoclast inhibits the progression of methylprednisolone-induced osteonecrosis</title> 
<description><![CDATA[ <p>Previous studies have described that NF-&#954;B signaling mediated by NF&#954;B-inducing kinase (NIK) plays a critical role of the differentiation of osteoclasts. We aim to explore the role of IKKe in methylprednisolone -induced osteonecrosis of the femoral head (ONFH). Methylprednisolone-induced ONFH mice model was successfully established, and subjected to micro computed tomography to detect the femoral head image of the mice. Bone marrow cells from experimental mice were collected and cultured. qPCR and immunoblot were performed to examine the possible signal pathways of IKKe involvement, and osteoclast-related gene expressions in IKKe<sup>+/+</sup> and IKKe<sup>-/-</sup> cells <i>in vitro</i> and <i>in vivo</i> were examined. It was found that the levels of IKKe decreased in ONFH patients, and IKKe interacted with NIK in the NF-&#954;B signal pathway to suppress osteoclasts <i>via</i> inhibiting the transcription of NIK. Furthermore, IKKe knockout promoted the osteoclastogenesis in mice model. Finally, IKKe knockout suppressed methylprednisolone-induced ONFH and pro-inflammatory responses in mice model. Our findings show a mechanism of IKKe inhibition of the progression of methylprednisolone-induced ONFH via the NIK/NF-&#954;B pathway.</p> ]]></description>  
<dc:creator>Yingjie Liu, Haojie Shan, Yang Zong, Yiwei Lin, Wenyang Xia, Nan Wang, Lihui Zhou, Youshui Gao, Xin Ma, Chaolai Jiang, Xiaowei Yu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1353</prism:startingPage> 
<prism:endingPage>1360</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1339.htm</link> 
<title>Peripheral Macrophage-derived Exosomes promote repair after Spinal Cord Injury by inducing Local Anti-inflammatory type Microglial Polarization via Increasing Autophagy</title> 
<description><![CDATA[ <p>Treatment for spinal cord injury (SCI) remains a challenge worldwide, and inflammation is a major cause of secondary injury after SCI. Peripheral macrophages (PMs) have been verified as a key factor that exert anti-inflammatory effects after SCI, but the mechanism is unidentified. As local macrophages, microglia also exert significant effects after SCI, especially polarization. Exosomes show source cell-like biological functions to target cells and have been the subject of much research in recent years. Thus, we hypothesized the PM-derived exosomes (PM-Exos) play an important role in signal transmission with local microglia and can be used therapeutic agents for SCI in a series of <i>in vivo</i> and <i>in vitro</i> studies. For the <i>in vivo</i> experiment, three groups of Sprague-Dawley (SD) rats subjected to spinal cord contusion injury were injected with 200 &#181;g/ml PM-Exos, 20 &#181;g/ml PM-Exos or PBS via the tail vein. Recovery of the rats and of spinal cord function were observed. <i>In vitro</i>, we investigated the potential anti-inflammatory mechanism of PM-Exos and evaluated microglial autophagy, anti-inflammatory type microglia polarization and the upstream signaling pathway. The results showed that spinal cord function and recovery were better in the PM-Exo groups than the control group. In the <i>in vitro</i> study, microglial autophagy levels and the expression of anti-inflammatory type microglia were higher in the experimental groups than the control group. Moreover, the expression of proteins related to the PI3K/AKT/mTOR autophagic signaling pathway was suppressed in the PM-Exo groups. PM-Exos have a beneficial effect in SCI, and activation of microglial autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway, enhancing the polarization of anti-inflammatory type microglia, that may play a major role in the anti-inflammatory process.</p> ]]></description>  
<dc:creator>Baokun Zhang, Fangqi Lin, Jiqing Dong, Jingwen Liu, Zhenyu Ding, Jianguang Xu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1339</prism:startingPage> 
<prism:endingPage>1352</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1328.htm</link> 
<title>Potential of exosomes as diagnostic biomarkers and therapeutic carriers for doxorubicin-induced cardiotoxicity</title> 
<description><![CDATA[ <p>Doxorubicin (DOX) is a kind of representative anthracyclines. It has greatly prolonged lifespan of cancer patients. However, a long course of DOX chemotherapy could induce various forms of deaths of cardiomyocytes, such as apoptosis, pyroptosis and ferroptosis, contributing to varieties of cardiac complications called cardiotoxicity. It has become a major concern considering the large number of cancer patients' worldwide and increased survival rates after chemotherapy. Exosomes, a subgroup of extracellular vesicles (EVs), are secreted by nearly all cells and consist of lipid bilayers, nucleic acids and proteins. They can serve as mediators between intercellular communication via the transfer of bioactive molecules from secretory to recipient cells, modulating multiple pathophysiological processes. It has been proven that exosomes in body fluids can serve as biomarkers for doxorubicin-induced cardiotoxicity (DIC). Moreover, exosomes have attracted considerable attention because of their capacity as carriers of certain proteins, genetic materials (miRNA and lncRNA), and chemotherapeutic drugs to decrease the dosage of DOX and alleviate cardiotoxicity. This review briefly describes the characteristics of exosomes and highlights their clinical application potential as diagnostic biomarkers and drug delivery vehicles for DIC, thus providing a strategy for addressing it based on exosomes.</p> ]]></description>  
<dc:creator>Chao Tian, Yanyan Yang, Baochen Bai, Shizhong Wang, Meixin Liu, Rui-Cong Sun, Tao Yu, Xian-ming Chu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1328</prism:startingPage> 
<prism:endingPage>1338</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1315.htm</link> 
<title>PAK5-mediated AIF phosphorylation inhibits its nuclear translocation and promotes breast cancer tumorigenesis</title> 
<description><![CDATA[ <p>Although p21 activated kinase 5 (PAK5) is related to the progression of multiple cancers, its biological function in breast cancer remains unclear. Apoptosis-inducing factor (AIF) is a vital apoptosis factor in mitochondria, which can be released from mitochondria and enter the nucleus, causing caspase-independent apoptosis. In this study, we reveal that PAK5 inhibits apoptosis by preventing the nuclear translocation of AIF. PAK5 inhibits the release of AIF from mitochondria in breast cancer cells by decreasing the mitochondria membrane permeability and increasing the membrane potential. Furthermore, PAK5 phosphorylates AIF at Thr281 site to inhibit the formation of AIF/importin &#945;3 complex, leading to decrease AIF nuclear translocation. Functionally, we demonstrate that PAK5-mediated AIF phosphorylation promotes the proliferation of breast cancer cells and accelerates the growth of breast cancer <i>in vivo</i>. Significantly, PAK5 and AIF expression in breast cancer are positively correlated with poor patient prognosis. PAK5 expression is negatively correlated with AIF nuclear translocation. These results suggest that PAK5-AIF signaling pathway may play an essential role in mammary tumorigenesis, providing a new therapeutic target for the treatment of breast cancer.</p> ]]></description>  
<dc:creator>Yao Xing, Yang Li, Bingtao Hu, Fuyi Han, Xin Zhao, Hongyan Zhang, Yanshu Li, Danni Li, Jiabin Li, Feng Jin, Feng Li</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1315</prism:startingPage> 
<prism:endingPage>1327</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1302.htm</link> 
<title>Aurka deficiency in the intestinal epithelium promotes age-induced obesity via propionate-mediated AKT activation</title> 
<description><![CDATA[ <p>Aurora-A kinase, a serine/threonine mitotic kinase involved in mitosis, is overexpressed in several human cancers. A recent study showed that Aurora-A mediates glucose metabolism via SOX8/FOXK1 in ovarian cancer. However, the roles of Aurora-A in metabolic diseases remain unclear. This study found that <i>Aurka</i> loss in the intestinal epithelium promoted age-induced obesity and enlargement of lipid droplets in parallel with an increase in infiltrated macrophages in the white adipocyte tissue (WAT) of male mice. Moreover, loss of <i>Aurka</i> induced the expression of lipid metabolism regulatory genes, including acetyl-coenzyme A carboxylase 1 (<i>Acc1</i>), in association with an increase in the levels of p-AKT in the intestinal epithelium as well as WAT. Blockade of AKT activation reduced the expression of lipid metabolism regulatory genes. In subsequent experiments, we found that the Firmicutes abundance and the levels of short-chain fatty acids (SCFAs) in the gut were dramatically increased in <i>Aurka<sup>f/+</sup>;Villin<sup>Cre/+</sup></i> mice compared with <i>Aurka<sup>f/+</sup></i> mice. Additionally, propionate increased the phosphorylation of AKT<i> in vitro</i>. These observations indicated that <i>Aurka</i> loss in the intestinal epithelium contributed to gut microbiota dysbiosis and higher levels of SCFAs, especially propionate, leading to AKT activation and lipid metabolism regulatory gene expression, which in turn promoted age-induced obesity.</p> ]]></description>  
<dc:creator>Na Sun, Fandong Meng, Jie Zhao, Xueqin Li, Rongqing Li, Jing Han, Xin Chen, Wanpeng Cheng, Xiaoying Yang, Yanbo Kou, Kuiyang Zheng, Jing Yang, Takayuki Ikezoe</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1302</prism:startingPage> 
<prism:endingPage>1314</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1289.htm</link> 
<title>Enforced expression of miR-92b blunts E. coli lipopolysaccharide-mediated inflammatory injury by activating the PI3K/AKT/&#946;-catenin pathway via targeting PTEN</title> 
<description><![CDATA[ <p>Endometritis is a reproductive disorder characterized by an inflammatory response in the endometrium, which causes significant economic losses to the dairy farming industry. MicroRNAs (miRNAs) are implicated in the inflammatory response and immune regulation following infection by pathogenic bacteria. Recent miRNA microarray analysis showed an altered expression of miR-92b in cows with endometritis. In the present study, we set out to investigate the regulatory mechanism of miR-92b in endometritis. Here, qPCR results first validated that miR-92b was down-regulated during endometritis. And then, bovine endometrial epithelial cells (BEND cells) stimulated by high concentration of lipopolysaccharide (LPS) were employed as an <i>in vitro</i> inflammatory injury model. Our data showed that overexpression of miR-92b significantly suppressed the activation of Toll-like receptor 4 (TLR4) and nuclear factor-&#954;B (NF&#8208;&#954;B) in LPS-stimulated BEND cells, thereby reducing pro-inflammatory cytokines release and inhibiting cell apoptosis. Looking into the molecular mechanisms of regulation of inflammatory injury by miR-92b, we observed that overexpression of miR-92b restrained TLR4/NF&#8208;&#954;B by activating the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT)/&#946;-catenin pathway. Furthermore, the luciferase reporter assay suggested that miR-92b targeted inhibition of phosphatase and tensin homolog (PTEN), an inhibitor of the PI3K/AKT/&#946;-catenin pathway. Importantly, <i>in vivo</i> experiments confirmed that up-regulation of miR-92b attenuated the pathological injury in an experimental murine model of LPS-induced endometritis. Collectively, these findings show that enforced expression of miR-92b alleviates LPS-induced inflammatory injury by activating the PI3K/AKT/&#946;-catenin pathway via targeting PTEN, suggesting a potential application for miR-92b-based therapy to treat endometritis or other inflammatory diseases.</p> ]]></description>  
<dc:creator>Kangfeng Jiang, Jing Yang, Chunlian Song, Fengping He, Liangyu Yang, Xiaobing Li</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1289</prism:startingPage> 
<prism:endingPage>1301</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1277.htm</link> 
<title>SARS-CoV-2-induced Overexpression of miR-4485 Suppresses Osteogenic Differentiation and Impairs Fracture Healing</title> 
<description><![CDATA[ <p>The angiotensin-converting enzyme 2 (ACE2) receptor has been identified as the cell entry point for SARS-CoV-2. Although ACE2 receptors are present in the bone marrow, the effects of SARS-CoV-2 on the biological activity of bone tissue have not yet been elucidated. In the present study we sought to investigate the impact of SARS-CoV-2 on osteoblastic activity in the context of fracture healing. MicroRNA-4485 (miR-4485), which we found to be upregulated in COVID-19 patients, negatively regulates osteogenic differentiation. We demonstrate this effect both <i>in vitro</i> and<i> in vivo</i>. Moreover, we identified the toll-like receptor 4 (TLR-4) as the potential target gene of miR-4485, and showed that reduction of TLR-4 induced by miR-4485 suppresses osteoblastic differentiation <i>in vitro</i>. Taken together, our findings highlight that up-regulation of miR-4485 is responsible for the suppression of osteogenic differentiation in COVID-19 patients, and TLR-4 is the potential target through which miR-4485 acts, providing a promising target for pro-fracture-healing and anti-osteoporosis therapy in COVID-19 patients.</p> ]]></description>  
<dc:creator>Bobin Mi, Yuan Xiong, Chenming Zhang, Wu Zhou, Lang Chen, Faqi Cao, Fenghua Chen, Zhi Geng, Adriana C. Panayi, Yun Sun, Lin Wang, Guohui Liu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1277</prism:startingPage> 
<prism:endingPage>1288</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1263.htm</link> 
<title>Targeting HLA-F suppresses the proliferation of glioma cells via a reduction in hexokinase 2-dependent glycolysis</title> 
<description><![CDATA[ <p>HLA-F, a nonclassical HLA class I molecule, is required for regulating immune tolerance. In recent years, HLA-F has been found to play a role in a variety of cancers, including glioma (GM). Additionally, high expression of HLA-F predicts the poor overall survival of individuals with GM. However, the functions of HLA-F in GM remain to be further elucidated. In this study, we found that HLA-F expression was elevated in GM tissues. High levels of HLA-F resulted in a high cell proliferation index and predicted GM recurrence. Forced expression of HLA-F promoted the growth of murine C8-D1A cells transplanted in immunodeficient <i>Rag2<sup>-/-</sup></i> mice. In contrast, silencing HLA-F inhibited cell growth <i>in vitro</i>. Furthermore, targeting HLA-F with an anti-HLA-F antibody suppressed the growth of C8-D1A cells stably expressing HLA-F transplanted in immunodeficient <i>Rag2<sup>-/-</sup></i> mice. In further experiments, we found that forced expression of HLA-F contributed to the aerobic glycolysis phenotype in C8-D1A cells along with an increase in HK2 protein stabilization. Conversely, silencing HK2 by shRNA reduced HLA-F-mediated glycolysis and cell proliferation. Our data indicated that HLA-F promoted cell proliferation via HK2-dependent glycolysis. HLA-F could be a potential therapeutic target for the treatment of GM.</p> ]]></description>  
<dc:creator>Xin Chen, Na Sun, Rongqin Li, Xuejia Sang, Xueqin Li, Jie Zhao, Jing Han, Jing Yang, Takayuki Ikezoe</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1263</prism:startingPage> 
<prism:endingPage>1276</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1250.htm</link> 
<title>Wild-type IDH1 inhibits the tumor growth through degrading HIF-&#945; in renal cell carcinoma</title> 
<description><![CDATA[ <p>The purpose of our study was to explore the effect and intrinsic mechanism of wild-type IDH1 and its substrate &#945;-KG on renal cell carcinoma (RCC). IDH1 was observed lower expression in RCC cell lines. Phenotype experiment was carried out in the wild-type IDH1 and mutant IDH1<sup>R132H</sup> plasmid treated cell line. The results showed that the wild-type IDH1 could significantly inhibit the proliferation, migration and promote the apoptosis of RCC cell lines, which were consistent with the IDH1's substrate &#945;-KG. The mutant IDH1<sup>R132H</sup> was found to lose this biological function of IDH1. Moreover, we verified the proliferation inhibition of IDH1 <i>in vivo</i>. In addition, we verified the correlation between IDH1 and hypoxia signal-related proteins <i>in vitro</i> and <i>in vivo</i>, specifically, IDH1 overexpression could significantly reduce the expression of HIF-1&#945; and HIF-2&#945; proteins and its downstream proteins (VEGF, TGF-&#945;). Furthermore, we preliminarily verified the possibility of &#945;-KG in the RCC's treatment by injecting &#945;-KG into the xenograft model. &#945;-KG significantly reduced tumor size and weight in tumor-bearing mice. This study provided a new therapeutic target and small molecule for the study of the treatment and mechanism of RCC.</p> ]]></description>  
<dc:creator>Song Chen, Yejinpeng Wang, Yaoyi Xiong, Tianchen Peng, Mengxin Lu, Lian Zhang, Zhongqiang Guo</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1250</prism:startingPage> 
<prism:endingPage>1262</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1234.htm</link> 
<title>Dickkopf-1 promotes Vascular Smooth Muscle Cell proliferation and migration through upregulating UHRF1 during Cyclic Stretch application</title> 
<description><![CDATA[ <p>Dickkopf-1 (DKK1) was recently shown to play an important role in cardiovascular disease. The aim of this work was to assess the role of DKK1 in the regulation of smooth muscle cell function by mechanical stretch and the mechanisms underlying this process.</p><p><b>Methods:</b> Wild-type C57BL/6J mice were subjected to sham or abdominal aortic constriction (AAC) surgery. The expression level of DKK1 was examined by immunohistochemical staining and Western blotting. Analyses of DKK1 function in vascular smooth muscle cell (VSMC) proliferation and migration were performed. Transcriptome sequencing analysis was performed to identify the differentially expressed genes and pathways regulated by DKK1. Smooth muscle-specific Dkk1 knockout mice were used to confirm the function of DKK1 <i>in vivo</i>. Chromatin immunoprecipitation (ChIP) was used to confirm DNA-protein interactions. Promoter luciferase analysis was used to detect transcription factor activity.</p><p><b>Results:</b> We found that AAC significantly increased DKK1 protein levels in the thoracic aorta and coronary artery <i>in vivo</i>. <i>In vitro</i>, high-level stretch (18%) induced the expression of DKK1 in VSMCs. Knocking down DKK1 inhibited VSMC proliferation and migration under high-level stretch (18%). We identified ubiquitin-like containing PHD and RING finger domains 1 (UHRF1) as a target gene of DKK1. Knockdown of UHRF1 with small interfering RNAs partially reversed the regulatory effect of recombinant DKK1 on VSMCs. Specific deletion of DKK1 in VSMCs was sufficient to attenuate the AAC-induced upregulation of UHRF1, thickening of arterial media and increase in VSMC proliferation. Furthermore, we found that DKK1 regulated UHRF1 expression through the YAP-TEAD pathway. TEAD1 and TEAD4 bound directly to the promoter of UHRF1, and blocking the YAP-TEAD interaction inhibited UHRF1 upregulation due to DKK1.</p><p><b>Conclusions:</b> This study reveals that DKK1 mediates the mechanical stretch regulation of smooth muscle cell function by modulating UHRF1 expression through the YAP-TEAD pathway.</p> ]]></description>  
<dc:creator>Teng-fei Zheng, Xiao-lin Liu, Xiao Li, Qian-qian Wang, Ya-chao Zhao, Xuan Li, Meng-meng Li, Yu Zhang, Meng Zhang, Wen-cheng Zhang, Cheng Zhang, Yun Zhang, Mei Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1234</prism:startingPage> 
<prism:endingPage>1249</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1217.htm</link> 
<title>3,3'-Diindolylmethane induces gastric cancer cells death via STIM1 mediated store-operated calcium entry</title> 
<description><![CDATA[ <p>3,3'-Diindolylmethane (DIM), a natural phytochemicals isolated from cruciferous vegetables, has been reported to inhibit human gastric cancer cells proliferation and induce cells apoptosis as well as autophagy, but its mechanisms are still unclear. Store-operated calcium entry (SOCE) is a main Ca<sup>2+</sup> influx pathway in various of cancers, which is activated by the depletion of endoplasmic reticulum (ER) Ca<sup>2+</sup> store. Stromal interaction molecular 1 (STIM1) is the necessary component of SOCE. In this study, we focus on to examine the regulatory mechanism of SOCE on DIM-induced death in gastric cancer. After treating the human BGC-823 and SGC-7901 gastric cancer cells with DIM, cellular proliferation was determined by MTT, apoptosis and autophagy were detected by flow cytometry or Hoechst 33342 staining. The expression levels of related proteins were evaluated by Western blotting. Free cytosolilc Ca<sup>2+</sup> level was assessed by fluorescence monitoring under a laser scanning confocal microscope. The data have shown that DIM could significantly inhibit proliferation and induce apoptosis as well as autophagy in two gastric cancer cell lines. After DIM treatment, the STIM1-mediated SOCE was activated by upregulating STIM1 and decreasing ER Ca<sup>2+</sup> level. Knockdown STIM1 with siRNA or pharmacological inhibition of SOCE attenuated DIM induced apoptosis and autophagy by inhibiting p-AMPK mediated ER stress pathway. Our data highlighted that the potential of SOCE as a promising target for treating cancers. Developing effective and selective activators targeting STIM1-mediated SOCE pathway will facilitate better therapeutic sensitivity of phytochemicals acting on SOCE in gastric cancer. Moreover, more research should be performed to validate the efficacy of combination chemotherapy of anti-cancer drugs targeting SOCE for clinical application.</p> ]]></description>  
<dc:creator>Yang Ye, Xue Li, Zhihua Wang, Fen Ye, Wenrong Xu, Rongzhu Lu, Haijun Shen, Shuhan Miao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1217</prism:startingPage> 
<prism:endingPage>1233</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1203.htm</link> 
<title>MnSOD Lysine 68 acetylation leads to cisplatin and doxorubicin resistance due to aberrant mitochondrial metabolism</title> 
<description><![CDATA[ <p>Manganese superoxide dismutase (MnSOD) acetylation (Ac) has been shown to be a key post-translational modification important in the regulation of detoxification activity in various disease models. We have previously demonstrated that MnSOD lysine-68 (K68) acetylation (K68-Ac) leads to a change in function from a superoxide-scavenging homotetramer to a peroxidase-directed monomer. Here, we found that estrogen receptor positive (ER+) breast cancer cell lines (MCF7 and T47D), selected for continuous growth in cisplatin (CDDP) and doxorubicin (DXR), exhibited an increase in MnSOD-K68-Ac. In addition, MnSOD-K68-Ac, as modeled by the expression of a validated acetylation mimic mutant gene (<i>MnSOD<sup>K68Q</sup></i>), also led to therapy resistance to CDDP and DXR, altered mitochondrial structure and morphology, and aberrant cellular metabolism. <i>MnSOD<sup>K68Q</sup></i> expression in mouse embryo fibroblasts (MEFs) induced an <i>in vitro</i> transformation permissive phenotype. Computerized molecular protein dynamics analysis of both MnSOD-K68-Ac and MnSOD-K68Q exhibited a significant change in charge distribution along the &#945;1 and &#945;2 helices, directly adjacent to the Mn<sup>2+</sup> binding site, implying that this decrease in surface charge destabilizes tetrameric MnSOD, leading to an enrichment of the monomer. Finally, monomeric MnSOD, as modeled by amber codon substitution to generate MnSOD-K68-Ac or MnSOD-K68Q expression in mammalian cells, appeared to incorporate Fe to maximally induce its peroxidase activity. In summary, these findings may explain the mechanism behind the observed structural and functional change of MnSOD-K68-Ac.</p> ]]></description>  
<dc:creator>Yucheng Gao, Yueming Zhu, Elizabeth L. Tran, Valerie Tokars, Angela E. Dean, Songhua Quan, David Gius</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1203</prism:startingPage> 
<prism:endingPage>1216</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1191.htm</link> 
<title>Characteristics of the PI3K/AKT and MAPK/ERK pathways involved in the maintenance of self-renewal in lung cancer stem-like cells</title> 
<description><![CDATA[ <p>Lung cancer is the leading cause of cancer-related mortality worldwide due to its early asymptomatic and late metastasis. While cancer stem cells (CSCs) may play a vital role in oncogenesis and development of lung cancer, mechanisms underlying CSCs self&#8208;renewal remain less clear. In the present study, we constructed a clinically relevant CSCs enrichment recognition model and evaluated the potential functions of phosphatidylinositol 3-kinase (PI3K)/AKT pathway (PI3K/AKT) and mitogen-activated protein kinases/extracellular signal-regulated kinase (MAPK/ERK) pathways in lung cancer via bioinformatic analysis, providing the basis for in depth mechanistic inquisition. Experimentally, we confirmed that PI3K/AKT pathway predominantly promotes proliferation through anti-apoptosis in lung adenocarcinoma cells, while MAPK/ERK pathway has an overwhelming superiority in regulating the proliferation in lung CSCs. Further, utilizing stemness score model, LLC-Symmetric Division (LLC-SD) cells and mouse orthotopic lung transplantation model, we elucidated an intricate cross-talk between the oncogenic pathway and the stem cell reprograming pathway that impact stem cell characteristics as well as cancer biology features of lung CSCs both <i>in vitro</i> and <i>in vivo</i>. In summary, our findings uncovered a new insight that PI3K/AKT and MAPK/ERK pathways as oncogenic signaling pathway and/or stem cell signaling pathway act distinctively and synergistically to regulate lung CSCs self-renewal.</p> ]]></description>  
<dc:creator>Jingyuan Li, Jianyu Wang, Dan Xie, Qin Pei, Xue Wan, H.Rosie Xing, Ting Ye</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1191</prism:startingPage> 
<prism:endingPage>1202</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1178.htm</link> 
<title>CircMETTL3, upregulated in a m6A-dependent manner, promotes breast cancer progression</title> 
<description><![CDATA[ <p>Growing evidence indicates N6-methyladenosine (m6A) has biological function in oncogenesis. METTL3, the catalytic component, is the most important part of methyltransferase complex and plays a crucial role in cancers. However, the biological function of circRNAs derived from <i>METTL3</i> in breast cancer and the underlying molecular mechanism remains unclear. Herein, we report circMETTL3, which has not been explored in breast cancer, and it is markedly upregulated in breast cancer. Moreover, we uncovered that circMETTL3 could facilitate cell proliferation, migration and invasion in breast cancer. Mechanism investigation showed that circMETTL3 might act as a competing endogenous RNA (ceRNA) of miR-31-5p and upregulate its target cyclin-dependent kinases (CDK1). Moreover, m6A modification of circMETTL3 might affect its expression. Taken together, our results elucidate that circMETTL3 promotes breast cancer progression through circMETTL3/miR-31-5p/CDK1 axis. Moreover, METTL3, the host gene of circMETTL3, may regulate circMETTL3 expression in an m6A-dependent manner, while circMETTL3 has no effect on METTL3 expression, providing a new relationship between the circRNA and the corresponding host gene. Thus, it may serve as a new therapeutic target for breast cancer.</p> ]]></description>  
<dc:creator>Zhi Li, Hai-Yan Yang, Xin-Yuan Dai, Xu Zhang, Yu-Zhou Huang, Liang Shi, Ji-Fu Wei, Qiang Ding</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>1178</prism:startingPage> 
<prism:endingPage>1190</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1153.htm</link> 
<title>MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types</title> 
<description><![CDATA[ <p><b>Background &#38; Aims:</b> Liver fibrosis is a common consequence of chronic liver injury and is characterized by the accumulation of extracellular matrix mainly generated from activated hepatic stellate cells (HSCs). At present, the mechanisms underlying liver fibrogenesis remain obscure and effective pharmacological therapies are lacking. Neutrophil-specific microRNA-223 (miR-223) plays an important role in controlling the development of various liver diseases; however, its role in HSC activation and liver fibrosis remains unclear.</p><p><b>Methods:</b> Liver fibrosis was induced by chronic carbon tetrachloride (CCl<sub>4</sub>) injection of miR-223 knockout (miR-223KO) mice and littermate wild-type controls. MiR-223 was overexpressed in cultured HSCs to determine its function and targets during HSC activation and proliferation. The expression of miR-223 and pri-miR-223 was examined in primary HSCs isolated from CCl<sub>4</sub>-treated mice and in cultured HSCs. The communication between HSCs and neutrophils was studied by performing <i>in vitro</i> co-culture experiments.</p><p><b>Results:</b> Genetic deletion of miR-223 exacerbated chronic CCl<sub>4</sub>-induced liver fibrosis. Administration of miR-223 inhibited liver fibrosis by inhibiting the transcriptional coactivator with PDZ-binding motif (TAZ)-Indian hedgehog (IHH)-GLI Family Zinc Finger 2 (GLI2) pathway via the crosstalk between hepatocytes and HSCs. Overexpression of miR-223 also directly attenuated <i>Gli2</i> as well as platelet-derived growth factor receptor &#945;/&#946; (<i>Pdgfra/b</i>) expression in HSCs, thereby suppressing HSC activation and proliferation. The expression of pri-miR-223 and miR-223 was downregulated during HSC activation <i>in vitro</i>. Expression of pri-miR-223 was also decreased in activated HSCs <i>in vivo</i> in fibrotic livers but mature miR-223 expression was not reduced. Finally, in co-culture experiments, activated HSCs were able to take up miR-223-enriched extracellular vesicles from neutrophils, resulting in elevation of miR-223.</p><p><b>Conclusion:</b> MiR-223 restricts liver fibrosis by targeting multiple genes in hepatocytes and HSCs, providing potential therapeutic targets for the treatment of liver fibrosis.</p> ]]></description>  
<dc:creator>Xiaolin Wang, Wonhyo Seo, Seol Hee Park, Yaojie Fu, Seonghwan Hwang, Robim M. Rodrigues, Dechun Feng, Bin Gao, Yong He</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1153</prism:startingPage> 
<prism:endingPage>1167</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1138.htm</link> 
<title>Betulinic acid inhibits pyroptosis in spinal cord injury by augmenting autophagy via the AMPK-mTOR-TFEB signaling pathway</title> 
<description><![CDATA[ <p>Spinal cord injury (SCI) results in a wide range of disabilities. Its complex pathophysiological process limits the effectiveness of many clinical treatments. Betulinic acid (BA) has been shown to be an effective treatment for some neurological diseases, but it has not been studied in SCI. In this study, we assessed the role of BA in SCI and investigated its underlying mechanism. We used a mouse model of SCI, and functional outcomes following injury were assessed. Western blotting, ELISA, and immunofluorescence techniques were employed to analyze levels of autophagy, mitophagy, pyroptosis, and AMPK-related signaling pathways were also examined. Our results showed that BA significantly improved functional recovery following SCI. Furthermore, autophagy, mitophagy, ROS level and pyroptosis were implicated in the mechanism of BA in the treatment of SCI. Specifically, our results suggest that BA restored autophagy flux following injury, which induced mitophagy to eliminate the accumulation of ROS and inhibits pyroptosis. Further mechanistic studies revealed that BA likely regulates autophagy and mitophagy via the AMPK-mTOR-TFEB signaling pathway. Those results showed that BA can significantly promote the recovery following SCI and that it may be a promising therapy for SCI.</p> ]]></description>  
<dc:creator>Chenyu Wu, Huanwen Chen, Rong Zhuang, Haojie Zhang, Yongli Wang, Xinli Hu, Yu Xu, Jiafeng Li, Yao Li, Xiangyang Wang, Hui Xu, Wenfei Ni, Kailiang Zhou</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1138</prism:startingPage> 
<prism:endingPage>1152</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1125.htm</link> 
<title>Paradoxical HBsAg and anti-HBs coexistence among Chronic HBV Infections: Causes and Consequences</title> 
<description><![CDATA[ <p>Hepatitis B surface antigen (HBsAg) and Hepatitis B surface antibody (anti-HBs) were reported simultaneously among Hepatitis B virus (HBV) infections. HBsAg is a specific indicator of acute or chronic HBV infections, while anti-HBs is a protective antibody reflecting the recovery and immunity of hosts. HBsAg and anti-HBs coexist during seroconversion and then form immune complex, which is rare detected in clinical cases. However, with the promotion of vaccination and the application of various antiviral drugs, along with the rapid development of medical technology, the coexistence of HBsAg and anti-HBs has become more prevalent. Mutations in the viral genomes, immune status and genetic factors of hosts may contribute to the coexistence. Novel HBsAg assays, with higher sensitivity and ability to detect mutations or immune complexes, can also yield HBsAg/anti-HBs coexistence. The discovery of coexistence has shattered the idea of traditional serological patterns and raised questions about the effectiveness of vaccines. Worth noting is that HBsAg/anti-HBs double positivity is strongly associated with progressive liver diseases, especially hepatocellular carcinoma. In conclusion, viral mutations, host factors, and methodology impacts can all lead to the coexistence of HBsAg and anti-HBs. This coexistence is not an indicator of improvement, as an increased risk of adverse clinical outcomes still exists.</p> ]]></description>  
<dc:creator>Xinyi Jiang, Le Chang, Ying Yan, Lunan Wang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1125</prism:startingPage> 
<prism:endingPage>1137</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1119.htm</link> 
<title>Assessment of global asymptomatic SARS-CoV-2 infection and management practices from China</title> 
<description><![CDATA[ <p>With ongoing research, it was found that asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was widespread in coronavirus disease 2019 (COVID-19) populations. Studies have confirmed asymptomatic patients with COVID-19 have potential infectivity, and most of the transmission occurred before symptoms appear. Asymptomatic infection rates varied widely in different countries and regions. Identifying the asymptomatic infected persons and cutting off the infection source is an effective way to prevent the spread of this disease. However, asymptomatic patients have hidden clinical symptoms, and screening based only on the clinical symptoms of COVID-19 can easily lead to a missed diagnosis. Therefore, determining asymptomatic infection patients by SARS-CoV-2 nucleic acid testing is the gold standard. A series of prevention and control measures adopted by the Chinese government, especially the &#8220;Four Early&#8221; policy, have achieved outstanding achievements, which are worth learning from by other countries.</p> ]]></description>  
<dc:creator>Zheng Chen, Bili Wang, Shanshan Mao, Qing Ye</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1119</prism:startingPage> 
<prism:endingPage>1124</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1104.htm</link> 
<title>Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma</title> 
<description><![CDATA[ <p>Head and neck squamous cell carcinoma (HNSCC) is the 9<sup>th</sup> most common malignant tumor in the world. Based on the etiology, HNSCC has two main subtypes: human papillomavirus (HPV) -related and HPV-unrelated. HPV-positive HNSCC is more sensitive to treatment with favorable survival. Due to the different biological behaviors, individual therapy is necessary and urgently required to deduce the therapeutic intensity of HPV-positive disease and look for a more effective and toxicity-acceptable regimen for HPV-negative disease. EGFR amplification and PI3K/AKT/mTOR pathway aberrant activation are quite common in HPV-positive HNSCC. Besides, HPV infection alters immune cell infiltrating in HNSCC and encompasses a diverse and heterogeneous landscape with more immune infiltration. On the other hand, the chance of HPV-negative cancers harboring mutation on the P53 gene is significantly higher than that of HPV-positive disease. This review focuses on the updated preclinical and clinical data of HPV-positive and HPV-negative HNSCC and discusses the therapeutic strategies of different HPV status in HNSCC.</p> ]]></description>  
<dc:creator>Yingming Sun, Zhe Wang, Sufang Qiu, Ruoyu Wang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1104</prism:startingPage> 
<prism:endingPage>1118</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1101.htm</link> 
<title>Inhibition of PERK Signaling Prevents Against Glucocorticoid-induced Endotheliocyte Apoptosis and Osteonecrosis of the Femoral Head: Erratum</title> 
<description><![CDATA[  ]]></description>  
<dc:creator>Yanchun Gao, Hongyi Zhu, Qiyang Wang, Yong Feng, Changqing Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1101</prism:startingPage> 
<prism:endingPage>1102</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Erratum</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1088.htm</link> 
<title>Genistein-3&#8242;-sodium sulfonate Attenuates Neuroinflammation in Stroke Rats by Down-Regulating Microglial M1 Polarization through &#945;7nAChR-NF-&#954;B Signaling Pathway</title> 
<description><![CDATA[ <p>Microglial M1 depolarization mediated prolonged inflammation contributing to brain injury in ischemic stroke. Our previous study revealed that Genistein-3&#8242;-sodium sulfonate (GSS) exerted neuroprotective effects in ischemic stroke. This study aimed to explore whether GSS protected against brain injury in ischemic stroke by regulating microglial M1 depolarization and its underlying mechanisms. We established transient middle cerebral artery occlusion and reperfusion (tMCAO) model in rats and used lipopolysaccharide (LPS)-stimulated BV2 microglial cells as <i>in vitro</i> model. Our results showed that GSS treatment significantly reduced the brain infarcted volume and improved the neurological function in tMCAO rats. Meanwhile, GSS treatment also dramatically reduced microglia M1 depolarization and IL-1&#946; level, reversed &#945;7nAChR expression, and inhibited the activation of NF-&#954;B signaling in the ischemic penumbra brain regions. These effects of GSS were further verified in LPS-induced M1 depolarization of BV2 cells. Furthermore, pretreatment of &#945;7nAChR inhibitor (&#945;-BTX) significantly restrained the neuroprotective effect of GSS treatment in tMCAO rats. &#945;-BTX also blunted the regulating effects of GSS on neuroinflammation, M1 depolarization and NF-&#954;B signaling activation. This study demonstrates that GSS protects against brain injury in ischemic stroke by reducing microglia M1 depolarization to suppress neuroinflammation in peri-infarcted brain regions through upregulating &#945;7nAChR and thereby inhibition of NF-&#954;B signaling. Our findings uncover a potential molecular mechanism for GSS treatment in ischemic stroke.</p> ]]></description>  
<dc:creator>Chaoming Liu, Song Liu, Lijiao Xiong, Limei Zhang, Xiao Li, Xingling Cao, Jinhua Xue, Liangdong Li, Cheng Huang, Zhihua Huang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1088</prism:startingPage> 
<prism:endingPage>1100</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1079.htm</link> 
<title>The role of Fibrinogen-like proteins in Cancer</title> 
<description><![CDATA[ <p>Fibrinogen-associated protein (FREP) family is a family of proteins with a fibrin domain at the carboxyl terminus. Recent investigations illustrated that two members of FREP family, fibrinogen-like protein-1 (FGL1) and fibrinogen-like protein-2 (FGL2), play crucial roles in cancer by regulating the proliferation, invasion, and migration of tumor cells, or regulating the functions of immune cells in tumor microenvironment. Meanwhile, they are potential targets for medical intervention of tumor development. In this review, we discussed the structure, and the roles of FGL1 and FGL2 in tumors, especially the roles in regulating immune cell functions.</p> ]]></description>  
<dc:creator>Jing Yu, Jing Li, Jing Shen, Fukuan Du, Xu Wu, Mingxing Li, Yu Chen, Chi Hin Cho, Xiaobing Li, Zhangang Xiao, Yueshui Zhao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1079</prism:startingPage> 
<prism:endingPage>1087</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1061.htm</link> 
<title>Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p/GRB14/PDGFR&#945; pathway as a key regulatory mechanism in Glioblastoma progression and radioresistance: Functional validation and clinical theranostic significance</title> 
<description><![CDATA[ <p>Glioblastoma is a central nervous malignancy with a very poor prognosis. This study attempted to explore the role of exosomes induced by low-dose radiation-induced (ldrEXOs) and ldrEXOs-derived circ-METRN in glioblastoma progression and radioresistance at the molecular, cellular, animal, and clinical levels. Results in the present study revealed that low-dose radiation stimulated the secretion of ldrEXOs which delivered high levels of circ-METRN. And circ-METRN-abundant ldrEXOs increased the expression of &#947;-H2AX, indicating an efficient DNA damage-repair process in glioblastoma cells. The ldrEXOs-derived circ-METRN enhanced the glioblastoma progression and radioresistance via miR-4709-3p/GRB14/PDGFR&#945; pathway. Up-regulating PDGFR&#945; can rescue the tumor-promoting function of ldrEXOs in groups previously treated with inhibition of GRB14. Additionally, in-vivo experiments revealed that treatments with ldrEXOs promoted the growth of xenografted tumors and shortened the survival period. Furthermore, clinical researches indicated that circ-METRN may be transported into the bloodstream by exosomes in the early stages of fractionated radiotherapy. It has important clinical values to detect the serum exosomal circ-METRN in the early stage of radiotherapy, which is not only conducive to predict radioresistance and prognosis but also to assist MRI diagnosis in detecting the very early recurrence of glioblastoma. In summary, this study reveals for the first time that low-dose radiation-induced exosomal circ-METRN plays an oncogenic role in glioblastoma progression and radioresistance through miR-4709-3p/GRB14/PDGFR&#945; pathway, providing mechanistic insights into the roles of circRNAs and a valuable marker for therapeutic targets in glioblastoma.</p> ]]></description>  
<dc:creator>Xinxin Wang, Qinchen Cao, Yonggang Shi, Xiaolong Wu, Yin Mi, Ke Liu, Quancheng Kan, Ruitai Fan, Zhangsuo Liu, Mingzhi Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1061</prism:startingPage> 
<prism:endingPage>1078</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1050.htm</link> 
<title>Theaflavin protects against oxalate calcium-induced kidney oxidative stress injury via upregulation of SIRT1</title> 
<description><![CDATA[ <p>Renal tubular cell injury induced by calcium oxalate (CaOx) is a critical initial stage of kidney stone formation. Theaflavin (TF) has been known for its strong antioxidative capacity; however, the effect and molecular mechanism of TF against oxidative stress and injury caused by CaOx crystal exposure in kidneys remains unknown. To explore the potential function of TF on renal crystal deposition and its underlying mechanisms, experiments were conducted using a CaOx nephrocalcinosis mouse model established by glyoxylate intraperitoneal injection, and HK-2 cells were subjected to calcium oxalate monohydrate (COM) crystals, with or without the treatment of TF. We discovered that TF treatment remarkably protected against CaOx-induced kidney oxidative stress injury and reduced crystal deposition. Additionally, miR-128-3p expression was decreased and negatively correlated with SIRT1 level in mouse CaOx nephrocalcinosis model following TF treatment. Moreover, TF suppressed miR-128-3p expression and further abolished its inhibition on SIRT1 to attenuate oxidative stress <i>in vitro</i>. Mechanistically, TF interacted with miR-128-3p and suppressed its expression. In addition, miR-128-3p inhibited SIRT1 expression by directly binding its 3'-untranslated region (UTR). Furthermore, miR-128-3p activation partially reversed the acceerative effect of TF on SIRT1 expression. Taken together, TF exhibits a strong nephroprotective ability to suppress CaOx-induced kidney damage through the recovery of the antioxidant defense system regulated by miR-128-3p/SIRT1 axis. These findings provide novel insights for the prevention and treatment of renal calculus.</p> ]]></description>  
<dc:creator>Tao Ye, Xiaoqi Yang, Haoran Liu, Peng Lv, Hongyan Lu, Kehua Jiang, Ejun Peng, Zhangqun Ye, Zhiqiang Chen, Kun Tang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1050</prism:startingPage> 
<prism:endingPage>1060</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1041.htm</link> 
<title>Progress of Gastric Cancer Surgery in the era of Precision Medicine</title> 
<description><![CDATA[ <p>With the development of genomics, the update of modern imaging technology and the advent of artificial intelligence and big data, the surgical treatment of gastric cancer has gradually stepped into precision medicine. Precision surgery treatment of gastric cancer is based on accurate molecular typing and staging using modern molecular diagnostic technology and imaging, and the formulation of precise and individualized surgical treatment plans, with the concept of minimally invasive and accelerated rehabilitation surgery running through it. For intermediate-stage gastric cancer, we have adopted a comprehensive treatment approach including traditional radiotherapy and chemotherapy, targeted therapy and immunotherapy. Utilize artificial intelligence and big data technology to improve the standardization and interconnectivity of specialty data and realize the transformation of evidence-based medicine. Promoting the standardization, standardization and individualization of gastric cancer surgical treatment, providing patients with precise diagnosis and treatment, and further improving patients' prognosis are the opportunities and challenges in the development of gastric cancer surgery.</p> ]]></description>  
<dc:creator>Yumin Wang, Luyuan Zhang, Yi Yang, Shan Lu, Hao Chen</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1041</prism:startingPage> 
<prism:endingPage>1049</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1026.htm</link> 
<title>Generation of VEGF knock-in Cashmere goat via the CRISPR/Cas9 system</title> 
<description><![CDATA[ <p>Cashmere is a rare and specialised animal fibre, which grows on the outer skin of goats. Owing its low yield and soft, light, and warm properties, it has a high economic value. Here, we attempted to improve existing cashmere goat breeds by simultaneously increasing their fibre length and cashmere yield. We attempted this by knocking in the vascular endothelial growth factor (<i>VEGF</i>) at the fibroblast growth factor 5(<i>FGF5</i>) site using a gene editing technology and then studying its hair growth-promoting mechanisms. We show that a combination of RS-1 and NU7441 significantly improve the efficiency of CRISPR/Cas9-mediated, homologous-directed repair without affecting the embryo cleavage rate or the percentages of embryos at different stages. In addition, we obtained a cashmere goat, which integrated the <i>VEGF</i> gene at the <i>FGF5</i> site, and the cashmere yield and fibre length of this gene-edited goat were improved. Through next-generation sequencing, we found that the up-regulation of <i>VEGF</i> and the down-regulation of <i>FGF5</i> affected the cell cycle, proliferation, and vascular tone through the PI3K-AKT signalling pathway and at extracellular matrix-receptor interactions. Owing to this, the gene-edited cashmere goat showed impressive cashmere performance. Overall, in this study, we generated a gene-edited cashmere goat by integrating <i>VEGF</i> at the <i>FGF5</i> site and provided an animal model for follow-up research on hair growth mechanisms.</p> ]]></description>  
<dc:creator>Xiao Hu, Fei Hao, Xiaocong Li, Zhiyuan Xun, Yuan Gao, Bingxu Ren, Ming Cang, Hao Liang, Dongjun Liu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1026</prism:startingPage> 
<prism:endingPage>1040</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p1010.htm</link> 
<title>Extrachromosomal Circular DNAs: Origin, formation and emerging function in Cancer</title> 
<description><![CDATA[ <p>The majority of cellular DNAs in eukaryotes are organized into linear chromosomes. In addition to chromosome DNAs, genes also reside on extrachromosomal elements. The extrachromosomal DNAs are commonly found to be circular, and they are referred to as extrachromosomal circular DNAs (eccDNAs). Recent technological advances have enriched our knowledge of eccDNA biology. There is currently increasing concern about the connection between eccDNA and cancer. Gene amplification on eccDNAs is prevalent in cancer. Moreover, eccDNAs commonly harbor oncogenes or drug resistance genes, hence providing a growth or survival advantage to cancer cells. eccDNAs play an important role in tumor heterogeneity and evolution, facilitating tumor adaptation to challenging circumstances. In addition, eccDNAs have recently been identified as cell-free DNAs in circulating system. The altered level of eccDNAs is observed in cancer patients relative to healthy controls. Particularly, eccDNAs are associated with cancer progression and poor outcomes. Thus, eccDNAs could be useful as novel biomarkers for the diagnosis and prognosis of cancer. In this review, we summarize current knowledge regarding the formation, characteristics and biological importance of eccDNAs, with a focus on the molecular mechanisms associated with their roles in cancer progression. We also discuss their potential applications in the detection and treatment of cancer. A better understanding of the functional role of eccDNAs in cancer would facilitate the comprehensive analysis of molecular mechanisms involved in cancer pathogenesis.</p> ]]></description>  
<dc:creator>Man Wang, Xinzhe Chen, Fei Yu, Han Ding, Yuan Zhang, Kun Wang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>1010</prism:startingPage> 
<prism:endingPage>1025</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0995.htm</link> 
<title>Homoharringtonine inhibited breast cancer cells growth via miR-18a-3p/AKT/mTOR signaling pathway</title> 
<description><![CDATA[ <p>Homoharringtonine (HHT), a natural alkaloid derived from the <i>cephalotaxus</i>, exhibited its anti-cancer effects in hematological malignancies clinically. However, its pesticide effects and mechanisms in treating solid tumors remain unclear. In this study, we found that HHT was capable of inhibiting tumor growth after 5-days treatment of breast cancer cells, MCF-7,<i> in vivo</i>. Furthemore, HHT also significantly inhibited the cancer cell growth and induced cell apoptosis <i>in vitro</i>. miRNA sequencing proved miR-18a-3p was noticeably downregulated in the cells after HHT treatment. Moreover, downregulating miR-18a-3p increased HHT-induced cell apoptosis; our data supported that HHT suppressed miR-18a-3p expression and inhibited tumorigenesis might via AKT-mTOR signaling pathway. In conclusion: our study proved that HHT suppressed breast cancer cell growth and promoted apoptosis mediated by regulating of the miR-18a-3p-AKT-mTOR signaling pathway, HHT may be a promising antitumor agent in breast cancer treatment.</p> ]]></description>  
<dc:creator>Li-bin Wang, Dan-ni Wang, Li-gang Wu, Jia Cao, Jin-hai Tian, Rong Liu, Rong Ma, Jing-jing Yu, Jia Wang, Qi Huang, Wen-yong Xiong, Xu Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>995</prism:startingPage> 
<prism:endingPage>1009</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0986.htm</link> 
<title>Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation</title> 
<description><![CDATA[ <p>As the most malignant subtype of breast cancers, triple-negative breast cancer (TNBC) lacks effective targeted therapeutics clinically to date. In this study, one lead compound FZU-0025-065 with isochromanoindolenine scaffold was identified by a cell-based screening. Among nine breast cancer cell lines tested, TNBC are the most sensitive cell lines to FZU-0025-065. FZU-0025-065 inhibits TNBC cell growth in a time- and dosage-dependent manner. FZU-0025-065 suppresses the expression of cell cycle dependent kinase 4 (CDK4), Cyclin D1 and Cyclin B1; meanwhile, elevates the expression of cell cycle dependent kinase inhibitor p21 and p27. Importantly, we found that FZU-0025-065 suppresses AKT activation in a time- and dosage-dependent manner. Over-expression of constitutive active AKT partially rescues FZU-0025-065 induced cell growth inhibition in MDA-MB-468 cells, indicating FZU-0025-065 suppresses TNBC cell growth partially via inhibiting AKT activation. Finally, FZU-0025-065 suppresses TNBC cell growth in a xenograft mouse model. Taken together, our findings suggested that isochromanoindolenine derivative FZU-0025-065 inhibits TNBC via suppressing the AKT signaling and that FZU-0025-065 may be useful for TNBC treatment.</p> ]]></description>  
<dc:creator>Xiaoyan Jiang, Xu Zhi, Peixia Zhang, Zhongmei Zhou, Jinxiang Ye, Yu Gao, Xinye Wang, Chuanyu Yang, Haijun Chen, Rong Liu, Ceshi Chen</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>986</prism:startingPage> 
<prism:endingPage>994</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0972.htm</link> 
<title>Circulating Exosomal miR-1-3p from Rats with Myocardial Infarction Plays a Protective Effect on Contrast-Induced Nephropathy via Targeting ATG13 and activating the AKT Signaling Pathway</title> 
<description><![CDATA[ <p><b>Rationale:</b> With the widespread development of the interventional technique for cardiovascular diseases and the widespread use of contrast medium (CM), the incidence of contrast-induced nephropathy (CIN) has been increasing, which is associated with poor prognosis for cardiovascular diseases. This study aims to explore the effect of circulating exosomal microRNA from patients with myocardial infarction (MI) on CIN and related molecular mechanism. <b>Methods:</b> A rat MI model was established by ligating the left anterior descending coronary artery. Circulating exosomes were isolated from control (Exo-NC) and MI rats (Exo-MI) using a commercial kit. The <i>in vivo</i> and <i>in vitro</i> models of CIN were created using iodixanol. Reverse transcription quantitative PCR (RT-qPCR) was utilized to detect the expression of miR-1-3p. Western blot (WB) was used to detect the expression of exosomal surface markers, and apoptosis-related and autophagy-related proteins. The apoptosis rate was examined by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining and flow cytometry (FC). Transmission electron microscopy (TEM) was utilized to observe the exosomes and autophagosomes. Rat kidney injury was assessed by hematoxylin and eosin (H&#38;E) staining and kidney injury molecule-1 (KIM-1) immunohistochemical staining. Renal function of rats was assessed by detecting the levels of blood urea nitrogen (BUN) and serum creatinine (Cr). The dual luciferase reporter assay was performed to identify the target gene of miR-1-3p. <b>Results:</b> The treatment of CM induced NRK-52E cell damage, which manifested as enhanced cell autophagy and enhanced apoptosis. The Exo-MI treatment significantly inhibited the CM-induced autophagy and apoptosis of NRK-52E cells. Furthermore, the Exo-MI treatment increased the Bcl-2 expression, but decreased the Bax expression and the ratio of LC3II/LC3I. Furthermore, the results of the TUNEL staining and FC showed that Exo-MI can reduce apoptotic rate. Through TEM, it was found that Exo-MI reduced the number of autophagosomes in NRK-52E cells. The rescue experiments revealed that the function of Exo-MI is to inhibit the CM-induced autophagy and apoptosis of NRK-52E cells, which can be inhibited by the miR-1-3p inhibitor. Furthermore, it was found that the overexpression of miR-1-3p can also inhibit the CM-induced autophagy and apoptosis of NRK-52E cells. Through dual luciferase reporter assay, ATG13 was found to be the target of miR-1-3p. In addition, the overexpression of miR-1-3p significantly reversed the CM-induced decrease in phosphorylation level of AKT. Furthermore, ATG13 silencing can also inhibit the CM-induced autophagy and apoptosis of NRK-52E cells. <i>In vivo</i>, Exo-MI significantly alleviated the renal injury, reduced the renal fibrosis, and improved the renal function of CIN rats. <b>Conclusion:</b> The circulating exosomal miR-1-3p after MI inhibited the CM-induced apoptosis and autophagy of renal tubular epithelial cells, and improved the renal function of rats by targeting ATG13 and activating the AKT signaling pathway.</p> ]]></description>  
<dc:creator>Pengcheng Zhao, Yeqian Zhu, Ling Sun, Wenwu Zhu, Yao Lu, Jian Zhang, Yangming Mao, Qiushi Chen, Fengxiang Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>972</prism:startingPage> 
<prism:endingPage>985</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0957.htm</link> 
<title>Silencing PRSS1 suppresses the growth and proliferation of gastric carcinoma cells via the ERK pathway</title> 
<description><![CDATA[ <p><b>Background:</b> Gastric carcinoma (GC) is one of the most common malignant tumors and seriously threatens human life and health.</p><p><b>Methods:</b> In the present study, 243 differentially expressed proteins in GC were identified using laser capture microdissection (LCM) combined with isotopically labeled quantitative proteomics technology. The expression of serine protease 1 (PRSS1) protein was analyzed by immunohistochemistry and Western blot. MTT and colony formation assays were employed to determine the effect of PRSS1 expression on the growth and proliferation of GC cells. Then, we observed the expression of miR-146a-5p in GC by qRT-PCR. A dual luciferase assay was performed to determine whether PRSS1 is a target gene of miR-146a-5p. We also explored the influence of miR-146a-5p expression on PRSS1 expression and on the growth and proliferation of GC cells. Finally, Western blotting was used to analyze the effect of PRSS1 expression on the activation of the ERK signaling pathway.</p><p><b>Results:</b> We confirmed that PRSS1 expression was significantly increased and was positively correlated with the differentiation, tumor size and lymph node metastasis of GC. Subsequently, we found that overexpression of PRSS1 promoted the growth and proliferation of cells, whereas silencing PRSS1 expression inhibited the growth and proliferation of MGC803 cells by inhibiting activation of the ERK signaling pathway via reductions in PAR-2 activation. MiR-146a-5p targets PRSS1 and suppresses the growth and proliferation of MGC803 cells.</p><p><b>Conclusions:</b> miR-146a-5p targets PRSS1 and suppresses the growth and proliferation of MGC803 cells. Silencing PRSS1 expression inhibits the ERK signaling pathway by reducing PAR-2 activation, resulting in suppressed growth and proliferation of MGC803 GC cells.</p> ]]></description>  
<dc:creator>Dongmei Ye, Yuxuan Li, Heliang Zhang, Zhiwei Zhou, Yujie Tang, Peng Wu, Qiang Zhao, Zhiwei Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>957</prism:startingPage> 
<prism:endingPage>971</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0942.htm</link> 
<title>Ferroptosis-related Genes for Overall Survival Prediction in Patients with Colorectal Cancer can be Inhibited by Gallic acid</title> 
<description><![CDATA[ <p>Colorectal cancer (CRC) is one of the most deadly malignant tumors, which seriously threatens human health. Ferroptosis, a new type of iron-dependent cell regulatory necrosis. Inducing ferroptosis of tumor cells is regarded as a potential treatment strategy. However, the prognostic value of ferroptosis-related genes in CRC remains to be further elucidated. Gallic acid, widely used in the chemical, pharmaceutical, and food fields, is a dietary supplement with potential prescription significance. In this study, the mRNA expression profiles and corresponding clinical data of CRC patients were downloaded from public databases. Gene Expression Profiling Interactive Analysis (GEPIA) was used to evaluate the expression levels of ferroptosis-related genes. In addition, bioinformatics analysis showed the prognostic value of ferroptosis-related genes in CRC. Molecular docking predicts the binding status of gallic acid and ferroptosis-related genes. The experiment confirmed the correctness of the predicted results. Our results show that in the TCGA cohort, 30 ferroptosis-related genes are differentially expressed between CRC and adjacent normal tissues. Among them, eight differentially expressed genes are related to overall survival. Gallic acid can bind to ferroptosis-related targets and regulate the expression of corresponding proteins, and ferroptosis inhibitors reversed the experimental results. In summary, eight new ferroptosis-related genes can be used to predict the prognosis of CRC. Gallic acid can improve CRC by regulating ferroptosis.</p> ]]></description>  
<dc:creator>Zongchao Hong, Peili Tang, Bo Liu, Chongwang Ran, Chong Yuan, Ying Zhang, Yi Lu, Xueyun Duan, Yanfang Yang, Hezhen Wu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>942</prism:startingPage> 
<prism:endingPage>956</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0926.htm</link> 
<title>Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF-&#945; signaling factors</title> 
<description><![CDATA[ <p><b>Objectives:</b> The roles of innate immunity including macrophages in radiation-induced abscopal effect (RIAE) are ambiguous. In this study, we evaluated the role of macrophage in RIAE and the interaction of cytokines in tumor microenvironment after irradiation.</p><p><b>Materials and Methods:</b> Transplanted tumor of breast cancer cells in BalB/C mice, severe combined immunodeficiency (SCID) mice and non-obese diabetic (NOD)-SCID mice were irradiated with fractionation doses to observe anti-tumor abscopal effect. The underlying mechanism of RIAE was investigated by treating the mice with TNF-&#945; inhibitor or macrophage depletion drug and analyzing the alteration of macrophage distribution in tumors. A co-culture system of breast cancer cells and macrophages was applied to disclose the signaling factors and related pathways involved in the RIAE.</p><p><b>Results:</b> The growth of nonirradiated tumor was effectively suppressed in mice with normal or infused macrophages but not in mice with insufficiency/depletion of macrophage or TNF-&#945; inhibition, where M1-macrophage was mainly involved. Investigation of the bystander signaling factors <i>in vitro</i> demonstrated that HMGB1 released from irradiated breast cancer cells promoted bystander macrophages to secret TNF-&#945; through TLR-4 pathway and further inhibited the proliferation and migration of non-irradiated cancer cells by PI3K-p110&#947; suppression.</p><p><b>Conclusions:</b> HMGB1 and TNF-&#945; contributes to M1-macrophages facilitated systemic anti-tumor abscopal response triggered by radiotherapy in breast cancer, indicating that the combination of immunotherapy and radiotherapy may has important implication in enhancing the efficiency of tumor treatment.</p> ]]></description>  
<dc:creator>Lin Zhu, Songling Hu, Qianping Chen, Haowen Zhang, Jiamei Fu, Yuchuan Zhou, Yang Bai, Yan Pan, Chunlin Shao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>926</prism:startingPage> 
<prism:endingPage>941</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0915.htm</link> 
<title>FOXM1-induced miR-552 expression contributes to pancreatic cancer progression by targeting multiple tumor suppressor genes</title> 
<description><![CDATA[ <p>Dysregulation of microRNAs (miRNAs) plays important roles during carcinogenesis. Forkhead box M1 (FOXM1), a well-known oncogenic transcription factor, has been implicated in the progression of multiple cancer types. To find out FOXM1-induced abnormal miRNAs in pancreatic cancer, we analyzed TCGA database and figured out miR-552 as the most relevant miRNA with FOXM1. Molecular experimental results demonstrated that FOXM1 transcriptionally activated miR-552 expression by directly binding to the promoter region of miR-552. In a pancreatic cancer tissue microarray, miR-552 expression was positively correlated with FOXM1 and high expression of miR-552 could predict poor patient outcome. Functionally, overexpression of miR-552 promoted pancreatic cancer cell migration and inhibition of miR-552 attenuated this phenotype. The inhibitory effect on cell migration caused by FOXM1 knockdown could be restored by exogenous expression of miR-552. By informatics analysis, we identified three tumor suppressor genes: DACH1, PCDH10 and SMAD4, all of which were negatively associated with FOXM1 and validated as functionally relevant targets of miR-552. Taken together, our findings provide a new FOXM1-miR-552-DACH1/PCDH10/SMAD4 axis to regulate pancreatic cancer cell progression and new opportunities for therapeutic intervention against this disease.</p> ]]></description>  
<dc:creator>Xiao Wang, Ning Dou, Jialin Wang, Yi Zhang, Yandong Li, Yong Gao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>915</prism:startingPage> 
<prism:endingPage>925</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0913.htm</link> 
<title>A novel vehicle-like drug delivery 3D printing scaffold and its applications for a rat femoral bone repairing in vitro and in vivo: Erratum</title> 
<description><![CDATA[  ]]></description>  
<dc:creator>Hui Wang, Zhengwei Deng, Jing Chen, Xin Qi, Libing Pang, Bocai Lin, Yan Teik Yuin Adib, Na Miao, Deping Wang, Yadong Zhang, Jiusheng Li, Xiangqiong Zeng</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>913</prism:startingPage> 
<prism:endingPage>914</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Erratum</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0911.htm</link> 
<title>The Role of CHK1 Varies with the Status of Oestrogen-receptor and Progesterone-receptor in the Targeted Therapy for Breast Cancer : Erratum</title> 
<description><![CDATA[  ]]></description>  
<dc:creator>Wei Xu, Minghua Huang, Jia Guo, Huiting Zhang, Depeng Wang, Tiantian Liu, Haiting Liu, Shiming Chen, Peng Gao, Kun Mu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>911</prism:startingPage> 
<prism:endingPage>912</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Erratum</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0897.htm</link> 
<title>Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19</title> 
<description><![CDATA[ <p>HSPA5 (BiP, GRP78) has been reported as a potential host-cell receptor for SARS-Cov-2, but its expression profiles on different tissues including tumors, its susceptibility to SARS-Cov-2 virus and severity of its adverse effects on malignant patients are unclear. In the current study, HSPA5 has been found to be expressed ubiquitously in normal tissues and significantly increased in 14 of 31 types of cancer tissues. In lung cancer, mRNA levels of<i> HSPA5</i> were 253-fold increase than that of <i>ACE2</i>. Meanwhile, in both malignant tumors and matched normal samples across almost all cancer types, mRNA levels of <i>HSPA5</i> were much higher than those of <i>ACE2</i>. Higher expression of <i>HSPA5</i> significantly decreased patient overall survival (OS) in 7 types of cancers. Moreover, systematic analyses found that 7.15% of 5,068 COVID-19 cases have malignant cancer coincidental situations, and the rate of severe events of COVID-19 patients with cancers present a higher trend than that for all COVID-19 patients, showing a significant difference (33.33% vs 16.09%, <i>p</i>&#60;0.01). Collectively, these data imply that the tissues with high HSPA5 expression, not low ACE2 expression, are susceptible to be invaded by SARS-CoV-2. Taken together, this study not only indicates the clinical significance of HSPA5 in COVID-19 disease and cancers, but also provides potential clues for further medical treatments and managements of COVID-19 patients.</p> ]]></description>  
<dc:creator>Jiewen Fu, Chunli Wei, Jiayue He, Lianmei Zhang, Ju Zhou, Kyathegowdanadoddi Srinivasa Balaji, Shiyi Shen, Jiangzhou Peng, Amrish Sharma, Junjiang Fu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>897</prism:startingPage> 
<prism:endingPage>910</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0882.htm</link> 
<title>Novel biomarkers for post-contrast acute kidney injury identified from long non-coding RNA expression profiles</title> 
<description><![CDATA[ <p><b>Background:</b> Post-contrast acute kidney injury (PC-AKI) is a severe complication of cardiac catheterization. Emerging evidence indicated that long non-coding RNAs (lncRNAs) could serve as biomarkers for various diseases. However, the lncRNA expression profile and potential biomarkers in PC-AKI remain unclear. This study aimed to investigate novel lncRNA biomarkers for the early detection of PC-AKI.</p><p><b>Methods:</b> lncRNA profile in the kidney tissues of PC-AKI rats was evaluated through RNA sequencing. Potential lncRNA biomarkers were identified through human-rat homology analysis, kidney and blood filtering in rats and verified in 112 clinical samples. The expression patterns of the candidate lncRNAs were detected in HK-2 cells and rat models to evaluate their potential for early detection.</p><p><b>Results:</b> In total, 357 lncRNAs were found to be differentially expressed in PC-AKI. We identified lnc-HILPDA and lnc-PRND were conservative and remarkably upregulated in both kidneys and blood from rats and the blood of PC-AKI patients; these lncRNAs can precisely distinguish PC-AKI patients (area under the curve (AUC) values of 0.885 and 0.875, respectively). The combination of these two lncRNAs exhibited improved accuracy for predicting PC-AKI, with 100% sensitivity and 83.93% specificity. Time-course experiments showed that the significant difference was first noted in the blood of PC-AKI rats at 12 h for lnc-HILPDA and 24 h for lnc-PRND.</p><p><b>Conclusion:</b> Our study revealed that lnc-HILPDA and lnc-PRND may serve as the novel biomarkers for early detection and profoundly affect the clinical stratification and strategy guidance of PC-AKI.</p> ]]></description>  
<dc:creator>Guanzhong Chen, Bowen Liu, Shiqun Chen, Huanqiang Li, Jin Liu, Ziling Mai, Enzhao Chen, Chunyun Zhou, Guoli Sun, Zhaodong Guo, Li Lei, Shanyi Huang, Liyao Zhang, Min Li, Ning Tan, Hong Li, Yulin Liao, Jia Liu, Jiyan Chen, Yong Liu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>882</prism:startingPage> 
<prism:endingPage>896</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0869.htm</link> 
<title>MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway</title> 
<description><![CDATA[ <p>Mixed lineage kinase domain-like protein (MLKL) plays an important role in necroptosis, but the role and mechanism of MLKL in intestinal tumorigenesis remain unclear. Here, we found that hematopoietic- and nonhematopoietic-derived MLKL affected intestinal inflammation, but nonhematopoietic-derived MLKL primarily inhibited intestinal tumorigenesis. Loss of MLKL enhanced intestinal regeneration and the susceptibility to intestinal tumorigenesis in <i>Apc<sup>min/+</sup></i> mice by hyperactivating the Janus kinase 2 (JAK2)/ signal transducer and activator of transcription 3 (STAT3) axis. Furthermore, MLKL deficiency increased interleukin-6 (IL-6) production in dendritic cells. Administration of anti-IL-6R antibody therapy reduced intestinal tumorigenesis in <i>Apc<sup>min/+</sup>Mlkl<sup>-/-</sup></i> mice. Notably, low MLKL expression in human colorectal tumors, which enhanced STAT3 activation, was associated with decreased overall survival. Together, our results reveal that MLKL exhibits a suppressive effect during intestinal tumorigenesis by suppressing the IL-6/JAK2/STAT3 signals.</p> ]]></description>  
<dc:creator>Qun Zhao, Xinran Cheng, Jian Guo, Yun Bi, Li Kuang, Jianhua Ren, Jing Zhong, Longrui Pan, Xudong Zhang, Yang Guo, Yongqiang Liu, Shu Jin, Yan Tan, Xianjun Yu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>869</prism:startingPage> 
<prism:endingPage>881</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0861.htm</link> 
<title>PTEN-mediated AKT/&#946;-catenin signaling enhances the proliferation and expansion of Lgr5+ hepatocytes</title> 
<description><![CDATA[ <p><b>Rationale</b>: Compelling evidence suggests that Lgr5+ hepatocytes repair liver damage by promoting the regeneration of hepatocytes and ductal cells in the case of liver injury. The PTEN-mediated AKT/&#946;-catenin signaling plays a key role in the regulation of innate immune regulation in the liver. However, the signaling pathways that control Lgr5+ hepatocyte proliferation in the liver remain unclear.</p><p><b>Methods</b>: In order to assess the involvement of PTEN-mediated AKT/&#946;-catenin signaling in the expansion of Lgr5+ hepatocytes upon liver injuries, the Lgr5-CreER; Rosa-mTmG lineage tracing system was used to target Lgr5+ hepatocytes.</p><p><b>Results:</b> The tracing of Lgr5+ hepatocytes showed that PTEN deletion and &#946;-catenin activation significantly promoted the proliferation of Lgr5+ hepatocytes. In converse, the simultaneous inhibition of PTEN and &#946;-catenin limited Lgr5+ hepatocyte proliferation in the liver. Our findings provide an insight into understanding how PTEN-mediated AKT/&#946;-catenin signaling regulates the proliferation of Lgr5+ hepatocytes.</p><p><b>Conclusion:</b> The outcomes can improve the application potential of Lgr5+ hepatocytes in the treatment of liver injury diseases and provide a new treatment option for liver cancer.</p> ]]></description>  
<dc:creator>Jimin Han, Kaijun Lin, Xuezheng Zhang, Lingchen Yan, Yu Chen, Haiyan Chen, Jianjun Liu, Jia Liu, Yaojiong Wu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>861</prism:startingPage> 
<prism:endingPage>868</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0848.htm</link> 
<title>CD151 promotes Colorectal Cancer progression by a crosstalk involving CEACAM6, LGR5 and Wnt signaling via TGF&#946;1</title> 
<description><![CDATA[ <p>CD151 impacts various signaling pathways in different cancers, and promotes colorectal cancer (CRC) cell malignancy by yet undefined mechanisms. This study aimed to comprehensively assess CD151's function in CRC. CD151 levels were significantly higher in CRC tissues and cells compared with controls in the tissue microarray. Cell viability, migration and invasion were suppressed by CD151 downregulation in CRC cells. Consistently, mouse xenografts were inhibited by CD151 silencing. RNA-seq revealed that multiple genes were significantly altered by CD151 knockdown in cultured CRC cells and xenografts. Particularly, transforming growth factor &#946;1 (TGF&#946;1), carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) alongside CD151 were downregulated both <i>in vitro</i> and <i>in vivo</i>. Co-immunoprecipitation and mass spectrometry results were validated by qRT-PCR and immunoblot. Moreover, pull-down assay and immunofluorescence confirmed the associations of TGF&#946;1, CEACAM6 and LGR5 with CD151. This study demonstrated CEACAM6, LGR5 and Wnt pathway suppression by CD151 silencing might occur through TGF&#946;1 regulation, offering a comprehensive view of CD151's roles in colorectal carcinogenesis. Our findings provide an insight into the CD151-involved signaling network in CRC oncogenesis, which could be utilized to design novel targeted therapies against CD151-based signaling in treatment for CRC.</p> ]]></description>  
<dc:creator>Tao Yang, Huibing Wang, Meng Li, Linqi Yang, Yu Han, Chao Liu, Baowen Zhang, Mingfa Wu, Gang Wang, Zhenya Zhang, Wenqi Zhang, Jianming Huang, Huaxing Zhang, Ting Cao, Pingping Chen, Wei Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>848</prism:startingPage> 
<prism:endingPage>860</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0834.htm</link> 
<title>Anterior gradient 2 increases long-chain fatty acid uptake via stabilizing FABP1 and facilitates lipid accumulation</title> 
<description><![CDATA[ <p>Anterior gradient 2 (AGR2), a protein disulfide isomerase (PDI), is a well-established oncogene. Here, we found that <i>Agr2<sup>-/-</sup></i> mice had a decreased fat mass and hepatic and serum lipid levels compared with their wild-type littermates after fasting, and exhibited reduced high-fat diet (HFD)-induced fat accumulation. Transgenic mice overexpressing AGR2 (<i>Agr2</i>/Tg) readily gained fat weight on a HFD but not a normal diet. Proteomic analysis of hepatic samples from <i>Agr</i>2<sup>-/-</sup> mice revealed that depletion of AGR2 impaired long-chain fatty acid uptake and activation but did not affect <i>de novo</i> hepatic lipogenesis. Further investigations led to the identification of several effector substrates, particularly fatty acid binding protein-1 (FABP1) as essential for the AGR2-mediated effects. AGR2 was coexpressed with FABP1, and knockdown of AGR2 resulted in a reduction in FABP1 stability. Physical interactions of AGR2 and FABP1 depended on the PDI motif in AGR2 and the formation of a disulfide bond between these two proteins. Overexpression of AGR2 but not a mutant AGR2 protein lacking PDI activity suppressed lipid accumulation in cells lacking FABP1. Moreover, AGR2 deficiency significantly reduced fatty acid absorption in the intestine, which might be resulted from decreased fatty acid transporter CD36 in mice. These findings demonstrated a novel role of AGR2 in fatty-acid uptake and activation in both the liver and intestine, which contributed to the AGR2-mediated lipid accumulation, suggesting that AGR2 is an important regulator of whole-body lipid metabolism and down-regulation of AGR2 may antagonize the development of obesity.</p> ]]></description>  
<dc:creator>Yunqiu Wang, Mengqi Jia, Chuanjie Liang, Nan Sheng, Xiaodan Wang, Fang Wang, Yanhai Luo, Jin Jiang, Liangyu Cai, Huanmin Niu, Deyu Zhu, Effat Un Nesa, Charles YF Young, Huiqing Yuan</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>834</prism:startingPage> 
<prism:endingPage>847</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0818.htm</link> 
<title>Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates</title> 
<description><![CDATA[ <p>Nonalcoholic fatty liver disease (NAFLD) is leading chronic liver syndrome worldwide. Gut microbiota dysbiosis significantly contributes to the pathogenesis and severity of NAFLD. However, its role is complex and even unclear. Treatment of NAFLD through chemotherapeutic agents have been questioned because of their side effects on health. In this review, we highlighted and discussed the current understanding on the importance of gut microbiota, its dysbiosis and its effects on the gut-liver axis and gut mucosa. Further, we discussed key mechanisms involved in gut dysbiosis to provide an outline of its role in progression to NAFLD and liver cirrhosis. In addition, we also explored the potential role of probiotics as a treatment approach for the prevention and treatment of NAFLD. Based on the latest findings, it is evident that microbiota targeted interventions mostly the use of probiotics have shown promising effects and can possibly alleviate the gut microbiota dysbiosis, regulate the metabolic pathways which in turn inhibit the progression of NAFLD through the gut-liver axis. However, very limited studies in humans are available on this issue and suggest further research work to identify a specific core microbiome association with NAFLD and to discover its mechanism of pathogenesis, which will help to enhance the therapeutic potential of probiotics to NAFLD.</p> ]]></description>  
<dc:creator>Ashiq Khan, Zitong Ding, Muhammad Ishaq, Ali Sher Bacha, Israr Khan, Anum Hanif, Wenyuan Li, Xusheng Guo</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>818</prism:startingPage> 
<prism:endingPage>833</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0807.htm</link> 
<title>Crucial roles of different RNA-binding hnRNP proteins in Stem Cells</title> 
<description><![CDATA[ <p>The self-renewal, pluripotency and differentiation of stem cells are regulated by various genetic and epigenetic factors. As a kind of RNA binding protein (RBP), the heterogeneous nuclear ribonucleoproteins (hnRNPs) can act as &#8220;RNA scaffold&#8221; and recruit mRNA, lncRNA, microRNA and circRNA to affect mRNA splicing and processing, regulate gene transcription and post-transcriptional translation, change genome structure, and ultimately play crucial roles in the biological processes of cells. Recent researches have demonstrated that hnRNPs are irreplaceable for self-renewal and differentiation of stem cells. hnRNPs function in stem cells by multiple mechanisms, which include regulating mRNA stability, inducing alternative splicing of mRNA, epigenetically regulate gene expression, and maintaining telomerase activity and telomere length. The functions and the underlying mechanisms of hnRNPs in stem cells deserve further investigation.</p> ]]></description>  
<dc:creator>Wen Xie, Hecheng Zhu, Ming Zhao, Lei Wang, Shasha Li, Cong Zhao, Yao Zhou, Bin Zhu, Xingjun Jiang, Weidong Liu, Caiping Ren</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>807</prism:startingPage> 
<prism:endingPage>817</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0796.htm</link> 
<title>LncRNA-NONHSAT024778 promote the proliferation and invasion of chordoma cell by regulating miR-1290/Robo1 axis</title> 
<description><![CDATA[ <p>Chordoma is a malignant bone tumor originating from the embryonic remnants of the notochord. lncRNAs act as competing endogenous RNAs (ceRNAs) and play a critical role in tumor pathology. However, the biological role of lncRNA-NONHSAT024778 and the underlying molecular mechanism in chordoma remains unknown. qRT-PCR was used to analyze the expression changes of NONHSAT024778 and miR-1290 in chordoma tissues and cell lines. Bioinformatics analysis and luciferase reporter assay were applied to detect the targeting binding effect between NONHSAT024778 and miR-1290, and between Robo1 and miR-1290. The effect of NONHSAT024778 on chordoma cell proliferation and invasion and its regulation of miR-1290 by acting as a ceRNA were also investigated. An increased NONHSAT024778 expression was correlated with a decreased miR-1290 level in chordoma tissues. NONHSAT024778 knockdown suppressed the proliferation and invasion of chordoma cells. miR-1290 restored expression rescued the carcinogenic function of NONHSAT024778. Bioinformatics analysis showed that NONHSAT024778 acted as ceRNA to regulate Robo1 via sponging miR-1290 in chordoma cells, thereby promoting chordoma cell malignant progression. <i>In vivo</i> results confirmed the anti-tumor effects of NONHSAT024778 knockdown activating miR-1290 to inhibit the oncogene Robo1. NONHSAT024778 is substantially overexpressed, whereas miR-1290 is decreased in chordoma tissue. NONHSAT024778-miR-1290-Robo1 axis plays a critical role in chordoma tumorigenesis and might be a potential predictive biomarker for the diagnosis and therapeutic target among patients with chordoma.</p> ]]></description>  
<dc:creator>Bin Wang, Kai Zhang, Sen Meng, Xiaofeng Shao, Zhangzhe Zhou, Haiqing Mao, Ziqiang Zhu, Hao Chen, Huilin Yang, Kangwu Chen</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>796</prism:startingPage> 
<prism:endingPage>806</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0781.htm</link> 
<title>miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy</title> 
<description><![CDATA[ <p>Multi-drug resistance is a major challenge to hepatocellular carcinoma (HCC) treatment, and the over-expression or deletion of microRNA (miRNA) expression is closely related to the drug-resistant properties of various cell lines. However, the underlying molecular mechanisms remain unclear. CCK-8, EdU, flow cytometry, and transmission electron microscopy were performed to determine cell viability, proliferation, apoptosis, autophagic flow, and nanoparticle characterization, respectively. In this study, the results showed that the expression of miR-26b was downregulated following doxorubicin treatment in human HCC tissues. An miR-26b mimic enhanced HCC cell doxorubicin sensitivity, except in the absence of p53 in Hep3B cells. Delivery of the proteasome inhibitor, MG132, reversed the inhibitory effect of miR-26b on the level of p53 following doxorubicin treatment. Tenovin-1 (an MDM2 inhibitor) protected p53 from ubiquitination-mediated degradation only in HepG2 cells with wild type p53. Tenovin-1 pretreatment enhanced HCC cell resistance to doxorubicin when transfected with an miR-26b mimic. Moreover, the miR-26b mimic inhibited doxorubicin-induced autophagy and the autophagy inducer, rapamycin, eliminated the differences in the drug sensitivity effect of miR-26b. <i>In vivo</i>, treatment with sp94dr/miR-26b mimic nanoparticles plus doxorubicin inhibited tumor growth. Our current data indicate that miR-26b enhances HCC cell sensitivity to doxorubicin through diminishing USP9X-mediated p53 de-ubiquitination caused by DNA damaging drugs and autophagy regulation. This miRNA-mediated pathway that modulates HCC will help develop novel therapeutic strategies.</p> ]]></description>  
<dc:creator>Enjiang Chen, Enliang Li, Hao Liu, Yue Zhou, Liang Wen, Jianxin Wang, Yi Wang, Longyun Ye, Tingbo Liang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>781</prism:startingPage> 
<prism:endingPage>795</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0768.htm</link> 
<title>Linc-KILH potentiates Notch1 signaling through inhibiting KRT19 phosphorylation and promotes the malignancy of hepatocellular carcinoma</title> 
<description><![CDATA[ <p>Long noncoding RNAs (LncRNAs) are emerging as crucial regulators in the pathophysiological process of various tumors, including HCC. Here, we identify a novel lncRNA Linc-KILH (KRT19 interacting long noncoding RNA in hepatocellular carcinoma), which is significantly up-regulated in HCC tissues and positively correlated with larger tumor size, severer microvascular invasion, more intrahepatic metastasis and decreased survival of HCC patients. Silence of Linc-KILH remarkably inhibited the proliferation and metastasis abilities of KRT19-positive HCC cells<i> in vitro</i> and <i>in vivo</i>. Mechanistically, Linc-KILH interacts with KRT19 and then inhibits the phosphorylation of KRT19 on Ser35, thereby, enhancing the translocation of KRT19 from cytoplasm to membrane in KRT19 positive HCC cells. Additionally, we validated that KRT19 interacts with &#946;-catenin but not RAC1 in HCC cells. Linc-KILH enhanced the interaction between &#946;-catenin and KRT19 in cytoplasm and promoted the nuclear translocation of &#946;-catenin in HCC cells. Furthermore, Linc-KILH could enhance the promoting function of KRT19 on Notch1 signaling with the existence of KRT19 in HCC cells. Collectively, we revealed that Linc-KILH exerts a vital function in KRT19 positive HCC progression and may likely be developed into an effective therapeutic target for HCC.</p> ]]></description>  
<dc:creator>Xudong Zhang, Xiaoliang Xu, Zechuan Zhang, Cailin Xue, Zhijun Kong, Siyuan Wu, Xiao Yun, Yue Fu, Chunfu Zhu, Xihu Qin</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>768</prism:startingPage> 
<prism:endingPage>780</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0756.htm</link> 
<title>AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-&#954;B axis in nasopharyngeal carcinoma</title> 
<description><![CDATA[ <p>Nasopharyngeal carcinoma (NPC) is one kind of human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. In spite of great innovations in radiation and chemotherapy treatments, the 5-year survival rate is not satisfactory. One of the main reasons is resistance to radiotherapy which leads to therapy failure and recurrence of NPC. The mechanism underlying remains to be fully elucidated. Aldo-keto reductase B10 (AKR1B10) plays a role in the formation and development of carcinomas. However, its role in resistance to radiotherapy of NPC is not clear. In this research, the relationships between AKR1B10 expression and the treatment effect of NPC patients, NPC cell survival, cell apoptosis, and DNA damage repair, as well as the effect and mechanism of AKR1B10 expression on NPC radioresistance were explored. A total of 58 paraffin tissues of NPC patients received radiotherapy were collected including 30 patients with radiosensitivity and 28 patients with radioresistance. The relationships between AKR1B10 expression and the treatment effect as well as clinical characteristics were analyzed by immuno-histochemical experiments, and the roles of AKR1B10 in cell survival, apoptosis and DNA damage repair were detected using the AKR1B10 overexpressed cell models. Furthermore the mechanism of AKR1B10 in NPC radioresistance was explored. Finally, the radioresistance effect of AKR1B10 expression was evaluated by the tumor xenograft model of nude mice and the method of radiotherapy. The results showed AKR1B10 expression level was correlated with radiotherapy resistance, and AKR1B10 overexpression promoted proliferation of NPC cells, reduced apoptosis and decreased cellular DNA damage after radiotherapy. The probable molecular mechanism is that AKR1B10 expression activated FFA/TLR4/NF-&#954;B axis in NPC cells. This was validated by using the TLR4 inhibitor TAK242 to treat NPC cells with AKR1B10 expression, which reduced the phosphorylation of NF-&#954;B. This study suggests that AKR1B10 can induce radiotherapy resistance and promote cell survival via FFA/TLR4/NF-&#954;B axis in NPC, which may provide a novel target to fight against radiotherapy resistance of NPC.</p> ]]></description>  
<dc:creator>Xiangting Liu, Zheng Hu, Jiayao Qu, Jia Li, Ke Gong, Li Wang, Jing Jiang, Xiangning Li, Rongzhang He, Lili Duan, Weihao Luo, Chenglai Xia, Dixian Luo</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>756</prism:startingPage> 
<prism:endingPage>767</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0742.htm</link> 
<title>Bovine serum albumin aggravates macrophage M1 activation and kidney injury in heterozygous Klotho-deficient mice via the gut microbiota-immune axis</title> 
<description><![CDATA[ <p>Klotho expression abnormalities induces kidney injury and chronic kidney disease, however, the underlying mechanism remains unclear. Here, Klotho<sup>+/-</sup> mice and wild-type mice were treated with low-dose bovine serum albumin (BSA). Pathological examination demonstrated that the area of glomerular collagen deposition and fibrosis in BSA-Kl<sup>-/+</sup> mice was significantly larger than that in BSA-WT mice. The serum levels of superoxide dismutase, malondialdehyde, creatinine, and urea in BSA-Kl<sup>-/+</sup> mice were significantly increased. Sequencing of gut microbiota 16S rRNA v3-v4 region indicated that BSA-Kl<sup>-/+</sup> mice showed a significantly higher relative abundance of the genera <i>Dubosiella</i>, <i>Akkermansia</i>, <i>Alloprevotella</i>, and <i>Lachnospiraceae</i> and a significantly lower relative abundance of the genera <i>Allobaculum</i> and <i>Muribaculaceae</i> than BSA-WT mice. KEGG analysis revealed that the metabolic pathways of signal transduction, xenobiotic biodegradation and metabolism, and lipid metabolism increased significantly in BSA-Kl<sup>-/+</sup> mice. Flow cytometry showed that the proportion of CD68<sup>+</sup>/CD11b<sup>+</sup> cells in the peripheral blood was significantly higher in BSA-KL<sup>-/+</sup> mice than that in BSA-WT mice. qPCR and western blot suggested that Klotho and Nrf2 expression in M&#934;1 cells of BSA-KL<sup>-/+</sup> mice was significantly decreased. Thus, the findings suggest during the immune activation and chronic inflammation induced by the gut microbiota imbalance in Klotho-deficient mice treated to BSA, disrupted expression of proteins in the Nrf2/NF-&#954;B signaling pathway in monocyte-derived macrophage M1 cells leads to the aggravation of inflammation and kidney injury.</p> ]]></description>  
<dc:creator>Lingyun Lai, Yi Li, Jianjun Liu, Lei Luo, Jianguo Tang, Jun Xue, Te Liu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>742</prism:startingPage> 
<prism:endingPage>755</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0728.htm</link> 
<title>The G1 phase optical reporter serves as a sensor of CDK4/6 inhibition in vivo</title> 
<description><![CDATA[ <p>Visualization of cell-cycle G1 phase for monitoring the early response of cell cycle specific drug remains challenging. In this study, we developed genetically engineered bioluminescent reporters by fusing full-length cyclin E to the C-terminal luciferase (named as CycE-Luc and CycE-Luc2). Next, HeLa cell line or an ER-positive breast cancer cell line MCF-7 was transfected with these reporters. In cellular assays, the bioluminescent signal of CycE-Luc and CycE-Luc2 was accumulated in the G1 phase and decreased after exiting from the G1 phase. The expression of CycE-Luc and CycE-Luc2 fusion protein was regulated in a cell cycle-dependent manner, which was mediated by proteasome ubiquitination and degradation. Next, our <i>in vitro</i> and <i>in vivo</i> experiment confirmed that the cell cycle arrested by anti-cancer agents (palbociclib or 5-FU) was monitored quantitatively and dynamically by bioluminescent imaging of these reporters in a real-time and non-invasive manner. Thus, these optical reporters could reflect the G1 phase alternation of cell cycle, and might become a future clinically translatable approach for predicting and monitoring response to palbociclib in patients with ER-positive breast cancer.</p> ]]></description>  
<dc:creator>Cuiping Guo, Yuxian Guo, Jingjing Liu, Yiyang Gao, Min Wei, Ruijun Zhao, Min Chen, Guojun Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>728</prism:startingPage> 
<prism:endingPage>741</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0712.htm</link> 
<title>Tight junctions and their regulation by non-coding RNAs</title> 
<description><![CDATA[ <p>Tight junction (TJ) is a &#8220;zippering up&#8221; junction structure located at the uppermost portion of adjacent epithelial/endothelial cells in organs and tissues. TJs maintain the relative stability of intracellular substances and functions by closing or opening intercellular pathways, coordinating the entry and exit of molecules of different sizes and charges, and regulating the permeability of paracellular barrier. TJs also prevent microbial invasion, maintain epithelial/endothelial cell polarity, and regulate cell proliferation. TJs are widely present in the skin and mucosal epithelial barriers, intestinal epithelial barrier, glomerular filtration barrier, bladder epithelial barrier, blood-brain barrier, brain-blood tumor barrier, and blood-testis barrier. TJ dysfunction in different organs can lead to a variety of diseases. In addition to signal pathways, transcription factors, DNA methylation, histone modification, TJ proteins can also be regulated by a variety of non-coding RNAs, such as micro-RNAs, long-noncoding RNAs, and circular RNAs, directly or indirectly. This review summarizes the structure of TJs and introduces the functions and regulatory mechanisms of TJs in different organs and tissues. The roles and mechanisms of non-coding RNAs in the regulation of TJs are also highlighted in this review.</p> ]]></description>  
<dc:creator>Xiaojiao Zhao, Hongliang Zeng, Li Lei, Xiaoliang Tong, Lun Yang, Yan Yang, Si Li, Ying Zhou, Liping Luo, Jinhua Huang, Rong Xiao, Jing Chen, Qinghai Zeng</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>712</prism:startingPage> 
<prism:endingPage>727</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0702.htm</link> 
<title>Ferroptosis-Related Long Non-Coding RNA signature predicts the prognosis of Head and neck squamous cell carcinoma</title> 
<description><![CDATA[ <p><b>Background</b>: Head and neck squamous cell carcinoma (HNSCC) are head and neck cancers. On the other hand, ferroptosis is a novel iron-dependent and ROS reliant type of cell death observed various disease conditions.</p><p><b>Method</b>: We constructed a prognostic multilncRNA signature based on ferroptosis-related differentially expressed lncRNAs in HNSCC.</p><p><b>Results</b>: We identified 25 differently expressed lncRNAs associated with prognosis of HNSCC. Kaplan-Meier analyses revealed the high-risk lncRNAs signature associated with poor prognosis of HNSCC. Moreover, the AUC of the lncRNAs signature was 0.782, underscoring their utility in prediction HNSCC prognosis. Indeed, our risk assessment model was superior to traditional clinicopathological features in predicting HNSCC prognosis. GSEA revealed the immune and tumor-related pathways in the low risk group individuals. Moreover, TCGA revealed T cell functions including cytolytic activity, HLA, regulation of inflammationp, co-stimulation, co-inhibition and coordination of type II INF response were significantly different between the low-risk and high-risk groups. Immune checkpoints such as PDCD-1 (PD-1), CTLA4 and LAG3, were also expressed differently between the two risk groups.</p><p><b>Conclusion:</b> A novel ferroptosis-related lncRNAs signature impacts on the prognosis of HNSCC.</p> ]]></description>  
<dc:creator>Yun Tang, Cheng Li, You-Jing Zhang, Zeng-Hong Wu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>702</prism:startingPage> 
<prism:endingPage>711</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0689.htm</link> 
<title>Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model</title> 
<description><![CDATA[ <p>Although germline mutations in <i>BRCA1</i> highly predispose women towards breast and ovarian cancer, few substantial improvements in preventing or treating such cancers have been made. Importantly, BRCA1 function is closely associated with DNA damage repair, which is required for genetic stability. Here, we examined the efficacy of radiotherapy, assessing the accumulation of genetic instabilities, in the treatment of <i>BRCA1</i>-associated breast cancer using a <i>Brca1</i>-mutant mouse model. Treatment of <i>Brca1</i>-mutant tumor-engrafted mice with X-rays reduced tumor progression by 27.9% compared with untreated controls. A correlation analysis of irradiation responses and biomarker profiles in tumors at baseline identified differences between responders and non-responders at the protein level (pER&#945;, pCHK2, p53, and EpCAM) and at the SOX2 target expression level. We further demonstrated that combined treatment of <i>Brca1</i>-mutant mammary tumors with irradiation and AZD2281, which inhibits PARP, significantly reduced tumor progression and extended survival. Our findings enhance the understanding of DNA damage and biomarker responses in <i>BRCA1</i>-associated mammary tumors and provide preclinical evidence that radiotherapy with synthetic DNA damage is a potential strategy for the therapeutic management of <i>BRCA1</i>-associated breast cancer.</p> ]]></description>  
<dc:creator>Eun Ju Cho, Jong Kwang Kim, Hye Jung Baek, Sun Eui Kim, Eun Jung Park, Bum Kyu Choi, Tae Hyun Kim, Dong Hoon Shin, Young Kyung Lim, Chu-Xia Deng, Sang Soo Kim</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>689</prism:startingPage> 
<prism:endingPage>701</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0683.htm</link> 
<title>Depression and its relationship with quality of life in frontline psychiatric clinicians during the COVID-19 pandemic in China: a national survey</title> 
<description><![CDATA[ <p>This was a national survey that determined the prevalence of depressive symptoms (depression thereafter) and its relationship with quality of life (QOL) in frontline clinicians working in psychiatric hospitals in China during the COVID-19 pandemic. Depression and QOL were assessed using the Patient Health Questionnaire nine items (PHQ-9) and the World Health Organization Quality of Life Questionnaire-brief version (WHOQOL-BREF), respectively. Multivariable logistic regression analyses and analysis of covariance were used. A total of 10,516 frontline clinicians participated in this study, of which, 28.52% (n=2,999) met screening criteria for depression. Compared to those without depression, clinicians with depression had a lower quality of life (<i>F</i> <sub>(1, 10515)</sub> =2874.66, <i>P</i>&#60;0.001). Higher educational level (<i>OR</i>=1.225, <i>P</i>=0.014), if the number of COVID-19 patients in the hospital catchment area surpassed 500 (<i>OR</i>=1.146, <i>P</i>=0.032), having family/friends/colleagues who were infected (<i>OR</i>=1.695, <i>P</i>&#60;0.001), being a current smoker (<i>OR</i>=1.533, <i>P</i>&#60;0.001), and longer working hours (<i>OR</i>=1.020, <i>P</i>=0.022) were independently associated with higher risk of depression. Living with family members (<i>OR</i>=0.786, <i>P</i>&#60;0.001), and being junior clinicians (<i>OR</i>=0.851, <i>P</i>=0.011) were independently associated with lower odds of depression. The results showed that depression was common in frontline psychiatric clinicians during the COVID-19 pandemic. Timely assessment and effective interventions of depression for frontline clinicians in psychiatric hospitals were warranted.</p> ]]></description>  
<dc:creator>Hong-He Zhang, Yan-Jie Zhao, Chun Wang, Qinge Zhang, Hai-Yang Yu, Teris Cheung, Brian J. Hall, Feng-Rong An, Yu-Tao Xiang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>683</prism:startingPage> 
<prism:endingPage>688</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0670.htm</link> 
<title>Basal-like breast cancer with low TGF&#946; and high TNF&#945; pathway activity is rich in activated memory CD4 T cells and has a good prognosis</title> 
<description><![CDATA[ <p>Basal-like breast cancer (BLBC) is a type of high-grade invasive breast cancer with high risk of recurrence, metastases, and poor survival. Immune activation in BLBC is a key factor that influences both cancer progression and therapeutic response, although its molecular mechanisms are not well clarified. In this study, we examined five cancer immunity-related pathways (IFN&#945;, IFN&#947;, STAT3, TGF&#946; and TNF&#945;) in four large independent breast cancer cohorts (<i>n</i> = 6,381) and their associations with the prognosis of breast cancer subtypes. Activities of the 5 pathways were calculated based on corresponding pathway signatures and associations between pathways and clinical outcomes were examined by survival analysis. Among the five PAM50-based subtypes, BLBC had the highest IFN&#945;, IFN&#947;, TNF&#945; pathway activities, and the lowest TGF&#946; activity. The IFN&#945;, IFN&#947;, TNF&#945; pathway activities were negatively correlated with BLBC recurrence. In contrast, positive association and no association with BLBC recurrence were observed for TGF&#946; and STAT3 pathways, respectively. TNF&#945;/TGF&#946; pathway combination improved the prediction of recurrence and chemotherapy response of BLBCs. Immune cell subset analysis in BLBC showed that M0, M1 and M2 macrophage levels were associated with either TNF&#945; or TGF&#946; pathways, whereas the level of activated memory CD4 T cells were associated with both pathways. Moreover, this T cell subset was most abundant in BLBCs with low TGF&#946; and high TNF&#945; pathway activities. These results suggested that cooperation of TNF&#945; and TGF&#946; signaling may be involved in the regulation of memory T cells and anti-cancer immunity in BLBCs. Our data also demonstrate that TNF&#945;/TGF&#946; pathway combination may represent a better biomarker for BLBC prognosis and clinical management.</p> ]]></description>  
<dc:creator>Dingxie Liu, Jaydutt Vadgama, Yong Wu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>670</prism:startingPage> 
<prism:endingPage>682</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0651.htm</link> 
<title>Advancement and properties of circular RNAs in prostate cancer: An emerging and compelling frontier for discovering</title> 
<description><![CDATA[ <p>Prostate cancer (PC) is the most common carcinoma among men worldwide which results in 26% of leading causes of cancer-related death. However, the ideal and effective molecular marker remains elusive. CircRNA, initially observed in plant-infected viruses and Sendai virus in 1979, is generated from pre-mRNA back-splicing and comes in to play by adequate expression. The differential expression in prostate tissues compared with the control reveals the promising capacity in modulating processes including carcinogenesis and metastasis. However, the biological mechanisms of regulatory network in PC needs to systemically concluded. In this review, we enlightened the comprehensive studies on the definite mechanisms of circRNAs affecting tumor progression and metastasis. What's more, we validated the potential clinical application of circRNAs serving as diagnostic and prognostic biomarker. The discussion and analysis in circRNAs will broaden our knowledge of the pathogenesis of PC and further optimize the current therapies against different condition.</p> ]]></description>  
<dc:creator>Hong Zhou, Xu-dong Zheng, Chang-ming Lin, Jie Min, Shuang Hu, Ying Hu, Liang-yun Li, Jia-si Chen, Yu-min Liu, Hao-dong Li, Xiao-ming Meng, Jun Li, Ya-ru Yang, Tao Xu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>651</prism:startingPage> 
<prism:endingPage>669</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0635.htm</link> 
<title>ITGB1 enhances the Radioresistance of human Non-small Cell Lung Cancer Cells by modulating the DNA damage response and YAP1-induced Epithelial-mesenchymal Transition</title> 
<description><![CDATA[ <p><b>Objectives:</b> Radiotherapy has played a limited role in the treatment of non-small cell lung cancer (NSCLC) due to the risk of tumour radioresistance. We previously established the radioresistant non-small cell lung cancer (NSCLC) cell line H460R. In this study, we identified differentially expressed genes between these radioresistant H460R cells and their radiosensitive parent line. We further evaluated the role of a differentially expressed gene, ITGB1, in NSCLC cell radioresistance and as a potential target for improving radiosensitivity.</p><p><b>Materials and Methods:</b> The radiosensitivity of NSCLC cells was evaluated by flow cytometry, colony formation assays, immunofluorescence, and Western blotting. Bioinformatics assay was used to identify the effect of ITGB1 and YAP1 expression in NSCLC tissues.</p><p><b>Results:</b> ITGB1 mRNA and protein expression levels were higher in H460R than in the parental H460 cells. We observed lower clonogenic survival and cell viability and a higher rate of apoptosis of ITGB1-knockdown A549 and H460R cells than of wild type cells post-irradiation. Transfection with an ITGB1 short hairpin (sh) RNA enhanced radiation-induced DNA damage and G2/M phase arrest. Moreover, ITGB1 induced epithelial-mesenchymal transition (EMT) of NSCLC cells. Silencing ITGB1 suppressed the expression and intracellular translocation of Yes-associated protein 1 (YAP1), a downstream effector of ITGB1.</p><p><b>Conclusions:</b> ITGB1 may induce radioresistance via affecting DNA repair and YAP1-induced EMT. Taken together, our data suggest that ITGB1 is an attractive therapeutic target to overcome NSCLC cell radioresistance.</p> ]]></description>  
<dc:creator>Yuexian Li, Cheng Sun, Yonggang Tan, Heying Zhang, Yuchao Li, Huawei Zou</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>635</prism:startingPage> 
<prism:endingPage>650</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0623.htm</link> 
<title>MEF2A-mediated lncRNA HCP5 Inhibits Gastric Cancer Progression via MiR-106b-5p/p21 Axis</title> 
<description><![CDATA[ <p><b>Background:</b> Long non-coding RNAs (lncRNAs) are deemed to be relevant to the tumorigenesis and development of a variety of tumors, containing gastric cancer (GC). The purpose of our investigations is to explore the character of HCP5 in GC.</p><p><b>Methods:</b> HCP5 expression was detected by quantitative real-time polymerase chain reaction (qRT-PCR) in 62 matched GC tissues and corresponding para-carcinoma tissues. In vitro and <i>in vivo</i> functional assays were subjected to verify the biological effects of HCP5 after alteration of HCP5. Chromatin immunoprecipitation assay (CHIP) assays were conducted to confirm that myocyte enhancer factor 2A (MEF2A) could bind to HCP5 promoter regions and thereby induce HCP5 expression. Analysis of the latent binding of miR-106b-5p to HCP5 and p21 was made by bioinformatics prediction and luciferase reporter assays.</p><p><b>Results:</b> Significant downregulation of HCP5 was detected in GC tissues. Negative correlation was determined between HCP5 expression level and tumor size and overall survival in GC patients. HCP5 depletion had a facilitating impact on proliferation, migration and invasion of GC cells. Consistently, overexpression of HCP5 came into an opposite effect. Moreover, we demonstrated that MEF2A could combine with the promoter region of HCP5 and thereby induce HCP5 transcription. Luciferase reporter assays revealed that HCP5 could compete with miR-106b-5p as a competing endogenous RNA (ceRNA) and upregulated p21 expression in GC.</p><p><b>Conclusions:</b> MEF2A-mediated HCP5 could exert an anti-tumor effect among the development of GC via miR-106b-5p/p21 axis, which provides a novel target for GC therapy.</p> ]]></description>  
<dc:creator>Weiwei Chen, Kundong Zhang, Yuhan Yang, Zengya Guo, Xiaofeng Wang, Buwei Teng, Qian Zhao, Chen Huang, Zhengjun Qiu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>623</prism:startingPage> 
<prism:endingPage>634</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0603.htm</link> 
<title>Dihydroartemisinin: A Potential Natural Anticancer Drug</title> 
<description><![CDATA[ <p>Dihydroartemisinin (DHA) is an active metabolite of artemisinin and its derivatives (ARTs), and it is an effective clinical drug widely used to treat malaria. Recently, the anticancer activity of DHA has attracted increasing attention. Nevertheless, there is no systematic summary on the anticancer effects of DHA. Notably, studies have shown that DHA exerts anticancer effects through various molecular mechanisms, such as inhibiting proliferation, inducing apoptosis, inhibiting tumor metastasis and angiogenesis, promoting immune function, inducing autophagy and endoplasmic reticulum (ER) stress. In this review, we comprehensively summarized the latest progress regarding the anticancer activities of DHA in cancer. Importantly, the underlying anticancer molecular mechanisms and pharmacological effects of DHA <i>in vitro</i> and<i> in vivo</i> are the focus of our attention. Interestingly, new methods to improve the solubility and bioavailability of DHA are discussed, which greatly enhance its anticancer efficacy. Remarkably, DHA has synergistic anti-tumor effects with a variety of clinical drugs, and preclinical and clinical studies provide stronger evidence of its anticancer potential. Moreover, this article also gives suggestions for further research on the anticancer effects of DHA. Thus, we hope to provide a strong theoretical support for DHA as an anticancer drug.</p> ]]></description>  
<dc:creator>Xiaoshuo Dai, Xiaoyan Zhang, Wei Chen, Yihuan Chen, Qiushuang Zhang, Saijun Mo, Jing Lu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>603</prism:startingPage> 
<prism:endingPage>622</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0589.htm</link> 
<title>Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cells</title> 
<description><![CDATA[ <p>Several natural products have been demonstrated to both enhance the anti-tumor efficacy and alleviate the side effects of conventional chemotherapy drugs. Rhein, a main constituent of the Chinese herb rhubarb, has been shown to induce apoptosis in various cancer types. However, the exact pharmacological mechanisms controlling the influence of Rhein on chemotherapy drug effects in pancreatic cancer (PC) remain largely undefined. In this study, we found that Rhein inhibited the growth and proliferation of PC cells through G1 phase cell cycle arrest. Moreover, Rhein induced caspase-dependent mitochondrial apoptosis of PC cells through inactivation of the PI3K/AKT pathway. Combination treatment of Rhein and oxaliplatin synergistically enhanced apoptosis of PC cells through increased generation of intracellular reactive oxygen species (ROS) and inactivation of the PI3K/AKT pathway. Pre-treatment with the ROS scavenger N-acetyl-L-cysteine attenuated the combined treatment-induced apoptosis and restored the level of phosphorylated AKT, indicating that ROS is an upstream regulator of the PI3K/AKT pathway. The combination therapy also exhibited stronger anti-tumor effects compared with single drug treatments <i>in vivo</i>. Taken together, these data demonstrate that Rhein can induce apoptosis and enhance the oxaliplatin sensitivity of PC cells, suggesting that Rhein may be an effective strategy to overcome drug resistance in the chemotherapeutic treatment of PC.</p> ]]></description>  
<dc:creator>Yuhui Liu, Chengjian Shi, Zheng He, Feng Zhu, Min Wang, Ruizhi He, Chunle Zhao, Xiuhui Shi, Min Zhou, Shutao Pan, Yang Gao, Xu Li, Renyi Qin</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>589</prism:startingPage> 
<prism:endingPage>602</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0574.htm</link> 
<title>Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway</title> 
<description><![CDATA[ <p><b>Objective:</b> CA125/MUC16 is an O-glycosylated protein that is expressed on the surfaces of ovarian epithelial cells. This molecule is a widely used tumor-associated marker for diagnosis of ovarian cancer. Recently, CA125 was shown to be involved in ovarian cancer metastasis. The purpose of this study was to investigate the mechanism of CA125 during ovarian cancer metastasis.</p><p><b>Methods:</b> We analyzed the Oncomine and CSIOVDB databases to determine the expression levels of DKK1 in ovarian cancer. DKK1 expression levels were upregulated or downregulated and applied with CA125 to Transwell and Western blot assays to ascertain the underlying mechanism by which CA125 stimulates cell migration via the SGK3/FOXO3 pathway. Anti-mesothelin antibodies (anti-MSLN) were used to block CA125 stimulation. Then the expression levels of DKK1were tested by enzyme-linked immunosorbent assay (ELISA) to eliminate the blocking effect of anti-MSLN to CA125 stimulation. Xenograft mouse models were used to detect the effects of CA125 and anti-MSLN on ovarian cancer metastasis <i>in vivo</i>.</p><p><b>Results:</b> DKK1 levels were downregulated in ovarian tumor tissues according to the analyses of two databases and significantly correlated with FIGO stage, grade and disease-free survival in ovarian cancer patients. DKK1 levels were downregulated by CA125 stimulation <i>in vitro</i>. Overexpression of DKK1 reversed the ability of exogenous CA125 to mediate cell migration by activating the SGK3/FOXO3 signaling pathway. Anti-MSLN abrogated the DKK1 reduction and increased the apoptosis of ovarian cancer cells. The use of anti-MSLN in xenograft mouse models significantly reduced tumor growth and metastasis accelerated by CA125.</p><p><b>Conclusions:</b> These experiments revealed that the SGK3/FOXO3 pathway was activated, wherein decreased expression of DKK1 was caused by CA125, which fuels ovarian cancer cell migration. Mesothelin is a potential therapeutic target for the treatment of ovarian cancer metastasis.</p> ]]></description>  
<dc:creator>Qianyu Huo, Chen Xu, Yanhong Shao, Qin Yu, Lunhui Huang, Yunde Liu, Huijing Bao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>574</prism:startingPage> 
<prism:endingPage>588</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0562.htm</link> 
<title>Exosomal circRNAs as novel cancer biomarkers: Challenges and opportunities</title> 
<description><![CDATA[ <p>Identifying high specificity and sensitivity biomarkers has always been the focus of research in the field of non-invasive cancer diagnosis. Exosomes are extracellular vesicles with a lipid bilayer membrane that can be released by all types of cells, which contain a variety of proteins, lipids, and a variety of non-coding RNAs. Increasing research has shown that the lipid bilayer can effectively protect the nucleic acid in exosomes. In cancers, tumor cell-derived exosomal circRNAs can act on target cells or organs through the transport of exosomes, and then participate in the regulation of tumor development and metastasis. Since exosomes exist in various body fluids and circRNAs in exosomes exhibit high stability, exosomal circRNAs have the potential as biomarkers for early and minimally invasive cancer diagnosis and prognosis judgment. In this review, we summarized circRNAs and their biological roles in cancers, with the emerging value biomarkers in cancer diagnosis, disease judgment, and prognosis observation. In addition, we briefly compared the advantages of exosomal circRNAs as biomarkers and the current obstacles in the exosome isolation technology, shed light to the future development of this technology.</p> ]]></description>  
<dc:creator>Shuai Wang, Yanhan Dong, Anjing Gong, Huimin Kong, Jinning Gao, Xiaodan Hao, Yongmei Liu, Zibo Wang, Yuqiao Fan, Chengyu Liu, Wenhua Xu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>562</prism:startingPage> 
<prism:endingPage>573</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0549.htm</link> 
<title>Extracellular vesicles and pancreatitis: mechanisms, status and perspectives</title> 
<description><![CDATA[ <p>Comprehensive reviews and large population-based cohort studies have played an important role in the diagnosis and treatment of pancreatitis and its sequelae. The incidence and mortality of pancreatitis have been reduced significantly due to substantial advancements in the pathophysiological mechanisms and clinically effective treatments. The study of extracellular vesicles (EVs) has the potential to identify cell-to-cell communication in diseases such as pancreatitis. Exosomes are a subset of EVs with an average diameter of 50&#126;150 nm. Their diverse and unique constituents include nucleic acids, proteins, and lipids, which can be transferred to trigger phenotypic changes of recipient cells. In recent years, many reports have indicated the role of EVs in pancreatitis, including acute pancreatitis, chronic pancreatitis and autoimmune pancreatitis, suggesting their potential influence on the development and progression of pancreatitis. Plasma exosomes of acute pancreatitis can effectively reach the alveolar cavity and activate alveolar macrophages to cause acute lung injury. Furthermore, upregulated exosomal miRNAs can be used as biomarkers for acute pancreatitis. Here, we summarized the current understanding of EVs in pancreatitis with an emphasis on their biological roles and their potential use as diagnostic biomarkers and therapeutic agents for this disease.</p> ]]></description>  
<dc:creator>Yu-Chen Jia, Yi-Xuan Ding, Wen-Tong Mei, Yu-Ting Wang, Zhi Zheng, Yuan-Xu Qu, Kuo Liang, Jia Li, Feng Cao, Fei Li</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>549</prism:startingPage> 
<prism:endingPage>561</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0539.htm</link> 
<title>A rapid screening classifier for diagnosing COVID-19</title> 
<description><![CDATA[ <p><b>Rationale:</b> Coronavirus disease 2019 (COVID-19) has caused a global pandemic. A classifier combining chest X-ray (CXR) with clinical features may serve as a rapid screening approach.</p><p><b>Methods:</b> The study included 512 patients with COVID-19 and 106 with influenza A/B pneumonia. A deep neural network (DNN) was applied, and deep features derived from CXR and clinical findings formed fused features for diagnosis prediction.</p><p><b>Results:</b> The clinical features of COVID-19 and influenza showed different patterns. Patients with COVID-19 experienced less fever, more diarrhea, and more salient hypercoagulability. Classifiers constructed using the clinical features or CXR had an area under the receiver operating curve (AUC) of 0.909 and 0.919, respectively. The diagnostic efficacy of the classifier combining the clinical features and CXR was dramatically improved and the AUC was 0.952 with 91.5% sensitivity and 81.2% specificity. Moreover, combined classifier was functional in both severe and non-serve COVID-19, with an AUC of 0.971 with 96.9% sensitivity in non-severe cases, which was on par with the computed tomography (CT)-based classifier, but had relatively inferior efficacy in severe cases compared to CT. In extension, we performed a reader study involving three experienced pulmonary physicians, artificial intelligence (AI) system demonstrated superiority in turn-around time and diagnostic accuracy compared with experienced pulmonary physicians.</p><p><b>Conclusions:</b> The classifier constructed using clinical and CXR features is efficient, economical, and radiation safe for distinguishing COVID-19 from influenza A/B pneumonia, serving as an ideal rapid screening tool during the COVID-19 pandemic.</p> ]]></description>  
<dc:creator>Yang Xia, Weixiang Chen, Hongyi Ren, Jianping Zhao, Lihua Wang, Rui Jin, Jiesen Zhou, Qiyuan Wang, Fugui Yan, Bin Zhang, Jian Lou, Shaobin Wang, Xiaomeng Li, Jie Zhou, Liming Xia, Cheng Jin, Jianjiang Feng, Wen Li, Huahao Shen</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>539</prism:startingPage> 
<prism:endingPage>548</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0527.htm</link> 
<title>The histone demethylase KDM2B regulates human primordial germ cell-like cells specification</title> 
<description><![CDATA[ <p>Germline specification is a fundamental step for human reproduction and this biological phenomenon possesses technical challenges to study <i>in vivo</i> as it occurs immediately after blastocyst implantation. The establishment of <i>in vitro</i> human primordial germ cell-like cells (hPGCLCs) induction system allows sophisticated characterization of human primordial germ cells (hPGCs) development. However, the underlying molecular mechanisms of hPGCLC specification are not fully elucidated. Here, we observed particularly high expression of the histone demethylase <i>KDM2B</i> in male fetal germ cells (FGCs) but not in male somatic cells. Besides, <i>KDM2B</i> shared similar expression pattern with hPGC marker genes in hPGCLCs, suggesting an important role of <i>KDM2B</i> in germ cell development. Although deletion of <i>KDM2B</i> had no significant effects on human embryonic stem cell (hESC)'s pluripotency, loss of <i>KDM2B</i> dramatically impaired hPGCLCs differentiation whereas ectopically expressed KDM2B could efficiently rescue such defect, indicating this defect was due to <i>KDM2B</i>'s loss in hPGCLC specification. Mechanistically, as revealed by the transcriptional profiling, <i>KDM2B</i> suppressed the expression of somatic genes thus inhibited somatic differentiation during hPGCLC specification. These data collectively indicate that KDM2B is an indispensable epigenetic regulator for hPGCLC specification, shedding lights on how epigenetic regulations orchestrate transcriptional events in hPGC development for future investigation.</p> ]]></description>  
<dc:creator>Weiyan Yuan, Zhaokai Yao, Veeramohan Veerapandian, Xinyan Yang, Xiaoman Wang, Dingyao Chen, Linzi Ma, Chaohui Li, Yi Zheng, Fang Luo, Xiao-yang Zhao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>527</prism:startingPage> 
<prism:endingPage>538</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0514.htm</link> 
<title>KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer</title> 
<description><![CDATA[ <p>Proliferation is one of the significant hallmarks of gallbladder cancer, which is a relatively rare but fatal malignance. Aim of this study was to examine the biological impact and molecular mechanism of the candidate hub-gene on the proliferation and tumorigenesis of gallbladder cancer. We analyzed the differentially expressed genes and the correlation between these genes with MKI67, and showed that KIF11 is one of the major upregulated regulators of proliferation in gallbladder cancer (GBC). The Gene Ontology, Gene Sets Enrichment Analysis and KEGG Pathway analysis indicated that KIF11 may promote GBC cell proliferation through the ERBB2/PI3K/AKT signaling pathway. Gain-of-function and loss-of-function assay demonstrated that KIF11 regulated GBC cell cycle and cancer cell proliferation in vitro. GBC cells exhibited G2M phase cell cycle arrest, cell proliferation and clone formation ability reduction after treatment with Monastrol, a specific inhibitor of KIF11. Xenograft model showed that KIF11 promotes GBC growth in vivo. Rescue experiments showed that KIF11-induced GBC cell proliferation dependented on ERBB2/PI3K/AKT pathway. Moreover, we found that H3K27ac signals are enriched among the promoter region of KIF11 in the UCSC Genome Browser Database. Differentially expressed analysis showed that EP300, a major histone acetyltransferase modifying H3K27ac signal, is highly expressed in gallbladder cancer and correlation analysis illustrated that EP300 is positively related with KIF11 in almost all the cancer types. We further found that KIF11 was significantly downregulated in a dose-dependent and time-dependent manner after histone acetylation inhibitor treatment. The present results highlight that high KIF11 expression promotes GBC cell proliferation through the ERBB2/PI3K/AKT signaling pathway. The findings may help deepen our understanding of mechanism underlying GBC cancer development and development of novel diagnostic and therapeutic target.</p> ]]></description>  
<dc:creator>Dang Wei, Bian Rui, Fan Qingquan, Cai Chen, Hu Yun ping, Song Xiaoling, Weng Hao, Gu Jun</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>514</prism:startingPage> 
<prism:endingPage>526</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0498.htm</link> 
<title>DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/&#946;-catenin pathway</title> 
<description><![CDATA[ <p>Long noncoding RNA DiGeorge syndrome critical region gene 5 (DGCR5) has been shown to be highly associated with cancer development. However, the biological role and molecular mechanism of DGCR5 in pancreatic cancer (PC) remains largely unknown. This study aimed to explore the role of DGCR5 in PC. It was revealed that DGCR5 was highly expressed in PC tissues compared with adjacent normal tissues and was associated with poor prognosis in PC patients. Furthermore, DGCR5 depletion inhibited the proliferation, migration and invasion by increasing apoptosis and inducing G0/G1 cell cycle arrest in vitro. Moreover, xenograft assay validated that DGCR5 promotes PC tumor growth in vivo. Mechanistically, DGCR5 was found to act as a ceRNA by sponging miR-3163 to regulate DNA topoisomerase 2-alpha (TOP2A) and inhibit Wnt/&#946;-catenin pathway. In addition, it was found that DGCR5 downregulation could enhance the sensitivity of PC cells to gemcitabine, and ChIP assay showed that PAX5 (Paired Box 5) could bind to the promoter region of DGCR5 and increase its transcription. The results of the present study indicated that DGCR5 may be a potential diagnostic biomarker and therapeutic target for PC.</p> ]]></description>  
<dc:creator>Shi-lei Liu, Chen Cai, Zi-yi Yang, Zi-you Wu, Xiang-song Wu, Xue-feng Wang, Ping Dong, Wei Gong</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>498</prism:startingPage> 
<prism:endingPage>513</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0487.htm</link> 
<title>The association of Metabolic Syndrome and its Components with the Incidence and Survival of Colorectal Cancer: A Systematic Review and Meta-analysis</title> 
<description><![CDATA[ <p><b>Background:</b> This meta-analysis was aimed to quantitatively assess the associations of metabolic syndrome (MetS) and its components with colorectal cancer (CRC).</p><p><b>Methods:</b> PubMed, EMBASE and Web of Science databases were systematically searched for eligible studies. A total of 18 studies for CRC incidence and 12 studies for CRC mortality were identified.</p><p><b>Results:</b> MetS was associated with an increased risk of CRC incidence and mortality in male (RR: 1.28, 95 % CI 1.16-1.39, and 1.24, 1.18-1.31, respectively) and correlated with an increased risk of CRC incidence in female (RR: 1.21, 1.13-1.30), but not with CRC mortality in female. MetS increased the risk of cancer-specific mortality (RR: 1.72, 1.03-2.42), but not overall mortality. The risk estimates of CRC incidence changed little depending on age, sex, cancer site, the type of studies, ethnicity, publication year, or definition of MetS. As for CRC mortality, further stratified analyses indicated statistical significance in studies with assessing cancer-specific survival outcome, in male, a cohort design, ethnicity of non-Chinese or with definition of MetS as &#8805; 3 metabolic abnormalities. Obesity and hyperglycemia are risk factors of CRC incidence in both male and female. Only dysglycemia is the risk factor for CRC mortality.</p><p><b>Conclusions:</b> MetS is associated with an increased risk of CRC incidence and cancer-specific mortality, but not overall mortality. In addition, MetS may increase the CRC mortality in male rather than in female. However, since most of the studies on CRC mortality were conducted in Chinese, further studies are needed to clarify this connection.</p> ]]></description>  
<dc:creator>Fei Han, Guanghai Wu, Shuai Zhang, Judong Zhang, Yongjie Zhao, Jing Xu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>487</prism:startingPage> 
<prism:endingPage>497</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0475.htm</link> 
<title>Application of radiomics and machine learning in head and neck cancers</title> 
<description><![CDATA[ <p>With the continuous development of medical image informatics technology, more and more high-throughput quantitative data could be extracted from digital medical images, which has resulted in a new kind of omics-Radiomics. In recent years, in addition to genomics, proteomics and metabolomics, radiomic has attracted the interest of more and more researchers. Compared to other omics, radiomics can be perfectly integrated with clinical data, even with the pathology and molecular biomarker, so that the study can be closer to the clinical reality and more revealing of the tumor development. Mass data will also be generated in this process. Machine learning, due to its own characteristics, has a unique advantage in processing massive radiomic data. By analyzing mass amounts of data with strong clinical relevance, people can construct models that more accurately reflect tumor development and progression, thereby providing the possibility of personalized and sequential treatment of patients. As one of the cancer types whose treatment and diagnosis rely on imaging examination, radiomics has a very broad application prospect in head and neck cancers (HNC). Until now, there have been some notable results in HNC. In this review, we will introduce the concepts and workflow of radiomics and machine learning and their current applications in head and neck cancers, as well as the directions and applications of artificial intelligence in the treatment and diagnosis of HNC.</p> ]]></description>  
<dc:creator>Zhouying Peng, Yumin Wang, Yaxuan Wang, Sijie Jiang, Ruohao Fan, Hua Zhang, Weihong Jiang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>475</prism:startingPage> 
<prism:endingPage>486</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0460.htm</link> 
<title>17&#946;-Estradiol promotes LC3B-associated phagocytosis in trained immunity of female mice against sepsis</title> 
<description><![CDATA[ <p>Sepsis is a common serious clinical infectious disease accompanied by more severe injuries and higher mortality rates in men than women. The much higher level of 17&#946;-estradiol (E<sub>2</sub>) in female is one of the significant reasons for better sepsis resistance ability. Trained immunity is a novel way to fight against infection by improving innate immunity. However, whether &#946;-glucan-induced trained immunity can promote macrophage phagocytosis to clear infections in early sepsis has not been clarified. And whether E<sub>2</sub> involved in this process needs further investigation. Symptoms among male, female and ovariectomized (OVX) C57BL/6 mice in early sepsis were detected. The effect of trained immunity on macrophage LC3B-associated phagocytosis (LAP) and the mechanism of E<sub>2</sub> functioned in this process have also been explored. We demonstrated compared with male mice, female has significantly more mild symptoms and more reactive oxygen species (ROS) production and stronger NADPH oxidase 2 (NOX2) expression in the macrophage of major organs. In contrary, these characteristics are disappeared in OVX mice. Furthermore, in macrophage cell lines and primary bone marrow- derived macrophages (BMDMs), &#946;-glucan-induced trained immunity can increase ROS production by activating NOX2 to promote macrophage LAP. E<sub>2</sub> can up-regulate RUBICON through estrogen receptor &#945; (ER&#945;) to further facilitate macrophage LAP. These results indicated that trained immunity can improve sepsis resistance ability by stimulating macrophage LAP. E<sub>2</sub> can boost ROS production and RUBICON expression to further promote macrophage LAP, which can provide a new perspective to recognize the mechanism of trained immunity in gender differences when responding to sepsis.</p> ]]></description>  
<dc:creator>Zhiheng Sun, Junxing Qu, Xiaoyu Xia, Yuchen Pan, Xinghan Liu, Huaping Liang, Huan Dou, Yayi Hou</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>460</prism:startingPage> 
<prism:endingPage>474</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0448.htm</link> 
<title>Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma</title> 
<description><![CDATA[ <p>Endometrial carcinoma (EnCa) is one of the deadliest gynecological malignancies. The purpose of the current study was to develop an immune-related lncRNA prognostic signature for EnCa. In the current research, a series of systematic bioinformatics analyses were conducted to develop a novel immune-related lncRNA prognostic signature to predict disease-free survival (DFS) and response to immunotherapy and chemotherapy in EnCa. Based on the newly developed signature, immune status and mutational loading between high&#8209; and low&#8209;risk groups were also compared. A novel 13-lncRNA signature associated with DFS of EnCa patients was ultimately developed using systematic bioinformatics analyses. The prognostic signature allowed us to distinguish samples with different risks with relatively high accuracy. In addition, univariate and multivariate Cox regression analyses confirmed that the signature was an independent factor for predicting DFS in EnCa. Moreover, a predictive nomogram combined with the risk signature and clinical stage was constructed to accurately predict 1-, 2-, 3-, and 5-year DFS of EnCa patients. Additionally, EnCa patients with different levels of risk had markedly different immune statuses and mutational loadings. Our findings indicate that the immune-related 13-lncRNA signature is a promising classifier for prognosis and response to immunotherapy and chemotherapy for EnCa.</p> ]]></description>  
<dc:creator>Jinhui Liu, Jie Mei, Yichun Wang, Xucheng Chen, Jiadong Pan, Laigen Tong, Yan Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>448</prism:startingPage> 
<prism:endingPage>459</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0430.htm</link> 
<title>Involvement of miR-619-5p in resistance to cisplatin by regulating ATXN3 in oral squamous cell carcinoma</title> 
<description><![CDATA[ <p>MicroRNAs are major post-transcriptional regulators responsible for the development of human cancers, including OSCC. The specific role of miR-619-5p in OSCC, however, is rarely reported. Cisplatin is one of the mostly applied chemotherapy drugs of OSCC. Nevertheless, drug resistance of cisplatin following the initial chemotherapy largely restricts its clinical benefits, and the mechanism of cisplatin resistance is unclear. This study intends to explore the biological function of miR-619-5p in the development of cisplatin resistance in OSCC cell lines and a xenograft model, as well as the potential molecular mechanism. Our results showed that miR-619-5p was down-regulated in OSCC samples and cisplatin-resistant OSCC cells. Ectopically expressed miR-619-5p inhibited proliferative, migratory and invasive abilities of OSCC cisplatin-resistant cells. The putative target gene ATXN3 was predicted by bioinformatic analysis and confirmed by dual-luciferase reporter assay. Importantly, ATXN3 was responsible for the regulatory effects of miR-619-5p on biological behaviors of cisplatin-resistant OSCC cells. Moreover, miR-619-5p mimics and ATXN3-siRNA significantly enhanced ATXN3 knockdown in both HN6/CDDPR and CAL27/CDDPR cells and inhibited expression of PI3K and AKT. <i>In vivo</i> evidences demonstrated that intratumoral injection of miR-619-5p agomir remarkably slowed down the growth of OSCC in xenograft mice. Collectively, microRNA-619-5p was the vital regulator for regulating cisplatin resistance of OSCC, which may be served as a potential therapeutic target.</p> ]]></description>  
<dc:creator>An Song, Yuanyuan Wu, Weiming Chu, Xueming Yang, Zaiou Zhu, Enshi Yan, Wei Zhang, Junbo Zhou, Xu Ding, Jie Liu, Hongxia Zhu, Jinhai Ye, Yunong Wu, Yang Zheng, Xiaomeng Song</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>430</prism:startingPage> 
<prism:endingPage>447</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0417.htm</link> 
<title>SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer</title> 
<description><![CDATA[ <p>Anaplastic thyroid cancer (ATC) is one of the most aggressive and virulent solid tumors. The ubiquitin proteasome system presents in all eukaryotic cells and is essential for cellular homeostasis. While its underlying role in ATC remains largely unclear. TRIM11 is an E3 ubiquitin ligase and has been reported to act as an oncogene in several human cancers. The present study aims to reveal the oncogenic function of TRIM11 in ATC. Western blot was used to measure the protein expression of TRIM11 and YAP, while the YAP target genes were measured by real-time PCR. CCK8 assay was used to detect cell viability; wound-healing assay and transwell assay were used to measure the migration ability of ATC. The xeno-graft tumor model was used for <i>in vivo</i> study. Immuno-precipitation assay was used to detect the interaction domain between YAP and TRIM11. And the ubiquitin-based Immuno-precipitation assays were used to detect the specific ubiquitination manner happened on YAP. TRIM11 depletion significantly decreases cell proliferation and migration capabilities of ATC cells, and elevates cell sensitivity to chemotherapy, which effect could be further rescued by YAP overexpression. TRIM11 depletion decreases YAP protein level and YAP/TEAD target genes, such as CTGF, ANKRD1 and CYR61 in ATC. Indicating that TRIM11 is a regulator of Hippo signaling pathway. Immuno-precipitation assay shows that the RING domain of TRIM11 is essential for the interaction with WW domain of YAP. Further mechanistic analysis suggests that TRIM11 promotes the mono-ubiquitination of YAP, thus prolongs its protein half. Furthermore, TRIM11 promoter analysis revealed that SOX13 activates TRIM11 transcription by binding to the promoter of TRIM11. In summary, our study describes the oncogenic function of TRIM11 in ATC, which acts as a post-translational modulating factor of Hippo pathway. Targeting TRIM11 may be a potential therapeutic method for ATC treatment.</p> ]]></description>  
<dc:creator>Jianing Tang, Zelin Tian, Xing Liao, Gaosong Wu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>417</prism:startingPage> 
<prism:endingPage>429</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0402.htm</link> 
<title>The role of miR-320 in glucose and lipid metabolism disorder-associated diseases</title> 
<description><![CDATA[ <p>Glucose and lipids are important nutrients that provide the majority of energy for each organ to maintain homeostasis of the body. With the continuous improvement in living standards, the incidence of metabolic disorder-associated diseases, such as diabetes, hyperlipidemia, and atherosclerosis, is increasing worldwide. Among them, diabetes, which could be induced by both glucose and lipid metabolic disorders, is one of the five diseases with the highest incidence and mortality worldwide. However, the detailed molecular mechanisms underlying glucose and lipid metabolism disorders and target-organ damage are still not fully defined. MicroRNAs (miRNAs) are small, non-coding, single-stranded RNAs, which usually affect their target mRNAs in the cytoplasm by post-transcriptional regulation. Previously, we have found that miR-320 contributed to glucose and lipid metabolism via different signaling pathways. Most importantly, we identified that nuclear miR-320 mediated diabetes-induced cardiac dysfunction by activating the transcription of fatty acid metabolic genes to cause lipotoxicity in the heart. Here, we reviewed the roles of miR-320 in glucose and lipid metabolism and target-organ damage.</p> ]]></description>  
<dc:creator>Hengzhi Du, Yanru Zhao, Zhongwei Yin, Dao Wen Wang, Chen Chen</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>402</prism:startingPage> 
<prism:endingPage>416</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0390.htm</link> 
<title>Spreading of pathological TDP-43 along corticospinal tract axons induces ALS-like phenotypes in Atg5+/- mice</title> 
<description><![CDATA[ <p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease, characterized by phosphorylated TDP-43 (pTDP-43)-positive inclusions in neurons and glial cells. However, the pathogenic mechanism that underlies ALS remains largely unknown. To investigate the effects of autophagy deficiency in the formation and spreading of pathological TDP-43 along corticospinal tract axons, TDP-43 preformed fibrils (PFFs) were prepared and unilaterally injected into the fifth layer of the left primary motor cortex (M1) or the left anterior horn of the seventh cervical spinal cord segment (C7) of Atg5<sup>+/-</sup> mice. After the injection of TDP-43 PFFs, the elevated levels of pTDP-43 were present in several pyramidal tract-associated regions of Atg5<sup>+/-</sup> mice. Additionally, the occurrence of spontaneous potentials detected by electromyography demonstrates evidence of lower motor neuron dysfunction in M1-TDP-43 PFFs-injected Atg5<sup>+/-</sup> mice, and prolonged central motor conduction time detected by motor evoked potentials provides evidence of upper motor neuron dysfunction in C7-TDP-43 PFFs-injected Atg5<sup>+/-</sup> mice. These results show that injection of TDP-43 PFFs into the M1 or C7 of Atg5<sup>+/-</sup> mice induces the spreading of pathological TDP-43 along corticospinal tract axons in both an anterograde and retrograde manner. Importantly, TDP-43 PFFs-injected Atg5<sup>+/-</sup> mice also display ALS-like motor dysfunction. Taken together, our findings provide direct evidence that TDP-43 PFFs-injected Atg5<sup>+/-</sup> mice exhibited ALS-like neuropathology and motor phenotypes, suggesting that autophagy deficiency promotes the formation and spreading of pathological TDP-43 <i>in vivo</i>.</p> ]]></description>  
<dc:creator>Rui Zhang, Yongkang Chen, Xinxin Wang, Haiyan Tian, Han Liu, Zhi Xiang, Dan Qi, Jason H. Huang, Erxi Wu, Xuebing Ding, Xuejing Wang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>390</prism:startingPage> 
<prism:endingPage>401</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0379.htm</link> 
<title>CircRNA ciRS-7: a Novel Oncogene in Multiple Cancers</title> 
<description><![CDATA[ <p>circular RNA ciRS-7 (ciRS-7) is a type of endogenous circular RNA (circRNA) with a closed circular structure. Since Hansen first demonstrated that ciRS-7 could serve as a microRNA sponge in 2013, researchers have paid increased attention to this circRNA. ciRS-7 plays a crucial role in regulating RNA transcription, downstream gene expression, and protein production. Moreover, ciRS-7 acts as an oncogene and promotes tumor progression through competitively inhibiting miR-7 in various types of cancers. ciRS-7 has been identified to be closely associated with breast cancer, nasopharyngeal carcinoma, lung cancer, hepatocellular carcinoma, cervical cancer, osteosarcoma, melanoma, colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, pancreatic cancer, laryngeal squamous cell carcinoma, and cholangiocarcinoma. In this review, we summarize the biological characteristics, molecular mechanisms, and future challenges of ciRS-7 in multiple tumors.</p> ]]></description>  
<dc:creator>Junwen Chen, Jun Yang, Xiang Fei, Xia Wang, Kefeng Wang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>379</prism:startingPage> 
<prism:endingPage>389</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0368.htm</link> 
<title>Niche Cells Crosstalk In Neuroinflammation After Traumatic Brain Injury</title> 
<description><![CDATA[ <p>Traumatic brain injury (TBI) is recognized as the disease with high morbidity and disability around world in spite of the work ongoing in neural protection. Due to heterogeneity among the patients, it's still hard to acquire satisfying achievements in clinic. Neuroinflammation, which exists since primary injury occurs, with elusive duality, appear to be of significance from recovery of injury to neurogenesis. In recent years, studied have revealed that communication in neurogenic niche is more than &#8220;cell to cell&#8221; communication, and study on NSCs represent it as central role in the progress of neural regeneration. Hence, the neuroinflammation-affecting crosstalk after TBI, and clarifying definitive role of NSCs in the course of regeneration is a promising subject for researchers, for its great potential in overcoming the frustrating status quo in clinic, promoting welfare of TBI patient.</p> ]]></description>  
<dc:creator>Yibin Jia, Guanyi Wang, Yuqing Ye, Enming Kang, Huijun Chen, Zishuo Guo, Xiaosheng He</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>368</prism:startingPage> 
<prism:endingPage>378</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0353.htm</link> 
<title>CDH1 is Identified as A Therapeutic Target for Skin Regeneration after Mechanical Loading</title> 
<description><![CDATA[ <p><b>Rationale:</b> Mechanical stimuli in the microenvironment are considered key regulators of cell function. Clinically, mechanical force (tissue expander) is widely used to regenerate skin for post-burn or trauma repair, implying that mechanical stretching can promote skin cell regeneration and proliferation. However, the underlying mechanism remains unknown.</p><p><b>Methods:</b> Microarray analysis was utilized to detect the hub gene. The expression of Cdh1 as examined in cells and tissues by western blot, q-PCR and immunohistochemistry staining respectively. Biological roles of Cdh1 was revealed by a series of functional in vitro and in vivo studies.</p><p><b>Results:</b> Microarray analysis identified <i>Cdh1</i> as a hub gene related to skin regeneration during rat cutaneous mechanical loading. In vitro studies suggested that both mechanical loading and <i>Cdh1</i> interference induced keratinocyte dedifferentiation and enhanced stemness, promoting cell proliferation and prevent apoptosis. Furthermore, the forkhead box O1/Kr&#252;ppel-like factor 4 (FOXO1/KLF4) pathway was activated and contributed to the keratinocyte dedifferentiation. In vivo studies showed that mechanical loading and <i>Cdh1</i> interference facilitated epidermal dedifferentiation and promoted dermal collagen deposition, and that <i>Cdh1</i> overexpression could block such influence.</p><p><b>Conclusions:</b> In this study, we show that E-cadherin (CDH1), a well-known cell-cell adhesion molecule, plays a crucial role in mechanical stretch-induced skin cell regeneration and proliferation. We have shown for the first time the process by which mechanical stress is transmitted to the epidermis and induces a downstream signaling pathway to induce epidermal cells to differentiate. These findings demonstrate that <i>Cdh1</i>-induced keratinocyte dedifferentiation is a crucial event in mechanical stretch-mediated skin regeneration and that <i>Cdh1</i> may serve as a potential therapeutic target for promoting skin regeneration.</p> ]]></description>  
<dc:creator>Xiaolu Huang, Xiao Liang, Yiwen Zhou, Haizhou Li, Hengyu Du, Yinjun Suo, Wenhui Liu, Rui Jin, Bangda Chai, Ran Duan, Haizhou Li, Qingfeng Li</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>353</prism:startingPage> 
<prism:endingPage>367</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0339.htm</link> 
<title>The IFN-&#947;-IDO1-kynureine pathway-induced autophagy in cervical cancer cell promotes phagocytosis of macrophage</title> 
<description><![CDATA[ <p><b>Background:</b> Cervical cancer is a common malignant disease in female patients accompanied by activation of autophagy in tumor cells. However, the exact regulatory factors of autophagy and its effects on the immune response remain unknown.</p><p><b>Methods:</b> The induction of autophagy in HeLa and SiHa cells treated with IFN-&#947;, tryptophan depletion, kynurenine and epacadostat was detected by western blot analysis and by an autophagy detection kit. Following co-culture with pre-treated HeLa and SiHa cells, U937 cells were analyzed by flow cytometry to detect CD80, CD86, CD163 and CD206 expression and the induction of phagocytosis.</p><p><b>Results:</b> IFN-&#947; caused a significant increase in the autophagy levels of HeLa and SiHa cells by promoting indoleamine-2,3-dioxygenase-1 (IDO1) expression. The induction of phagocytosis in HeLa and SiHa cells and the expression levels of CD80 and CD86 in U937 cells were increased significantly following treatment with recombinant human IFN-&#947;. This effect was associated with the induction of tumor cell autophagy. IFN-&#947; treatment and IDO1 overexpression promoted tryptophan depletion and kynurenine accumulation in cervical cancer cells. The latter was more potent in inducing autophagy of cervical cancer cells and promoting phagocytosis of macrophages. <i>In vivo</i>, IDO1 overexpression restricted tumor growth in C57 mice and enhanced the induction of phagocytosis in macrophages.</p><p><b>Conclusions:</b> IFN-&#947; promoted induction of autophagy and macrophage phagocytosis in cervical cancer cells possibly via IDO1 expression and kynurenine metabolism.</p> ]]></description>  
<dc:creator>Shao-Liang Yang, Hai-Xia Tan, Tian-Tian Niu, Yu-Kai Liu, Chun-Jie Gu, Da-Jin Li, Ming-Qing Li, Hai-Yan Wang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>339</prism:startingPage> 
<prism:endingPage>352</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0328.htm</link> 
<title>Potential roles of mediator Complex Subunit 13 in Cardiac Diseases</title> 
<description><![CDATA[ <p>Mediator complex subunit 13 (MED13, previously known as THRAP1 and TRAP240) is a subunit of the cyclin-dependent kinase 8 (CDK8) kinase module in the eukaryotic mediator complex. MED13 has been known to play critical roles in cell cycle, development, and growth. The purpose of this review is to comprehensively discuss its newly identified potential roles in myocardial energy metabolism and non-metabolic cardiovascular diseases. Evidence indicates that cardiac MED13 mainly participates in the regulation of nuclear receptor signaling, which drives the transcription of genes involved in modulating cardiac and systemic energy homeostasis. MED13 is also associated with several pathological conditions, such as metabolic syndrome and thyroid disease-associated heart failure. Therefore, MED13 constitutes a potential therapeutic target for the regulation of metabolic disorders and other cardiovascular diseases.</p> ]]></description>  
<dc:creator>Wenqian Zhou, He Cai, Jia Li, He Xu, Xiang Wang, Hongbo Men, Yang Zheng, Lu Cai</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>328</prism:startingPage> 
<prism:endingPage>338</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0307.htm</link> 
<title>A Perspective Of Intestinal Immune-Microbiome Interactions In Alcohol-Associated Liver Disease</title> 
<description><![CDATA[ <p>Uncovering the intricacies of the gut microbiome and how it interacts with the host immune system has opened up pathways in the search for the treatment of disease conditions. Alcohol-associated liver disease is a major cause of death worldwide. Research has shed light on the breakdown of the protective gut barriers, translocation of gut microbes to the liver and inflammatory immune response to microbes all contributing to alcohol-associated liver disease. This knowledge has opened up avenues for alternative therapies to alleviate alcohol-associated liver disease based on the interaction of the commensal gut microbiome as a key player in the regulation of the immune response. This review describes the relevance of the intestinal immune system, the gut microbiota, and specialized and non-specialized intestinal cells in the regulation of intestinal homeostasis. It also reflects how these components are altered during alcohol-associated liver disease and discusses new approaches for potential future therapies in alcohol-associated liver disease.</p> ]]></description>  
<dc:creator>Ryan Bruellman, Cristina Llorente</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>307</prism:startingPage> 
<prism:endingPage>327</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0298.htm</link> 
<title>A review of physiological and cellular mechanisms underlying fibrotic postoperative adhesion</title> 
<description><![CDATA[ <p>Postoperative adhesions (PA) are fibrotic tissues that are the most common driver of long-term morbidity after abdominal and pelvic surgery. The optimal drug or material to prevent adhesion formation has not yet been discovered. Comprehensive understanding of cellular and molecular mechanisms of adhesion process stimulates the design of future anti-adhesive strategies. Recently, disruption of peritoneal mesothelial cells were suggested as the 'motor' of PA formation, followed by a cascade of events (coagulation, inflammation, fibrinolysis) and influx of various immune cells, ultimately leading to a fibrous exudate. We showed that a variety of immune cells were recruited into adhesive peritoneal tissues in patients with small bowel obstruction caused by PA. The interactions among various types of immune cells contribute to PA development following peritoneal trauma. Our review focuses on the specific role of different immune cells in cellular and humoral mechanisms underpinning adhesion development.</p> ]]></description>  
<dc:creator>Qiongyuan Hu, Xuefeng Xia, Xing Kang, Peng Song, Zhijian Liu, Meng Wang, Wenxian Guan, Song Liu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>298</prism:startingPage> 
<prism:endingPage>306</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0285.htm</link> 
<title>Novel Functions of CD147 in the Mitochondria Exacerbates Melanoma Metastasis</title> 
<description><![CDATA[ <p>Melanoma is an aggressive form of skin cancer characterized by rapid invasion and metastasis. CD147 is known to be functioning in cell invasion. In this study, we showed that CD147 was translocated from the cell membrane to the mitochondria in advanced melanoma. Melanoma patients with CD147 localized to the mitochondria confer a worse prognosis. The mitochondrial CD147 levels are correlated with the invasion potential of various melanoma cell lines as well as mitochondrial energy metabolism. Depletion of CD147 decreased the activity of mitochondrial complex V. STRING analysis for protein-protein interaction networks (PPIN) in CD147-depleted melanoma cells showed that mitochondrial proteins HSP60 and ATP5B, a subunit of mitochondrial complex V, were node proteins. HSP60 upregulation was correlated with a worse prognosis of melanoma patients. Co-immunoprecipitation (Co-IP) assay indicates that CD147 interacts with HSP60. These data suggested that mitochondrial CD147 may prompt HSP60 to activate ATP5B, thereby promoting the mitochondrial aerobic oxidation and the invasive abilities of melanoma cells. Correlation analysis of the data acquired from patients was helpful to draw a 5-year survival curve for patients who screened positive and negative for mitochondrial CD147. This study unravels the function of CD147 in tumor invasion and highlights it as a potential tumor therapeutic target.</p> ]]></description>  
<dc:creator>Lixia Lu, Jianglin Zhang, Pingping Gan, Lisha Wu, Xu Zhang, Cong peng, Jianda Zhou, Xiang Chen, Juan Su</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>285</prism:startingPage> 
<prism:endingPage>297</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0271.htm</link> 
<title>The emerging roles of m6A modification in liver carcinogenesis</title> 
<description><![CDATA[ <p>The 'epitranscriptome', a collective term for chemical modifications that influence the structure, metabolism, and functions of RNA, has recently emerged as vitally important for the regulation of gene expression. N<sup>6</sup>-methyladenosine (m<sup>6</sup>A), the most prevalent mammalian mRNA internal modification, has been demonstrated to have a pivotal role in almost all vital bioprocesses, such as stem cell self-renewal and differentiation, heat shock or DNA damage response, tissue development, and maternal-to-zygotic transition. Hepatocellular carcinoma (HCC) is prevalent worldwide with high morbidity and mortality because of late diagnosis at an advanced stage and lack of effective treatment strategies. Epigenetic modifications including DNA methylation and histone modification have been demonstrated to be crucial for liver carcinogenesis. However, the role and underlying molecular mechanism of m<sup>6</sup>A in liver carcinogenesis are mostly unknown. In this review, we summarize recent advances in the m<sup>6</sup>A region and how these new findings remodel our understanding of m<sup>6</sup>A regulation of gene expression. We also describe the influence of m<sup>6</sup>A modification on liver carcinoma and lipid metabolism to instigate further investigations of the role of m<sup>6</sup>A in liver biological diseases and its potential application in the development of therapeutic strategies.</p> ]]></description>  
<dc:creator>Xue-yin Pan, Cheng Huang, Jun Li</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>271</prism:startingPage> 
<prism:endingPage>284</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0259.htm</link> 
<title>NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway</title> 
<description><![CDATA[ <p>Esophageal squamous cell carcinoma (ESCC) causes aggressive and lethal malignancies with extremely poor prognoses, and accounts for about 90% of cases of esophageal cancer. Neuropilin and tolloid-like 2 (NETO2) protein coding genes have been associated with various human cancers. Nevertheless, little information is reported about the phenotypic expression and its clinical significance in ESCC progression. Here, our study found that NETO2 expression in ESCC patients was associated with tumor clinical stage and lymph node metastasis status. Gain-of-function and loss-of-function analyses showed that NETO2 stimulated ESCC cell proliferation while suppressing apoptosis <i>in vitro</i> and enhanced tumor growth <i>in vivo</i>. Moreover, knockdown of NETO2 significantly inhibited migration and invasion in combination with regulation of epithelial-mesenchymal transition (EMT) related markers. Mechanistically, overexpression of NETO2 increased the phosphorylation of ERK, PI3k/AKT, and Nuclear factor erythroid-2-related factor 2(Nrf2), whereas silencing NETO2 decreased the phosphorylation of these targets. Our data suggest that Nrf2 was a critical downstream event responsible for triggering the PI3K/AKT and ERK signaling pathways and plays a crucial role in NETO2-mediated tumorigenesis. Taken together, NETO2 acts as an oncogene and might serve as a novel therapeutic target or prognostic biomarker in ESCC patients.</p> ]]></description>  
<dc:creator>Jia-cheng Xu, Tian-yin Chen, Le-tai Liao, Tao Chen, Quan-lin Li, Jia-xin Xu, Jian-wei Hu, Ping-hong Zhou, Yi-qun Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>259</prism:startingPage> 
<prism:endingPage>270</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0247.htm</link> 
<title>HES1 promotes breast cancer stem cells by elevating Slug in triple-negative breast cancer</title> 
<description><![CDATA[ <p>Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. TNBC is enriched with breast cancer stem cells (BCSCs), which are responsible for cancer initiation, cancer progression and worse prognosis. Our previous study found that HES1 was overexpressed and promoted invasion in TNBC. However, the role of HES1 in modulating BCSC stemness of TNBC remains unclear. Here, we found that HES1 upregulates Slug both in transcriptional level and in protein level. HES1 also has a positive correlation with Slug expression in 150 TNBC patient samples. TNBC patients with high HES1 and Slug levels show worse prognosis in both progression-free survival and overall survival analyses. Survival analyses indicate that the effects of HES1 on survival prognosis may depend on Slug. Furthermore, we reveal that HES1 is a novel transcriptional activator for Slug through acting directly on its promoter. Meanwhile, HES1 knockdown reduces BCSC self-renewal, BCSC population, and cancer cell proliferation in TNBC, whereas overexpression of Slug restores the oncogenic function of HES1, both <i>in vitro</i> and <i>in vivo</i>, suggesting that HES1 performs its oncogenic role through upregulating Slug. Taken together, HES1 promotes BCSC stemness properties via targeting Slug, highlighting that HES1 might be a novel candidate for BCSC stemness regulation in TNBC and providing new clues for identifying promising prognostic biomarkers and therapeutic targets of TNBC.</p> ]]></description>  
<dc:creator>Xiaoying Li, Yang Li, Xianqiang Du, Xu Wang, Shu Guan, Yu Cao, Feng Jin, Feng Li</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>247</prism:startingPage> 
<prism:endingPage>258</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0236.htm</link> 
<title>miR-340: A multifunctional role in human malignant diseases</title> 
<description><![CDATA[ <p>MicroRNAs (miRNAs) are a class of short non-coding RNAs of approximately 22 nucleotides in length, which function by binding to the 3' UTR sequences of their target mRNAs. It has been reported that dysregulated miRNAs play pivotal roles in numerous diseases, including cancers, such as gastric, breast, colorectal, ovarian, and other cancers. Recent research efforts have been devoted to translating these basic discoveries into clinical applications that could improve the therapeutic outcome in patients with cancer. Early studies have shown that miR-340 may act either as an oncogene or a tumor suppressor by targeting genes related to proliferation, apoptosis, and metastasis, as well as those associated with diagnosis, treatment, chemoresistance, and prognosis. miR-340 has been shown to have a role in other diseases, such as autoimmune diseases, acute stroke, and alcoholic steatohepatitis. Nevertheless, the roles of miR-340 in human malignancies are still unclear, and the associated mechanisms are complex, involving a variety of signaling pathways, such as Wnt/&#946;-catenin and the JAK-STAT pathways. Herein, we review the crucial roles of miR-340 in human cancers through the analysis of the latest research studies, with the aim of clarifying miR-340 function in malignant disease diagnosis, treatment, and prognosis, and to propose further investigations.</p> ]]></description>  
<dc:creator>Zheng Huang, Yesha Xu, Maoping Wan, Xixi Zeng, Jianmin Wu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>236</prism:startingPage> 
<prism:endingPage>246</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0220.htm</link> 
<title>Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis</title> 
<description><![CDATA[ <p>Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Increasing studies showed that long non-coding RNAs (lncRNAs), a novel class of RNAs that are greater than 200 nucleotides in length but lack the ability to encode proteins, exert crucial roles in the occurrence and progression of HCC. LncRNAs promote the proliferation, migration, invasion, autophagy, and apoptosis of tumor cells by regulating downstream target gene expression and cancer-related signaling pathways. Meanwhile, lncRNA can be used as biomarkers to predict the efficacy of HCC treatment strategies, such as surgery, radiotherapy, chemotherapy, and immunotherapy, and as a potential individualized tool for HCC diagnosis and treatment. In this review, we overview up-to-date findings on lncRNAs as potential biomarkers for HCC surgery, radiotherapy, chemotherapy resistance, target therapy, and immunotherapy, and discuss the potential clinical application of lncRNA as tools for HCC diagnosis and treatment.</p> ]]></description>  
<dc:creator>Donghong Yuan, Yu Chen, Xiaobing Li, Jing Li, Yueshui Zhao, Jing Shen, Fukuan Du, Parham Jabbarzadeh Kaboli, Mingxing Li, Xu Wu, Huijiao Ji, Chi Hin Cho, Qinglian Wen, Wanping Li, Zhangang Xiao, Bo Chen</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>220</prism:startingPage> 
<prism:endingPage>235</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0204.htm</link> 
<title>Biological characteristics of IL-6 and related intestinal diseases</title> 
<description><![CDATA[ <p>The intestine serves as an important digestive and the largest immune organ in the body. Interleukin-6(IL-6), an important mediator of various pathways, participates in the interactions between different kinds of cells and closely correlates with intestinal physiological and pathological condition. In this review we summarize the signaling pathways of IL-6 and its functions in maintaining intestinal homeostasis. We also explored its relation with nervous system and highlight its potential role in Parkinson's disease. Based on its specialty of the double-side influences on intestinal tumors and inflammation, we summarize how they are done through distinctive process.</p> ]]></description>  
<dc:creator>Yuexin Guo, Boya Wang, Tiantian Wang, Lei Gao, Ze-jun Yang, Fei-fei Wang, Hong-wei Shang, Rongxuan Hua, Jing-dong Xu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>204</prism:startingPage> 
<prism:endingPage>219</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0188.htm</link> 
<title>PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells</title> 
<description><![CDATA[ <p>Androgen receptor (AR) and its variants play vital roles in development and progression of prostate cancer. To clarify the mechanisms involved in the enhancement of their actions would be crucial for understanding the process in prostate cancer and castration-resistant prostate cancer transformation. Here, we provided the evidence to show that pre-mRNA processing factor 6 (PRPF6) acts as a key regulator for action of both AR full length (AR-FL) and AR variant 7 (AR-V7), thereby participating in the enhancement of AR-FL and AR-V7-induced transactivation in prostate cancer. In addition, PRPF6 is recruited to <i>cis</i>-regulatory elements in AR target genes and associates with JMJD1A to enhance AR-induced transactivation. PRPF6 also promotes expression of AR-FL and AR-V7. Moreover, PRPF6 depletion reduces tumor growth in prostate cancer-derived cell lines and results in significant suppression of xenograft tumors even under castration condition in mouse model. Furthermore, PRPF6 is obviously highly expressed in human prostate cancer samples. Collectively, our results suggest PRPF6 is involved in enhancement of oncogenic AR signaling, which support a previously unknown role of PRPF6 during progression of prostate cancer and castration-resistant prostate cancers.</p> ]]></description>  
<dc:creator>Wei Liu, Chunyu Wang, Shengli Wang, Kai Zeng, Shan Wei, Ning Sun, Ge Sun, Manlin Wang, Renlong Zou, Wensu Liu, Lin Lin, Huijuan Song, Zining Jin, Yue Zhao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>188</prism:startingPage> 
<prism:endingPage>203</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0178.htm</link> 
<title>MYC dysfunction modulates stemness and tumorigenesis in breast cancer</title> 
<description><![CDATA[ <p>As a transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast cancer. However, no consistent conclusion on the role and mechanism of MYC deregulation during breast cancer carcinogenesis has been formed. Here, we used the UALCAN, bc-GenExMiner, TCGA, cBioportal, STRING and Kaplan-Meier Plotter databases to explore the mRNA expression, prognosis, transcriptional profile changes, signal pathway rewiring and interaction with the cancer stem cells of MYC in breast cancer. We found that the expression of MYC varies in different subtypes of breast cancer, with relatively high frequency in TNBC. As a transcription factor, MYC not only participates in the rewiring of cancer signaling pathways, such as estrogen, WNT, NOTCH and other pathways, but also interacts with cancer stem cells. MYC is significantly positively correlated with breast cancer stem cell markers such as CD44, CD24, and ALDH1. Collectively, our results highlight that MYC plays an important regulatory role in the occurrence of breast cancer, and its amplification can be used as a predictor of diagnosis and prognosis. The interaction between MYC and cancer stem cells may play a crucial role in regulating the initiation and metastasis of breast cancer.</p> ]]></description>  
<dc:creator>Yiqiu Liu, Chengjun Zhu, Lin Tang, Qin Chen, Nan Guan, Kun Xu, Xiaoxiang Guan</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>178</prism:startingPage> 
<prism:endingPage>187</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0163.htm</link> 
<title>Regulation of exosome production and cargo sorting</title> 
<description><![CDATA[ <p>Cellular communication can be mediated by the exchange of biological information, mainly in the form of proteins and RNAs. This can occur when extracellular vesicles, such as exosomes, secreted by a donor cell are internalized by an acceptor cell. Exosomes bear specific repertoires of proteins and RNAs, indicating the existence of mechanisms that control the sorting of molecules into them. Knowledge about loadings and processes and mechanisms of cargo sorting of exosomes is essential to shed light on the physiological and pathological functions of these vesicles as well as on clinical applications involving their use and/or analysis. In this review, we will discuss the molecular mechanisms associated with exosome secretion and their specific cargo sorting, with special attention to the sorting of RNAs and proteins, and thus the outcome and the emerging therapeutic opportunities of the communication between the exosome-producer and recipient cells.</p> ]]></description>  
<dc:creator>Hong Wei, Qi Chen, Li Lin, Chunli Sha, Taoqiong Li, Yueqin Liu, Xinming Yin, Yuhao Xu, Lu Chen, Wujiang Gao, Yuefeng Li, Xiaolan Zhu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>163</prism:startingPage> 
<prism:endingPage>177</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0151.htm</link> 
<title>Ferroptosis in a sarcopenia model of senescence accelerated mouse prone 8 (SAMP8)</title> 
<description><![CDATA[ <p>As a systemic syndrome characterized by age-associated degenerative skeletal muscle atrophy, sarcopenia leads to a risk of adverse outcomes in the elderly. Age-related iron accumulation is found in the muscles of sarcopenia animal models and patients, but the role of iron in sarcopenia remains poorly understood. It has been recently found that iron overload in several diseases is involved in ferroptosis, an iron- dependent form of programmed cell death. However, whether this excess iron can result in ferroptosis in muscles is still unclear. In our present study, we found that ferric citrate induced ferroptosis in C2C12 cells, as well as impaired their differentiation from myoblasts to myotubes. Due to the decreased muscle mass and fiber size, 40-week-old senescence accelerated mouse prone 8 (SAMP8) mice were used as a sarcopenia model, in whose muscles the iron content and markers of ferroptosis were found to increase, compared to 8-week- old SAMP8 controls. Moreover, our results showed that iron overload upregulated the expression of P53, which subsequently repressed the protein level of Slc7a11 (solute carrier family 7, member 11), a known ferroptosis-related gene. The downregulation of Slc7a11 then induced the ferroptosis of muscle cells through the accumulation of lipid peroxidation products, which may be one of the causes of sarcopenia. The findings in this study indicate that iron plays a key role in triggering P53- Slc7a11-mediated ferroptosis in muscles, and suggest that targeting iron accumulation and ferroptosis might be a therapeutic strategy for treating sarcopenia.</p> ]]></description>  
<dc:creator>Yan Huang, Beiling Wu, Dingzhu Shen, Jiulin Chen, Zhihua Yu, Chuan Chen</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>151</prism:startingPage> 
<prism:endingPage>162</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0134.htm</link> 
<title>The Emerging Roles of Autophagy-Related MicroRNAs in Cancer</title> 
<description><![CDATA[ <p>Autophagy is a conserved catabolic process involving the degradation and recycling of damaged biomacromolecules or organelles through lysosomal-dependent pathways and plays a crucial role in maintaining cell homeostasis. Consequently, abnormal autophagy is associated with multiple diseases, such as infectious diseases, neurodegenerative diseases and cancer. Currently, autophagy is considered to be a dual regulator in cancer, functioning as a suppressor in the early stage while supporting the growth and metastasis of cancer cells in the later stage and may also produce therapeutic resistance. MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression at the post-transcriptional level by silencing targeted mRNA. MiRNAs have great regulatory potential for several fundamental biological processes, including autophagy. In recent years, an increasing number of studies have linked miRNA dysfunction to the growth, metabolism, migration, metastasis, and responses of cancer cells to therapy. Therefore, the study of autophagy-related miRNAs in cancer will provide insights into cancer biology and lead to the development of novel anti-cancer strategies. In the present review, we summarise the current knowledge of miRNA dysregulation during autophagy in cancer, focusing on the relationship between autophagy and miRNAs, and discuss their involvement in cancer biology and cancer treatment.</p> ]]></description>  
<dc:creator>Chan Shan, Xinzhe Chen, Hongjing Cai, Xiaodan Hao, Jing Li, Yinfeng Zhang, Jinning Gao, Zhixia Zhou, Xinmin Li, Cuiyun Liu, Peifeng Li, Kun Wang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>134</prism:startingPage> 
<prism:endingPage>150</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0119.htm</link> 
<title>Genome-to-phenome research in rats: progress and perspectives</title> 
<description><![CDATA[ <p>Because of their relatively short lifespan (&#60;4 years), rats have become the second most used model organism to study health and diseases in humans who may live for up to 120 years. First-, second- and third-generation sequencing technologies and platforms have produced increasingly greater sequencing depth and accurate reads, leading to significant advancements in the rat genome assembly during the last 20 years. In fact, whole genome sequencing (WGS) of 47 strains have been completed. This has led to the discovery of genome variants in rats, which have been widely used to detect quantitative trait loci underlying complex phenotypes based on gene, haplotype, and sweep association analyses. DNA variants can also reveal strain, chromosome and gene functional evolutions. In parallel, phenome programs have advanced significantly in rats during the last 15 years and more than 10 databases host genome and/or phenome information. In order to discover the bridges between genome and phenome, systems genetics and integrative genomics approaches have been developed. On the other hand, multiple level information transfers from genome to phenome are executed by differential usage of alternative transcriptional start (ATS) and polyadenylation (APA) sites per gene. We used our own experiments to demonstrate how alternative transcriptome analysis can lead to enrichment of phenome-related causal pathways in rats. Development of advanced genome-to-phenome assays will certainly enhance rats as models for human biomedical research.</p> ]]></description>  
<dc:creator>Amy L. Zinski, Shane Carrion, Jennifer J. Michal, Maria A. Gartstein, Raymond M. Quock, Jon F. Davis, Zhihua Jiang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>119</prism:startingPage> 
<prism:endingPage>133</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0107.htm</link> 
<title>Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer</title> 
<description><![CDATA[ <p>Aerobic glycolysis, also known as the Warburg effect, is emerged as a hallmark of most cancer cells. Increased aerobic glycolysis is closely associated with tumor aggressiveness and predicts a poor prognosis. Pancreatic ductal adenocarcinoma (PDAC) is characterized by prominent genomic aberrations and increased glycolytic phenotype. However, the detailed molecular events implicated in aerobic glycolysis of PDAC are not well understood. In this study, we performed a comprehensive molecular characterization using multidimensional ''omic'' data from The Cancer Genome Atlas (TCGA). Detailed analysis of 89 informative PDAC tumors identified substantial copy number variations (<i>MYC</i>, <i>GATA6</i>, <i>FGFR1</i>, <i>IDO1,</i> and <i>SMAD4</i>) and mutations (<i>KRAS</i>, <i>SMAD4</i>, and <i>RNF43</i>) related to aerobic glycolysis. Moreover, integrated analysis of transcriptional profiles revealed many differentially expressed long non-coding RNAs involved in PDAC aerobic glycolysis. Loss-of-function studies showed that LINC01559 and UNC5B-AS1 knockdown significantly inhibited the glycolytic capacity of PDAC cells as revealed by reduced glucose uptake, lactate production, and extracellular acidification rate. Moreover, genetic silencing of LINC01559 and UNC5B-AS1 suppressed tumor growth and resulted in alterations in several signaling pathways, such as TNF signaling pathway, IL-17 signaling pathway, and transcriptional misregulation in cancer. Notably, high expression of LINC01559 and UNC5B-AS1 predicted poor patient prognosis and correlated with the maximum standard uptakevalue (SUVmax) in PDAC patients who received preoperative<sup> 18</sup>F-FDG PET/CT. Taken together, our results decipher the glycolysis-associated copy number variations, mutations, and lncRNA landscapes in PDAC. These findings improve our knowledge of the molecular mechanism of PDAC aerobic glycolysis and may have practical implications for precision cancer therapy.</p> ]]></description>  
<dc:creator>Li-Li Zhu, Zheng Wu, Rong-Kun Li, Xin Xing, Yong-Sheng Jiang, Jun Li, Ya-Hui Wang, Li-Peng Hu, Xu Wang, Wei-Ting Qin, Yong-Wei Sun, Zhi-Gang Zhang, Qin Yang, Shu-Heng Jiang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>107</prism:startingPage> 
<prism:endingPage>118</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0097.htm</link> 
<title>SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations</title> 
<description><![CDATA[ <p>The outbreak of the coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic apparently started in December 2019 in Wuhan, China, and has since affected many countries worldwide, turning into a major global threat. Chinese researchers reported that SARS-CoV-2 could be classified into two major variants. They suggest that investigating the variations and characteristics of these variants might help assess risks and develop better treatment and prevention strategies. The two variants were named L-type and S-type, in which L-type was prevailed in an initial outbreak in Wuhan, Central China's Hubei Province, and S-type was phylogenetically older than L-type and less prevalent at an early stage, but with a later increase in frequency in Wuhan. There were 149 mutations in 103 sequenced SARS-CoV-2 genomes, 83 of which were nonsynonymous, leading to alteration in the amino acid sequence of proteins. Much effort is currently being devoted to elucidate whether or not these mutations affect viral transmissibility and virulence. In this review, we summarize the mutations in SARS-CoV-2 during the early phase of virus evolution and discuss the significance of the gene alterations in infections.</p> ]]></description>  
<dc:creator>Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>97</prism:startingPage> 
<prism:endingPage>106</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0089.htm</link> 
<title>The Regulatory Effect of SIRT1 on Extracellular Microenvironment Remodeling</title> 
<description><![CDATA[ <p>The sirtuins family is well known by its unique nicotinamide adenine dinucleotide (NAD<sup>+</sup>)-dependent deacetylase function. The most-investigated member of the family, Sirtuin 1 (SIRT1), accounts for deacetylating a broad range of transcription factors and coregulators, such as p53, the Forkhead box O (FOXO), and so on. It serves as a pivotal regulator in various intracellular biological processes, including energy metabolism, DNA damage response, genome stability maintenance and tumorigenesis. Although the most attention has been focused on its intracellular functions, the regulatory effect on extracellular microenvironment remodeling of SIRT1 has been recognized by researchers recently. SIRT1 can regulate cell secretion process and participate in glucose metabolism, neuroendocrine function, inflammation and tumorigenesis. Here, we review the advances in the understanding of SIRT1 on remodeling the extracellular microenvironment, which may provide new ideas for pathogenesis investigation and guidance for clinical treatment.</p> ]]></description>  
<dc:creator>Zhuo Wang, Wendong Guo, Fei Yi, Tingting Zhou, Xiaoman Li, Yanling Feng, Qiqiang Guo, Hongde Xu, Xiaoyu Song, Liu Cao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>89</prism:startingPage> 
<prism:endingPage>96</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0073.htm</link> 
<title>Role of hydrogen sulfide donors in cancer development and progression</title> 
<description><![CDATA[ <p>In recent years, a vast number of potential cancer therapeutic targets have emerged. However, developing efficient and effective drugs for the targets is of major concern. Hydrogen sulfide (H<sub>2</sub>S), one of the three known gasotransmitters, is involved in the regulation of various cellular activities such as autophagy, apoptosis, migration, and proliferation. Low production of H<sub>2</sub>S has been identified in numerous cancer types. Treating cancer cells with H<sub>2</sub>S donors is the common experimental technique used to improve H<sub>2</sub>S levels; however, the outcome depends on the concentration/dose, time, cell type, and sometimes the drug used. Both natural and synthesized donors are available for this purpose, although their effects vary independently ranging from strong cancer suppressors to promoters. Nonetheless, numerous signaling pathways have been reported to be altered following the treatments with H<sub>2</sub>S donors which suggest their potential in cancer treatment. This review will analyze the potential of H<sub>2</sub>S donors in cancer therapy by summarizing key cellular processes and mechanisms involved.</p> ]]></description>  
<dc:creator>Ebenezeri Erasto Ngowi, Attia Afzal, Muhammad Sarfraz, Saadullah Khattak, Shams Uz Zaman, Nazeer Hussain Khan, Tao Li, Qi-Ying Jiang, Xin Zhang, Shao-Feng Duan, Xin-Ying Ji, Dong-Dong Wu</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>73</prism:startingPage> 
<prism:endingPage>88</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0062.htm</link> 
<title>A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19</title> 
<description><![CDATA[ <p>Multi-system involvement and rapid clinical deterioration are hallmarks of coronavirus disease 2019 (COVID-19) related mortality. The unique clinical phenomena in severe COVID-19 can be perplexing, and they include disproportionately severe hypoxemia relative to lung alveolar-parenchymal pathology and rapid clinical deterioration, with poor response to O<sub>2</sub> supplementation, despite preserved lung mechanics. Factors such as microvascular injury, thromboembolism, pulmonary hypertension, and alteration in hemoglobin structure and function could play important roles. Overwhelming immune response associated with &#8220;cytokine storms&#8221; could activate reactive oxygen species (ROS), which may result in consumption of nitric oxide (NO), a critical vasodilation regulator. In other inflammatory infections, activated neutrophils are known to release myeloperoxidase (MPO) in a natural immune response, which contributes to production of hypochlorous acid (HOCl). However, during overwhelming inflammation, HOCl competes with O<sub>2</sub> at heme binding sites, decreasing O<sub>2</sub> saturation. Moreover, HOCl contributes to several oxidative reactions, including hemoglobin-heme iron oxidation, heme destruction, and subsequent release of free iron, which mediates toxic tissue injury through additional generation of ROS and NO consumption. Connecting these reactions in a multi-hit model can explain generalized tissue damage, vasoconstriction, severe hypoxia, and precipitous clinical deterioration in critically ill COVID-19 patients. Understanding these mechanisms is critical to develop therapeutic strategies to combat COVID-19.</p> ]]></description>  
<dc:creator>Pravin T Goud, David Bai, Husam M Abu-Soud</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>62</prism:startingPage> 
<prism:endingPage>72</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0050.htm</link> 
<title>Eomesodermin in CD4+T cells is essential for Ginkgolide K ameliorating disease progression in experimental autoimmune encephalomyelitis</title> 
<description><![CDATA[ <p>Eomesodermin (Eomes), a transcription factor, could suppress the Th17 cell differentiation and proliferation through directly binding to the promoter zone of the <i>Rorc</i> and<i> Il17a</i> gene, meanwhile the expression of <i>Eomes</i> is suppressed when c-Jun directly binds to its promoter zone. Ginkgolide K (1,10-dihydroxy-3,14-didehydroginkgolide, GK) is a diterpene lactone isolated from the leaves of Ginkgo biloba. A previous study indicated that GK could decrease the level of phospho JNK (c-Jun N-terminal kinase). Here, we reported the therapeutic potential of Ginkgolide K (GK) treatment to ameliorate experimental autoimmune encephalomyelitis (EAE) disease progression.</p><p><b>Methods:</b> EAE was induced in both wildtype and CD4-<i>Eomes</i> conditional knockout mice. GK was injected intraperitoneally. Disease severity, inflammation, and tissue damage were assessed by clinical evaluation, flow cytometry of mononuclear cells (MNCs), and histopathological evaluation. Dual-luciferase reporter assays were performed to measure Eomes transcription activity in vitro. The potency of GK (IC<sub>50</sub>) was determined using JNK1 Kinase Enzyme System.</p><p><b>Results:</b> We revealed that GK could ameliorate EAE disease progression by the inhibition of the Th17 cells. Further mechanism studies demonstrated that the level of phospho JNK was decreased and the level of Eomes in CD4<sup>+</sup>T cells was dramatically increased. This therapeutic effect of GK was almost completely interrupted in CD4-<i>Eomes</i> conditional knockout mice.</p><p><b>Conclusions:</b> These results provided the therapeutic potential of GK treatment in EAE, and further suggested that Eomes expression in CD4<sup>+</sup>T cells might be essential in this process.</p> ]]></description>  
<dc:creator>Sheng Chen, Juan Zhang, Wen-Bo Yu, Jing-Cong Zhuang, Wei Xiao, Zhi-Ying Wu, Bao-Guo Xiao</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>50</prism:startingPage> 
<prism:endingPage>61</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0032.htm</link> 
<title>&#946;II spectrin (SPTBN1): biological function and clinical potential in cancer and other diseases</title> 
<description><![CDATA[ <p>&#946;II spectrin, the most common isoform of non-erythrocyte spectrin, is a cytoskeleton protein present in all nucleated cells. Interestingly, &#946;II spectrin is essential for the development of various organs such as nerve, epithelium, inner ear, liver and heart. The functions of &#946;II spectrin include not only establishing and maintaining the cell structure but also regulating a variety of cellular functions, such as cell apoptosis, cell adhesion, cell spreading and cell cycle regulation. Notably, &#946;II spectrin dysfunction is associated with embryonic lethality and the DNA damage response. More recently, the detection of altered &#946;II spectrin expression in tumors indicated that &#946;II spectrin might be involved in the development and progression of cancer. Its mutations and disorders could result in developmental disabilities and various diseases. The versatile roles of &#946;II spectrin in disease have been examined in an increasing number of studies; nonetheless, the exact mechanisms of &#946;II spectrin are still poorly understood. Thus, we summarize the structural features and biological roles of &#946;II spectrin and discuss its molecular mechanisms and functions in development, homeostasis, regeneration and differentiation. This review highlight the potential effects of &#946;II spectrin dysfunction in cancer and other diseases, outstanding questions for the future investigation of therapeutic targets. The investigation of the regulatory mechanism of &#946;II spectrin signal inactivation and recovery may bring hope for future therapy of related diseases.</p> ]]></description>  
<dc:creator>Panyu Yang, Yanyan Yang, Pin Sun, Yu Tian, Fang Gao, Chen Wang, Tingyu Zong, Min Li, Ying Zhang, Tao Yu, Zhirong Jiang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>32</prism:startingPage> 
<prism:endingPage>49</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0020.htm</link> 
<title>ACE2 Correlated With Immune Infiltration Serves As A Novel Prognostic Biomarker In Clear Cell Renal Cell Carcinoma: Implication For COVID-19</title> 
<description><![CDATA[ <p>The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global infection, and is seriously threatening human life, especially cancer patients. Thus, we sought to determine the clinical roles of ACE2 (the cell entry receptor of SARS-CoV-2) in ccRCC (clear cell renal cell carcinoma). TCGA, GEO and TIP datasets, and immunohistochemistry and western blot results were used to determine the prognostic and clinicopathological characteristics of ACE2. ACE2 expression was down-regulated in ccRCC tissues and cell lines. The multivariate Cox regression analysis results indicated that increased ACE2 expression was independent predictor of longer OS (HR: 0.8259, 95%CI: 0.7734-0.8819, P&#60;0.0001) and RFS (HR: 0.8023, 95%CI: 0.7375-0.8729, P&#60;0.0001) in ccRCC patients. Lower ACE2 expression was also associated with advanced tumor stage, higher histological grade and pathological stage, and metastasis. Besides, ACE2 expression was significantly positively and negatively correlated with CD4 Na&#239;ve infiltration and CD4 Memory infiltration, respectively. Moreover, higher CD4 Na&#239;ve and lower CD4 Memory infiltration levels were associated with better pathological features and longer OS and RFS. Furthermore, high ACE2 expression group in decreased CD4 Na&#239;ve, enriched CD4 Na&#239;ve and enriched CD4 memory cohort had favorable prognosis. These findings identified that AEC2 was significantly reduced in ccRCC, and decreased ACE2 was related to worse pathological features and poor prognosis. Low ACE2 expression in ccRCC may partially affect the prognosis due to altered immune cells infiltration levels.</p> ]]></description>  
<dc:creator>Wuping Yang, Lei Li, Kenan Zhang, Kaifang Ma, Haibiao Xie, Yanqing Gong, Jingcheng Zhou, Kan Gong</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>20</prism:startingPage> 
<prism:endingPage>31</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0008.htm</link> 
<title>Current advances in the development of SARS-CoV-2 vaccines</title> 
<description><![CDATA[ <p>Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc globally, which has put a heavy toll on public health, lives, and the world economy. Vaccination is considered as one of the greatest successes in medical history. Based on prior experience with the development of SARS-CoV vaccines, all COVID-19 vaccines must be subjected to the tests for protective effects and harmful risks derived from antibody-dependent enhancement that may contribute to augmented infectivity and/or eosinophilic infiltration. The SARS-CoV-2 vaccine is now being developed urgently in several different ways. China is regarded as one of the world's leading countries in SARS-CoV-2 vaccine development, up to date the last inactivated vaccine international clinical (Phase III) trial was launched in the United Arab Emirates by Sinopharm China National Biotec Group (CNBG). In this review, we outline the current status of vaccine development against clinically relevant SARS-CoV-2 strains, anticipating that such attempts would help create efficacious and sage SARS-CoV-2 vaccines.</p> ]]></description>  
<dc:creator>Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>8</prism:startingPage> 
<prism:endingPage>19</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.ijbs.com/v17p0001.htm</link> 
<title>Clinical characteristics and analysis of risk factors for disease progression of COVID-19: A retrospective Cohort Study</title> 
<description><![CDATA[ <p><b>Objective:</b> Since December 2019, an outbreak of coronavirus disease 2019 (COVID 19) has been experienced from Wuhan, China to the world. A retrospective cohort study was conducted to summarize the clinical characteristics of patients with COVID-19 and to explore the risk factors affecting the disease duration in Jiangan Fangcang shelter hospital, Wuhan, China.</p><p><b>Methods:</b> Clinical characteristics of 409 patients with COVID-19 were retrospectively analyzed. We describe the clinical characteristics and distribution of discharge time or transfer time for each patient. Then we performed univariate and multivariate Cox regression analysis to identify potential risk factors for progression from non-severe to severe COVID-19 or death.</p><p><b>Results:</b> The median disease duration of all patients was 23 days (IQR 19-28). The main symptoms of the patient were fever (95.6%), cough (74.3%), tiredness (21.5%), and so on. Comorbidities mainly included hypertension (30.6%) diabetes (17.6%) and heart disease (12.5%). The univariate Cox regression analysis showed that old age, number of symptoms, the combination of hypertension, heart disease and pulmonary disease were associated with the progression of disease. The multivariate Cox regression analysis showed that old age (HR: 7.294; 95% CI: 1.442-36.888; <i>P</i> = 0.016), the combination of hypertension (HR: 2.230; 95% CI: 1.090-4.562; <i>P</i> = 0.028) and heart disease (HR: 2.650; 95% CI: 1.079-6.510; <i>P</i> = 0.034) were independent risk factors for progression of COVID-19.</p><p><b>Conclusions:</b> The age of the patient, the combination of hypertension and heart disease were independent risk factors for the progression of COVID-19. Cautions should be raised for patients with these risk factors.</p> ]]></description>  
<dc:creator>Zhengtong Lv, Shubin Lv</dc:creator>
<dc:source>International Journal of Biological Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>17</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>1</prism:startingPage> 
<prism:endingPage>7</prism:endingPage> 
<pubDate>2021</pubDate>
<category>Research Paper</category>
</item>

<atom:link href="http://www.ijbs.com/rss/current.xml" rel="self" type="application/rss+xml" />
  </channel>
</rss>
